{
  "responseHeader":{
    "status":0,
    "QTime":2,
    "params":{
      "q":"(Background: \"acute myeloid leukemia\"^4 OR \"acute myelocytic leukemia\" OR \"acute myelogenous leukemia\" OR \"acute granulocytic leukemia\" OR \"acute non-lymphocytic leukemia\" OR AML OR Doc_title: \"acute myeloid leukemia\"^4 OR \"acute myelocytic leukemia\" OR \"acute myelogenous leukemia\" OR \"acute granulocytic leukemia\" OR \"acute non-lymphocytic leukemia\" OR AML) AND (Background: \"FLT3\"^4 OR \"FLK2\" OR \"STK1\" OR \"CD135\" OR \"FLK-2\" Doc_title: \"FLT3\"^4 OR \"FLK2\" OR \"STK1\" OR \"CD135\" OR \"FLK-2\")"}},
  "response":{"numFound":156,"start":0,"docs":[
      {
        "Meeting_name":" The role of FLT3 in sole trisomy 8 acute myeloid leukemia.",
        "Background":"['Background', ' FLT3 (fms-related tyrosine kinase 3) with internal tandem duplication (ITD) is a known adverse prognostic factor in normal karyotype acute myeloid leukemia (AML). We asked whether FLT3 ITD carries any prognostic significance in sole trisomy 8 AML. Methods', ' A total of 37 AML patients (25 males', '12 females) with sole trisomy 8 were seen at Roswell Park Cancer Institute between 1991 and 2008. Treatment differed according to available protocols at the time. Results', ' Nucleophosmin (NPM1) was detected in only one case (FLT3 ITD/D835 negative). Interestingly, FLT3 D835 was detected in five (20%) of the 25 patients without FLT3 ITD but was not detected in any of the 7 FLT3 ITD- positive patients. A total of 22 (59%) patients achieved complete remission (CR). There was no difference in achievement of CR, overall or disease-free survival between trisomy 8 patients with or without FLT3 ITD. Of interest, patients with FLT3 ITD were significantly younger (mean', ' 50 year old; 95% confidence interval [CI]', ' 33.51, 66.49) compared to patients without FLT3 ITD (mean', ' 69.8 year old; 95% CI', ' 65.87, 73.73) (p = 0.006). In addition, patients with FLT3 ITD were less likely to have normal metaphases in their karyotype than patients without FLT3 ITD (86.7% [95% CI', ' 0.693, 0.963] vs. 42.8% [95% CI', ' 0.099, 0.816]; p = 0.027). Conclusions', ' The presence of FLT3 ITD in trisomy 8 AML was associated with younger age and presence of trisomy 8 in all analyzed metaphases when compared to those without FLT3 ITD. AML patients with trisomy 8 and FLT3 ITD had similar CR, overall and progression-free survival as those without FLT3 ITD.']",
        "Doc_id":"ASCO_53629-74",
        "Doc_title":" The role of FLT3 in sole trisomy 8 acute myeloid leukemia.",
        "_version_":1606189029780357120},
      {
        "Meeting_name":" High FLT3 mRNA expression without FLT3-ITD in infants with acute myeloid leukemia",
        "Background":"['Introduction', ' When compared to older patients, infants with acute leukemia exhibit high frequency of MLL gene rearrangement (MLL-R), and are known to have higher vulnerability to intensive cytotoxic therapy, such as hematopoietic stem cell transplantation (HSCT). In contrast to acute lymphoblastic leukemia (ALL) in infants, there have been a few reports on acute myeloid leukemia (AML) in infants including our group (A. Shimada et al, ASH 2011). We and other group reported that MLL-R had the clinical impact in infant ALL, however, not in infant AML. Infant ALL with MLL-R expressed high FLT3 mRNA, on the other hand, the importance of FLT3 mRNA remains to be obscure in infant AML. Patients', ' Forty four infants with AML, aged less than 1 year at diagnosis, registered in JPLSG AML-05 from 2006-2010. Patients with Down syndrome were excluded. The most frequent FAB classification type was M7 (18/44, 40.9%), followed by M5 (15/44, 34.1%), and M4 (4/44, 9.0%). Total 16 of 44 (36.4%) infant AML patients had MLL-R, 9 patients were detected by G-banding method, and other 7 patients were by FISH analysis or RT-PCR. There was not t(8;21), t(15;17) except for one inv(16) patient. Methods', ' FLT3 mRNA expression and internal tandem duplication (ITD) were analyzed in the first diagnostic bone marrow samples by RQ-PCR and PCR. Results', ' No patients had FLT3-ITD, however, higher FLT3 mRNA expression was found in MLL-R patients (n=16) (median 623,150 copies/gRNA) compared with MLL-wild type (WT) (n=28) (median 25,105) (p<0.005). This phenomenon was also observed in 12-23 months AML patients. Discussion', ' High FLT3 mRNA expression was reported in infant ALL with MLL-R and it can be a molecular target for FLT3 inhibitor. On the other hand, there was no report in infant AML. Our previous data suggested that SCT had the limited efficacy for infant AML, FLT3 inhibitor might be considered to be used for infant AML with MLL-R in future.']",
        "Doc_id":"AACR_2012-1422",
        "Doc_title":" High FLT3 mRNA expression without FLT3-ITD in infants with acute myeloid leukemia",
        "_version_":1606189028043915264},
      {
        "Meeting_name":" HEC73543 is a novel potent, selective Flt3 receptor tyrosine kinase (RTK) Inhibitor for the treatment of refractory acute myeloid leukemia (AML).",
        "Background":"['Background', ' Adults acute myeloid leukemia (AML) account for ~30% of leukemia and ~40% of leukemia-related deaths. FLT3 is a receptor tyrosine kinase that is normally expressed on immature hematopoietic cells and functions in the development of both stem cells and the immune system. FLT3 is the most frequently mutated gene in AML, with an estimated 30 % of AML patients harboring FLT3 mutations. FLT3-ITD is a common mutation in AML and correlates with a poor prognosis and higher risk of relapse of AML patients.']",
        "Doc_id":"AACR_2017-2093",
        "Doc_title":" HEC73543 is a novel potent, selective Flt3 receptor tyrosine kinase (RTK) Inhibitor for the treatment of refractory acute myeloid leukemia (AML).",
        "_version_":1606188983114530816},
      {
        "Meeting_name":" Leukemic FLT3 signals via Grb10 and elevated Grb10 expression correlates with poor prognosis in acute myeloid leukemia.",
        "Background":"['The adaptor protein Grb10 plays important roles in mitogenic signaling. However, its roles in acute myeloid leukemia (AML) are predominantly unknown. Here we describe the role of Grb10 in FLT3-ITD-mediated AML. The type III receptor tyrosine kinase, FLT3 is widely expressed in AML and approximately 30% of AML patients carry an oncogenic FLT3-internal tandem duplication (ITD) mutation. We observed that Grb10 physically associates with normal and oncogenic FLT3 through FLT3 phospho-tyrosine 572 and 793 residues. Although Grb10 expression did not affect FLT3 activation or stability, its expression enhanced FLT3-mediated Akt and STAT5 phosphorylation without affecting Erk or p38 phosphorylation. Selective Grb10 depletion reduced Akt and STAT5 phosphorylation in Ba/F3 and OCI-AML-5 cells. Grb10 regulates cell cycle by accelerating G2-M transition followed by an increased cell population in S-phase. Expression of Grb10 furthermore resulted in an increased proliferation, survival and colony formation of Ba/F3-FLT3-ITD cells. Grb10 expression was significantly increased in AML patients compared to healthy controls and was also elevated in patients carrying FLT3-ITD mutants. The elevated Grb10 expression correlated to relapse as well as to poor prognosis. In addition, Grb10 expression led to resistance to chemotherapy. These results suggest that Grb10 binds to FLT3 and induces PI3K-Akt and STAT5 signaling pathways resulting in an enhanced proliferation, survival and colony formation of hematopoietic cells that furthermore initiates drug-resistance and poor prognosis in AML.']",
        "Doc_id":"AACR_2013-4121",
        "Doc_title":" Leukemic FLT3 signals via Grb10 and elevated Grb10 expression correlates with poor prognosis in acute myeloid leukemia.",
        "_version_":1606189032098758656},
      {
        "Meeting_name":" Discovery of SC110237, a highly potent, selective and orally active FLT3 inhibitor for the treatment of acute myeloid leukemia",
        "Background":"['FLT3 (Fms-like tyrosine kinase 3) is the most frequently mutated gene in acute myeloid leukemia (AML). Activating Flt3 mutations occur in about 30% of patients with AML, often as internal tandem duplication(ITD) mutations. These mutations are associated with the poor prognosis. Here, we report the Denovo preclinical candidate SC110237, a novel, selective, highly potent, and orally active FLT3 inhibitor which has very similar antitumor efficacy in MV4-11 xenograft models, but has better cardiac safety, and more favorable pharmacokinetic profiles compared with AC220, the first-in-class FLT3 inhibitor in clinical trial.SC110237 showed potent activity against FLT3 enzyme (IC50 = 91 nM) and anti-proliferative activity against MV4-11 tumor cells (SC110237 IC50 = 0.09 nM, AC220 IC50 = 0.56 nM). Unlike most FLT3 inhibitors in clinical trials, SC110237 showed good selectivity within the Class III RTK family. In vivo, SC110237showed excellent efficacy in the subcutaneous models of AML and CEL (Chronic Eosinophilic Leukemia)', ' MV4-11, MOLM-13 and EOL-1 model. MV4-11, MOLM-13 human AML cells have FLT3-ITD mutations, EOL-1 human CEL (Chronic Eosinophilic Leukemia) cells have FIP1L1-PDGFRA and over-expression of wild-type FLT3 receptor. In s.c. MV4-11 AML model, SC110237-2 (2, 6, 18 mg/kg) demonstrated potent activity. Tumor is completely eradicated in all groups even at the lowest dose of 2 mg/kg, with prolonged inhibition effect on tumor growth after drug withdrawal. At the lowest dose of 2 mg/kg for SC110237-2, there is 1 tumor re-growth until day 55 (12 days post last dose) compared to 3 tumors re-growth (one of the mice died) on the day 55 (12 days post dose) for AC220 at the same dose of 2 mg/kg. At higher dose of 6 mg/kg for SC110237-2, there is no sign of tumor re-growth until day 82 (39 days post last dose) comparing with 1 tumor re-growth on the day 76 (33 days post dose) for AC220 at the same dose of 6 mg/kg. In s.c. MOLM-13 and EOL-1 models, Tumor is completely eradicated in 4/8 mg/kg groups after 5 or 8 days dosing. SC110237-2 has no inhibition on CYP450 2C9, 2D6, 3A4 (Midazolam). Exposure of SC110237 is similar to that of AC220 which has the best PK profile among FLT3 inhibitors, while Cmax of SC110237 is lower than that of AC220. SC110237-2 exhibits linear dose-proportional exposure in mice and dog, and easier to adjust the dosage. Bioavailability of SC110237-2 in dog is 35%. To evaluate the effects of SC110237-2 and AC220 on the cardiovascular system, real time ECG was observed in conscious monkeys by a telemetry system. No abnormal phenomena have been observed in the 20 and 40 mg/kg SC110237 group, only with faster heart rate in the 80 mg/kg SC110237-2. On the other hand, 40 mg/kg AC220 can obviously prolong the QTcB interval. In conclusion, SC110237 exhibited a remarkable anti-tumor activity with favorable pharmacokinetic profiles and showed promise as a novel oral drug for the treatment of acute myeloid leukemia.']",
        "Doc_id":"AACR_2015-2631",
        "Doc_title":" Discovery of SC110237, a highly potent, selective and orally active FLT3 inhibitor for the treatment of acute myeloid leukemia",
        "_version_":1606189042067570688},
      {
        "Meeting_name":" Pim-1 kinase inhibition in the absence of FLT3 inhibition results in cytostatic effects in acute myeloid leukemia cells",
        "Background":"['The serine threonine kinase Pim-1 regulates expression of proteins involved in cell cycle, proliferation, apoptosis and drug resistance. Pim-1 has been identified as a potential therapeutic target in acute myeloid leukemia (AML). Notably, it is overexpressed downstream of FLT3 with internal tandem duplication (ITD), present in 30% of AML cases and associated with adverse treatment outcomes. SGI-1776 is the only Pim inhibitor in clinical testing to date, but testing was discontinued due to QTc prolongation. SGI-1776 has been used in laboratory studies of AML, but is also a FLT3 inhibitor, and effects of Pim-1 and FLT3 inhibition have been difficult to distinguish, particularly in cells with FLT3-ITD. To better characterize the effects of Pim-1 inhibition in AML, we compared SGI-1776 (from SuperGen, Inc., Dublin, CA) with two Pim inhibitors without FLT3 inhibitory activity, SMI-4a and quercetagetin in FLT3-wt and FLT3-ITD cells in 96-hour WST-1 cell viability, flow cytometric cell cycle and apoptosis, colony formation and liquid culture proliferation assays. SGI-1776 had no effect on cell cycle in FLT3-wt cells at concentrations up to 5 M, and caused apoptosis at 10 M, while G1 arrest and apoptosis occurred at 100 nM in FLT3-ITD cells, and SMI-4a and quercetagetin did not alter cell cycle nor induce apoptosis in FLT3-wt nor FLT3-ITD cell lines. IC50 (M) comparisons are summarized below', ' In liquid culture assays, all three Pim inhibitors slowed proliferation of all cell lines, indicating a cytostatic effect. Thus FLT3 inhibition plays a substantial role in the cellular effects of SGI-1776, and Pim inhibitors without FLT3 inhibitory activity appear to have primarily cytostatic effects in AML cells. Other Pim kinase inhibitors in development should be characterized with regard to pro-apoptotic versus cytostatic effects.']",
        "Doc_id":"AACR_2012-4581",
        "Doc_title":" Pim-1 kinase inhibition in the absence of FLT3 inhibition results in cytostatic effects in acute myeloid leukemia cells",
        "_version_":1606188978368675840},
      {
        "Meeting_name":" FLT3-driven redox signalling in acute myeloid leukemia",
        "Background":"['The concept of reactive oxygen species (ROS) being produced via the activation of specific oncogenes provides a basis for generating genomic instability and pro-survival signalling in tumor cells. The purpose of this study was to identify downstream targets of NADPH oxidase (Nox)-derived ROS signalling in acute myeloid leukemia cells, by performing a proteomic analysis utilizing two-dimensional phosphotyrosine immnoblotting. The majority of the targets identified were cytoskeletal-associated proteins including Ezrin, a known regulator of the cytoskeleton, which was examined further. The study demonstrated that inhibition of Nox enzymes, using diphenyleneiodonium chloride in the acute myeloid leukemia cell line MOLM-13, resulted in a decrease in Ezrin tyrosine phosphorylation and also triggered a shift in Ezrin sub-cellular localization as detected by immunofluorescence. The change in Ezrin localization coincided with altered cell morphology, observed using scanning electron microscopy and a decreased ability to migrate through a polycarbonate transwell membrane. Similar effects were observed upon inhibition of the oncogenic receptor tyrosine kinase FLT3 using the staurosporine derivate PKC412, implicating a role for FLT3 as an upstream regulator of Ezrin. Our results indicate that FLT3 drives production of ROS by Nox, which stimulates changes in Ezrin tyrosine phosphorylation and localization via redox regulation of Src. Furthermore, the modulation of Ezrin by FLT3 leads to subsequent alterations of MOLM-13 cell morphology and a significant influence on cell motility.']",
        "Doc_id":"AACR_2012-2545",
        "Doc_title":" FLT3-driven redox signalling in acute myeloid leukemia",
        "_version_":1606188993510113280},
      {
        "Meeting_name":" A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.",
        "Background":"['Background', ' FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML) and FLT3 internal tandem duplication (ITD) mutations are associated with high relapse rates, short remission durations, and poor overall survival (OS). Gilteritinib (ASP2215) is a highly selective FLT3 tyrosine kinase inhibitor with activity against FLT3-ITD mutations. It also inhibits FLT3-D835 mutations that can confer clinical resistance to other FLT3 inhibitors. A phase 1/2 study of gilteritinib in relapsed/refractory AML showed favorable tolerability across a wide dose range and consistent, potent, FLT3 inhibition in correlative assays. Cohort expansion in FLT3-mutated patients generated an overall response rate of 55% (CR/CRp/CRi = 44%, PR = 11%) and survival that was longer than in prior reports of cytotoxic chemotherapy or other FLT3 inhibitors. Therefore, a phase 3 trial was initiated. Methods', ' This randomized phase 3 study (NCT02421939) will enroll 369 adult AML subjects at ~140 centers across North America, Europe, and Asia. Subjects must be in first relapse or refractory to frontline therapy and have a centrally confirmed FLT3 mutation. Subjects will be randomized 2', '1 to treatment with either 120 mg gilteritinib QD or to investigators pre-randomization choice of specified salvage chemotherapy. Randomization will be stratified by prior chemotherapy response and salvage chemotherapy regimen intensity. Subjects randomized to gilteritinib or low-intensity chemotherapy will receive continuous 28-day cycles until a discontinuation event occurs; high-intensity chemotherapy subjects will receive up to 2 cycles before response measurement. The primary objective is OS; key secondary objectives are event-free survival and complete remission (CR) rate. Other secondary objectives include leukemia-free survival, remission duration, composite CR rate, subsequent transplantation rate, patient-reported fatigue, and overall safety. A formal interim analysis is planned after ~50% of deaths have occurred. Study enrollment began October 23, 2015; as of February 1, 2016, 10 subjects have been randomized. Clinical trial information', ' NCT02421939']",
        "Doc_id":"ASCO_165082-176",
        "Doc_title":" A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.",
        "_version_":1606189005758529536},
      {
        "Meeting_name":" CDK4/FLT3 dual inhibitors as potential therapeutics for acute myeloid leukemia.",
        "Background":"['CDK4 is a cyclin D dependent kinase that promotes cell cycle progression in a broad range of tumor types by phosphorylating the tumor suppressor retinoblastoma protein (Rb) and releasing transcription factor E2F. Critical involvement of the cyclin D-CDK4-Rb pathway in carcinogenesis is strongly supported by a large amount of genetic evidence. In addition, promoter methylation with consequent silencing of expression of the CDK4 inhibitor, p15, has been reported in 44-60% of acute myeloid leukemia (AML) patients. It is also well established that constitutive activation of the tyrosine kinase FLT3 via mutation contributes to the development of AML, with 30% of AML carrying such activating mutations. FLT3 tyrosine kinase inhibitors used as single agents reduce peripheral blood and bone marrow blasts in only a minority of AML patients, and the effect tends to be transient. This may be due to insufficient FLT3 inhibition, the selection of drug-resistant clones, or the independence of the cell on FLT3 signaling for proliferation and survival. In preclinical models, a synergistic effect of CDK4 inhibition and FLT3 inhibition resulting in increased apoptosis of AML cell lines was reported (Wang et al., Blood, 2007). From a HTS hit through SAR optimization led to AM-5992, a potent and orally bioavailable dual inhibitor of CDK4 and FLT3 including all FLT3 mutants reported to date. AM-5992 inhibits the proliferation of a panel of human tumor cell lines including MDA-MB-435(Rb+), colo-205(Rb+), U937(FLT3WT) and induced cell death in MOLM13(FLT3ITD), MV4-11(FLT3ITD), and even in MOLM13(FLT3ITD, D835Y) which exhibits resistance to a number of FLT3 inhibitors currently under clinical development. In mouse models of leukemia using cells with the FLT3ITD mutation, AM-5992 treatment at 150 mpk qd on days 6-16 after leukemia cell injection significantly reduced the leukemia burden and prolonged survival 11 days over that of vehicle controls. Collectively, these data support the hypothesis that simultaneously inhibition of CDK4 and FLT3 may improve the durability of clinical response in AML; and consequently that this hypothesis should be tested in the clinic.']",
        "Doc_id":"AACR_2013-2351",
        "Doc_title":" CDK4/FLT3 dual inhibitors as potential therapeutics for acute myeloid leukemia.",
        "_version_":1606188981530132480},
      {
        "Meeting_name":" The clinically applicable pan-Pim kinase inhibitor PIM447 sensitizes acute myeloid leukemia cells with FLT3-ITD to induction of apoptosis by FLT3 inhibitors and by topoisomerase 2 inhibitors",
        "Background":"['Introduction', 'Internal tandem duplication of the fms-like tyrosine kinase-3 receptor (FLT3-ITD) is present in acute myeloid leukemia (AML) cells in 30% of patients and these patients have short disease-free survival following chemotherapy. FLT3 inhibitors are clinically active, but their activity is limited and transient. The oncogenic serine/threonine kinase Pim-1 is transcriptionally upregulated downstream of FLT3-ITD, and promotes FLT3 signaling in a positive feedback loop in FLT3-ITD cells. We have previously demonstrated that inhibiting Pim kinase sensitizes AML cell lines and primary AML patient blasts with FLT3-ITD to induction of apoptosis by FLT3 inhibitors and by topoisomerase 2 inhibitor chemotherapy drugs. Here we studied the effects of the pan-Pim kinase inhibitor PIM447 (formerly LGH447; Novartis Pharmaceuticals), currently in clinical trials, on response of FLT3-ITD-expressing cell lines and AML patient samples to FLT3 inhibitors and to topoisomerase 2 inhibitors, with the ultimate goal of developing clinically applicable combination regimens.Methods', 'Cell lines and AML patient samples with FLT3-ITD were cultured with FLT3 inhibitors or topoisomerase 2 inhibitors at clinically applicable concentrations and PIM447 at a range of concentrations. Apoptosis was measured by Annexin V labeling and PARP cleavage. Mcl-1 expression was measured by immunoblotting. Reactive oxygen species (ROS) were measured with the redox-sensitive dye CM-H2DCFDA and DNA double-strand breaks (DSBs) by immunoblotting for H2AX.Results', 'Transfected Ba/F3-ITD and 32D/ITD cells, MV4-11 and MOLM-14 human AML cells and primary AML patient blasts, all expressing FLT3-ITD, were treated with FLT3 inhibitors, including 100 nM midostaurin and 1 nM quizartinib, with 0, 10, 100 and 500 nM PIM447. Co-treatment with PIM447 produced a concentration-dependent increase in apoptosis induced by each FLT3 inhibitor (p<0.001). FLT3-ITD-expressing cells were also treated with the topoisomerase 2 inhibitors daunorubicin and etoposide at IC50 concentrations, with 0, 10, 100 and 500 nM PIM447. Co-treatment with PIM447 also produced a concentration-dependent increase in apoptosis induced by each topoisomerase 2 inhibitor (p<0.001). Increased apoptosis induced by PIM447 with FLT3 inhibitors was associated with Mcl-1 downregulation, while increased apoptosis induced by PIM447 with topoisomerase 2 inhibitors was associated with increased generation of ROS and increased DNA DSBs.Conclusions', 'The clinically applicable pan-Pim kinase inhibitor PIM447 sensitizes AML cells with FLT3-ITD to induction of apoptosis by FLT3 inhibitors and by topoisomerase 2 inhibitors. Our data support in vivo testing of combination regimens and design of clinical trials aimed at improving outcomes for patients with AML with FLT3-ITD.']",
        "Doc_id":"AACR_2016-3866",
        "Doc_title":" The clinically applicable pan-Pim kinase inhibitor PIM447 sensitizes acute myeloid leukemia cells with FLT3-ITD to induction of apoptosis by FLT3 inhibitors and by topoisomerase 2 inhibitors",
        "_version_":1606189030350782464},
      {
        "Meeting_name":" FYN expression potentiates FLT3-ITD-induced mitogenic signaling in acute myeloid leukemia",
        "Background":"['FYN is a non-receptor tyrosine kinase belonging to the SRC family of kinases. SRC family kinases are frequently over-expressed in human cancers, and play key roles in cancer cell invasion, metastasis, proliferation, survival and many other biological processes. SRC has long been recognized as an important oncogene; but little attention has been given to its other family members such as FYN. In this report, we have studied the role of FYN in FLT3 signaling with respect to acute myeloid leukemia (AML). FLT3 is a type III receptor tyrosine kinase which is found to be mutated in around 30% of AML cases. We observed that FYN displays a strong association with wild-type FLT3 as well as oncogenic FLT3-ITD. While association with wild-type FLT3 is dependent on ligand stimulation, it is constitutively associated with FLT3-ITD. In addition, a kinase-dead FLT3 mutant was unable to associate with FYN suggesting that FLT3 activation is required for association with FYN. A FYN SH2-domain mutant lacking a critical arginine residue was unable to associate with FLT3 indicating that FYN associates with FLT3 through its SH2 domain. A phopho-peptide fishing experiment identified multiple FYN binding sites in FLT3, which partially overlap with the known SRC binding sites but also differ from these sites. To understand the role of FYN in FLT3 signaling, we have generated Ba/F3-FLT3/FYN or Ba/F3-FLT3/empty vector cell lines. We observed that expression of FYN results in enhanced phosphorylation of AKT, ERK1/2 and p38 phosphorylation in response to ligand stimulation. Ba/F3-FLT3-ITD cells overexpressing FYN also showed higher STAT5 activation. Furthermore, FYN expression led to a significant increase in FLT3-ITD-dependent cell proliferation but did not alter apoptosis induced by cytokine starvation. Finally, we showed that FYN expression was deregulated in AML patient samples and that higher expression of FYN in combination with FLT3-ITD expression correlates with poor prognosis in AML. Taken together our data suggest that FYN cooperates with oncogenic FLT3-ITD which results in poor prognosis in AML and therefore inhibition of FYN in combination with FLT3 inhibition will most likely be beneficial for AML patients.']",
        "Doc_id":"AACR_2016-1135",
        "Doc_title":" FYN expression potentiates FLT3-ITD-induced mitogenic signaling in acute myeloid leukemia",
        "_version_":1606188991605899264},
      {
        "Meeting_name":" Race and overall survival in acute myeloid leukemia.",
        "Background":"['Background', ' Racial differences in outcomes have been identified in a number of malignancies, but have not been extensively studied in the adult acute myeloid leukemia (AML) population. Our goal was to determine if overall survival (OS) in AML differs by race. Methods', ' Patients with AML evaluated at the University of Maryland Greenebaum Cancer Center from 2000 through 2009 were reviewed for age, sex, race, karyotype and FLT3 status. Cytogenetic data were categorized by Southwest Oncology Group risk criteria. OS was evaluated by the method of Kaplan and Meier. Results', ' 548 AML patients were identified. Racial distribution was 72% white, 20% black, and 8% other. Cytogenetic data were available for 93% and FLT3 data for 32%. Cytogenetic and molecular findings and OS (months) were compared in black and white patients (see Table). While blacks had a higher incidence of complex karyotypes (27% vs. 13%, p=0.002) and a lower incidence of normal karyotypes (30% vs. 45%, p=0.04), OS did not differ (15 vs. 14 months; p NS) and did not differ within cytogenetic subsets. OS of black males was longer than that of white males (21 vs. 12 months, p=0.02), likely attributable to a younger median age (53 vs. 63 years, p<0.001) and a trend toward a higher incidence of t(15;17) (13% vs. 6%, p=0.09) in black males. Females did not differ by race in median age or OS but there was a much higher incidence of complex karyotypes in black females (30% vs. 12%, p=0.003) and also a trend toward more total unfavorable karyotypes (45% vs. 28%, p=0.06). Additionally, in intermediate karyotype patients, wild type FLT3 status more strongly predicted OS in blacks (NR vs. 7 months; p=0.03) than in whites (18 vs. 13 months, p=0.07). Conclusions', ' While there are biologic differences in AML between black and white patients, OS does not differ. White Blackn (%) median OS n (%) median OS pAll patients 368 14 99 15 0.21 t (15;17) 24 (7) * 9 (9) 55 0.31 Favorable 23 (6) 42 9 (9) * 0.31 Normal 165 (45) 20 30 (30) 15 0.30 All intermediate 208 (57) 15 43 (43) 16 0.26 Wild-type FLT3 45 18 6 * 0.03 Mutated FLT3 32 10 7 7 0.17 Complex 49 (13) 7 27 (27) 8 0.48 All unfavorable113 (31) 7 38 (38) 8 0.81* Not reached.']",
        "Doc_id":"ASCO_50851-74",
        "Doc_title":" Race and overall survival in acute myeloid leukemia.",
        "_version_":1606188979055493120},
      {
        "Meeting_name":" Covalent Flt3-Cys828 inhibition represents a novel therapeutic approach for the treatment of Flt3-ITD and Flt3-D835 mutant acute myeloid leukemia",
        "Background":"['Inhibition of Flt3 kinase activity is a promising strategy for the treatment of Flt3 mutant acute myeloid leukemia (AML). However, clinical studies with Flt3 kinase inhibitors have shown that mutations of the gate keeper or an activation loop residue in the Flt3 catalytic domain limits the duration of response. Such mutations generally reduce kinase domain binding affinity and residence time of the kinase inhibitor, and consequently its efficacy. We therefore investigated whether covalent, irreversible binding to Flt3 could overcome some of the limitations of classic non-covalent Flt3 inhibitors. Here, we report for the first time on the high-affinity Cys828-covalent binding mode of a resorcylic acid lactone to the isolated Flt3 kinase domain using X-ray crystallography and kinetic binding assays. In a cellular context (Ba/F3-Flt3-ITD), mutation of Cys828 to Ala reduces potency (IC50) from low nM to microM, demonstrating all relevant Flt3 inhibition in cells critically depends on Cys828. Consistently, the molecule is a low nM inhibitor of both Flt3-ITD and Flt3D835Y in vitro and in BaF3 cells, translating to potent nM inhibition of Flt3-ITD driven AML cell line proliferation, with only microM antiproliferative activity in non-Flt3 driven AML and unrelated leukemia cell lines. Finally, in spite of its fast clearance when dosed to MV4-11 (Flt3-ITD AML) xenograft bearing mice, robust anti-tumor activity was observed using a once-daily treatment schedule. These data demonstrate the feasibility of covalent Flt3 inhibition, and suggest it represents an attractive novel therapeutic approach for the treatment of Flt3-driven AML.']",
        "Doc_id":"AACR_2016-4800",
        "Doc_title":" Covalent Flt3-Cys828 inhibition represents a novel therapeutic approach for the treatment of Flt3-ITD and Flt3-D835 mutant acute myeloid leukemia",
        "_version_":1606188994642575360},
      {
        "Meeting_name":" Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib.",
        "Background":"['Background', '    Outcome of patients with relapsed acute myeloid leukemia (AML) with FLT3-ITD mutation is poor. Elevated FLT3 ligand levels (FL) secondary to cytotoxic chemotherapy is a putative mechanism of resistance to the FLT3 kinase inhibitors. We hypothesized that FL levels will be lower when combining sorafenib with less intensive therapy such as 5-Azacytidine (5-Aza). This study was conducted to evaluate the efficacy and tolerability of the combination of sorafenib and 5-Aza in patients with refractory or relapsed AML with FLT3-ITD mutation.  Methods', '    Patients were eligible if they had relapsed or refractory AML and were 18 years of age or older. They received 5-Aza 75 mg/m2 IV daily x 7 days and sorafenib 400 mg PO BID continuously; cycles were repeated in approximately one month intervals.  Results', '    38 patients with AML with a median age of 60 years (range, 24-87) were enrolled. 4 were inevaluable as they never received therapy or discontinued it before response assessment.  FLT-3-ITD was detected in 30 (88%) patients. They had received a median of 2 prior treatments (range, 0-6); 13 (38%) had received  3 prior regimens and 8 had failed prior FLT3 kinase inhibitor. Response rate was 41%, including 6 (17%) with CRi, 4 (12) with CRp, 3 (9%) with CR, and 1(3%) PR. The median time to achieving CR/CRi was 2 cycles (Range, 1-6) and the median duration of CR/CRi was 3 months (Range, 112).  Conclusions', '   Combination of 5-Aza and sorafenib is effective for patients with relapsed AML with FLT-3-ITD mutation.']",
        "Doc_id":"ASCO_103555-127",
        "Doc_title":" Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib.",
        "_version_":1606188983800299520},
      {
        "Meeting_name":" Targeting E-selectin/CXCR4 with GMI-1359 effectively mobilizes bone marrow leukemia cells and enhances FLT3 inhibitor-induced anti-leukemia efficacy in a murine acute myeloid leukemia model",
        "Background":"['FLT3 internal tandem duplication (ITD) mutations are the most common alterations in acute myeloid leukemia (AML) and are associated with poor disease prognosis. Targeted therapy using FLT3-ITD inhibitors showed limited effect in reducing leukemia blasts in bone marrow (BM) than that in peripheral blood. The BM microenvironment is enriched with cytokines and adhesion molecules, such as CXCR4 and E-selectin, which are believed to provide AML cells protection against chemotherapeutic agents. Therefore, blocking CXCR4 and E-selectin concomitantly with FLT3 inhibition could theoretically eliminate the protection in FLT3-mutant AML patients. We recently reported that targeting CXCR4/E-selectin with the dual inhibitor GMI-1359 showed significant prolongation of survival of mice engrafted with FLT3-ITD mutant MV4-11 leukemia cells. In the present study, we further investigated anti-leukemia effects of dual CXCR4/E-selectin inhibition. Results indicate efficient mobilization of leukemia cells into the circulation by GMI-1359 in a MOLM14-engrafted murine model 2h after drug treatment, which was 3.3-fold ( 0.3) higher compared with the CXCR4 antagonist plerixafor, and 7.4-fold ( 2.7) higher compared with controls. In addition, GMI-1359 also mobilized normal murine leukocytes from the BM, suggesting that GMI-1359 may block interactions of leukemia cells with various BM components. Combination therapy of GMI-1359 and sorafenib significantly reduced leukemia burden (1.9e7 vs. 2.3e9, 1.0e9 and 8.5e7 photons/sec in the combination group versus control, GMI-1359 and sorafenib groups, respectively, at day 20 as determined by Xenogen IVIS bioluminescence Imaging; p < 0.001). Moreover, the combination treatment profoundly reduced leukemia burden in the BM of leukemic mice after a 15-day treatment (1.7e7 vs. 1.6e9, 6.3e8 and 7.0e7 photons/sec, p < 0.01; and 1.76% vs. 70.96%, 72.8% and 33.8%.leukemia cell engraftment measured as GFP positive leukemic cells in BM by flow cytometry, in the combination group vs. vehicle, GMI-1359 and Sorafenib groups, respectively, p < 0.01). Of note, the combination therapy profoundly extended the median survival of the leukemia-bearing mice from 27 days in the control group to 46.5 days in the combination treatment groups (p < 0.001). Mechanistically, we demonstrated that direct blockade of the interaction of E-selectin-CXCR4/SDF-1 with GMI-1359 was critical for leukemic cell mobilization via the disruption of adhesion to stromal cells. Furthermore, the presence of GMI-1359 enhanced sorafenib-induced apoptosis in FLT3-ITD mutated leukemic cells co-cultured with stromal cells. This effect occurred even under hypoxia, which is characteristic for the leukemic BM microenvironment. These findings provide the pre-clinical basis for the evaluation of GMI-1359 in patients with FLT3-mutant AML.']",
        "Doc_id":"AACR_2016-3284",
        "Doc_title":" Targeting E-selectin/CXCR4 with GMI-1359 effectively mobilizes bone marrow leukemia cells and enhances FLT3 inhibitor-induced anti-leukemia efficacy in a murine acute myeloid leukemia model",
        "_version_":1606189032239267840},
      {
        "Meeting_name":" High efficacy of T-LAK cell-originated protein kinase inhibitor in acute myeloid leukemia with FLT3-ITD mutation",
        "Background":"['The internal tandem duplication (FLT3-ITD) a gain-of-function mutation of FLT3, is associated with poor outcome in acute myeloid leukemia (AML). The use of FLT3 inhibitors currently undergoing clinical investigation has not yet improved overall survival. Therefore, novel therapies are needed. T-LAK cell-originated protein kinase (TOPK), a serine-threonine protein kinase, is highly expressed and associated with an aggressive cancer phenotype, but is hardly detectable in normal tissues. Here, we investigate TOPK in AML and demonstrate that it is highly expressed in most AML cell lines and some primary blasts, but is not detected in CD34+ cells of healthy donors. MV4-11 and U937 cells transfected with TOPK-siRNA showed significant decrease in cell viability (70%, P<0.001). We then examined the anti-leukemia activity of TOPK inhibitor OTS514 in AML. Primary blasts obtained from 3 patients (pts) with AML showed significant decrease in cell viability in a dose-dependent manner (IC50 values were 10-20nM). Moreover, OTS514 treatment resulted in significant decrease in number of colonies of CD34+ cells obtained from a pt with AML (41 vs 73, P = 0.01), but not of CD34+ cells obtained from healthy donors (39 vs 36, P = 0.67).Treatment of 10 AML cell lines with OTS514 showed that FLT3 mutated cell lines were significantly more sensitive (IC5020nM). Annexin/PI staining showed 80% and 70% increase in apoptosis in FLT3-ITDmut cells (MV4-11 and MOLM13) treated with OTS514 (40nM; 48hrs). In contrast, only 40% and 10% apoptosis was observed in FLT3wt cells (U937 and KG1, respectively) treated under the same conditions. Additionally, cell cycle analysis in cells treated with OTS514 (20nM; 24 and 48 hrs) showed a dramatic decrease of S phase (98%; P = 0.003) in MV4-11 but only 70% (P<0.001) and 30% (P = 0.02) in THP-1 (FLT3wt) cells compared with untreated cells.Importantly, OTS514 treatment decreased cell viability and increased cell differentiation and apoptosis in primary blasts from pts relapsed after FLT3 inhibitor treatment (AC220). Furthermore, using a MV4-11-engrafted mouse model, we found that mice treated with 7.5mg/kg IV every day for 3 weeks survived significantly longer than vehicle treated mice (median survival 46 vs 29, P<0.001). Mechanistically, OTS514 or TOPK-siRNA significantly decreased FLT3 mRNA and protein levels and decreased CEBPA phosphorylation in FLT3-ITDmut cells. Furthermore, activating FLT3 in THP-1 cells via FLT3 ligand increased TOPK protein. Also, FLT3 knockdown or inhibition with MLN518 (50 and 100nM) decreased TOPK levels in MV4-11 and MOLM13 cells, but not in U937 cells, suggesting that TOPK is a downstream target of FLT3.In conclusion, TOPK inhibitor exhibits preferential activity in FLT3-ITDmut AML, partially via inhibition of FLT3 expression. Thus, OTS514 represents new targeted therapy for this adverse risk subset of AML.']",
        "Doc_id":"AACR_2015-4381",
        "Doc_title":" High efficacy of T-LAK cell-originated protein kinase inhibitor in acute myeloid leukemia with FLT3-ITD mutation",
        "_version_":1606188971278204928},
      {
        "Meeting_name":" Recurrently detected germline mutation of FLT3 (D358V) associated with prevalence of hematopoietic malignancy and prognosis of AML patients.",
        "Background":"['FLT3 is most frequently mutated gene in acute myeloid leukemia patients. While somatic mutation of FLT3 is well known, germline mutation of FLT3 and predispose to AML remain poorly understood. Here we identify a germline FLT3 p.D358V affected prognosis of AML patients. We performed whole exome sequencing (WES) using 76 patientsâ€™ saliva sample to detect FLT3 germline mutation in buccal epithelial cell and demonstrate FLT3 p.D358V mutation for 6 patients among 76 patients. The frequency of FLT3 p.D358V mutation in AML patients is significantly higher in general population (p=9.50E-07), suggesting association of FLT3 mutation with AML predisposition. Asian population especially carried this locus more than other ethic population. When we compared between AML patients and general population of Asian, the chi-square p-value was 0.07 and odd ratio was 2.26. Overall survival was significantly reduced in patients who had FLT3 p.D358V mutation (p=0.03) and disease free survival was show a tendency of reducing in the patients with FLT3 p.D358V mutation.']",
        "Doc_id":"AACR_2017-3565",
        "Doc_title":" Recurrently detected germline mutation of FLT3 (D358V) associated with prevalence of hematopoietic malignancy and prognosis of AML patients.",
        "_version_":1606189018074054656},
      {
        "Meeting_name":" Systematic analysis of potential targets for immunotherapy in acute myeloid leukemia.",
        "Background":"['Background', '   The ability to target myeloid malignancies using immunotherapy, without allogeneic transplantation, depends on the capability to target leukemic clones while sparing normal tissues.  A variety of putative leukemia associated antigens (LAA) have been identified but an evidence-based list of targets for acute myeloid leukemia (AML) has not yet been established.  Methods', '   De-identified, clinically annotated, samples of peripheral blood and/or bone marrow aspirate from untreated AML patients were collected under IRB-approved protocols from three NCCN cancer centers.  Samples were analyzed for commonly observed somatic mutations in ASXL1, DNMT3A, FLT3, IDH1/2, KIT, NPM1, NRAS, RUNX1, TET2, and WT1.  Gene expression of 75 consensus LAAs were determined using a custom-designed RT-PCR array. 12 samples underwent extended LAA analysis by flow sorting into bulk leukemia and stem cell enriched populations.  LAA expression was normalized using the geometric mean of three control genes.   Results', '  Samples from 48 AML patients (30 blood, 22 marrow) were suitable for analysis. Average age of patients was 53 (24-86), 50% were female.  Cytogenetics were favorable (17%), intermediate (65%) or adverse (19%); 29% presented with a white blood cell count >50,000.  Over 10,000 individual data-points were collected. Five distinct patterns of LAA expression were observed in blood from AML patients compared to healthy donors. Conclusions', '   Understanding the heterogeneity and patterns of AML LAA expression between individuals allows the rational prioritization of potential targets for immunotherapy.  Based on our data we predict that targeting any single LAA will likely often be ineffective but that it may be possible to create an inclusive panel of multiple targets with coverage of most AMLs, eliminating the need for individualized personalization of therapy.  Such AML antigen signatures may also have utility for minimal residual disease monitoring.']",
        "Doc_id":"ASCO_117212-132",
        "Doc_title":" Systematic analysis of potential targets for immunotherapy in acute myeloid leukemia.",
        "_version_":1606188976521084928},
      {
        "Meeting_name":" Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML).",
        "Background":"['Background', ' Mutations of the FLT3 gene (in special internal tandem duplication -ITD) are common in normal karyotype AML (NK-AML) and are associated with shorter relapse free and overall survival (OS). The frequency of FLT3 mutations is lower in other cytogenetic subgroups and the impact on outcome is unclear. Methods', ' The records of patients (pts) with newly diagnosed AML (from 2003 to 2007) were reviewed. Pts were divided among three cytogenetic subgroups', ' Good-risk (t(8;21), Inv(16)/t(16;16)) Intermediate-Risk (Diploid,-Y) and Poor Risk (-5,-7, 11q abnormalities). FLT3 ITD and tyrosine kinase domain (TKD) mutations were determined on baseline DNA samples by a PCR based method with 1% sensitivity. Since the frequencies of FLT3 mutations were lower in good- and poor-risk subgroups, ITD/TKD mutations were considered together in the analysis, while in the intermediate risk group they were analyzed separately. Survival curves stratified by FLT3 mutation were estimated by Kaplan Meier plots and compared by logrank test. A Cox model was fit for OS, and non-significant variables were eliminated in a step-down fashion with a p- value cut-off of p = .10. Results', ' A total of 481 pts were included (65 pts=good risk, 272 pts=intermediate risk and 144 pts= poor risk). Prevalence of FLT3 mutations is shown in the Table. No difference was found in median OS between FLT3-mutated and FLT3- wild type pts in the good risk group (not reached (NR) vs NR, P = 0.57) nor in the poor risk group (55 vs 24 weeks, P = 0.44). In intermediate risk, OS was worse in FLT3-ITD positive pts (33 vs 89 weeks, P < 0.0001) but not in FLT3-TKD positive pts (77 vs 70 weeks, P = 0.89). In the Cox model, FLT3 mutations were prognostic for OS only in intermediate risk pts with FLT3-ITD (HR 2.63, P < 0.0001). Conclusions', ' In our cohort of pts, FLT3 mutations did not have a prognostic impact in AML with good and poor risk karyotype. Prevalence of FLT3 mutation in AML by cytogenetic groupCytogeneticsFLT3-All, n (%)FLT3- ITD, n (%)FLT3-TKD, n (%)Good Risk13 (20)5 (7.6)11 (17)*Intermediate Risk87 (32)67 (25)28 (10)**Poor Risk11 (7.6)3 (2)8 (5.5)*- 3  pts', ' double positive; **- 8 pts', ' double positive']",
        "Doc_id":"ASCO_34733-65",
        "Doc_title":" Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML).",
        "_version_":1606188991720194048},
      {
        "Meeting_name":" The AKT inhibitor MK-2206 promotes apoptosis in acute myeloid leukemia cells",
        "Background":"['The need for improved therapies for acute myeloid leukemia (AML) is urgent as the disease is still highly fatal. Protein Kinase B (AKT) activation has been shown to predict poor clinical outcome for patients with AML. In 253 newly diagnosed AML cases, we have found that AKT phosphorylation on Thr308 analyzed by reverse-phase protein arrays was significantly higher in patients with unfavorable cytogenetics (p=0.037). The adverse prognostic factor of high levels of pAKT was observed among patients with intermediate-risk cytogenetics (p=0.013), as it was associated with an inferior survival (median survival 44.2 weeks) compared to patients with low or intermediate pAKT (78.7 weeks). Recently, Merck Sharp & Dohme Corp. has developed a compound, MK-2206, that is a highly specific allosteric inhibitor for all three AKT isoforms. In the current study, we have determined that MK-2206 as a single agent used at clinically achievable concentrations suppresses cell growth of a variety of AML derived cell lines including OCI-AML3, U937, and MOLM13. MK-2206 can also induce apoptosis in blast cells derived from AML patients. Consistent with its role as an AKT inhibitor, the drug suppresses phosphorylation of AKT at serine 473 and inhibits phosphorylation of AKT downstream targets including S6 ribosomal protein, 4-EBP1, and PRAS40 in the AML cells. We recently identified that low expression of the PP2A isoform that acts as the AKT phosphatase (i.e. the one containing the B55 subunit) in AML negatively correlates with AKT T308 phosphorylation and activation in a cohort of 511 AML patients (Ruvolo et al Leukemia, 2011). Patients with low B55 expression exhibited shorter complete remission duration. We suppressed B55 expression by shRNA in OCI-AML3 cells to determine if loss of the AKT phosphatase promotes AKT activation and chemoresistance. Cells with reduced B55 exhibited higher levels of AKT phosphorylation and were more resistant to killing by the conventional chemotherapy agent AraC. OCI-AML3 B55 shRNA transductant cells were also more resistant to MK-2206 compared to cells expressing control non-specific shRNA. These results suggest that AKT phosphatase activity in AML may affect response to MK-2206. A recent study in liver cancer demonstrated that MK-2206 synergized with the multi-kinase inhibitor Sorafenib. Since Sorafenib targets the Fms-like tyrosine kinase 3 (FLT3) and mutations that activate the kinase in AML confer poor prognosis, we examined if MK-2206 could synergize with Sorafenib to kill leukemia cells with mutation of FLT3 internal tandem duplication (ITD) mutation. The combination of MK-2206 and Sorafenib was effective at killing MOLM13 cells and AML blast cells with the FLT3-ITD. Taken together, these findings suggest that MK-2206 may be effective to block AKT signaling pathways and could be beneficial as a therapeutic agent perhaps as a single agent or in combination with a drug such as Sorafenib in the therapy of AML.']",
        "Doc_id":"AACR_2012-3659",
        "Doc_title":" The AKT inhibitor MK-2206 promotes apoptosis in acute myeloid leukemia cells",
        "_version_":1606188971427102720},
      {
        "Meeting_name":" Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia.",
        "Background":"['Background', '    LY3012218 (IMC-EB10) is a monoclonal antibody that binds FLT3 with high affinity and prevents binding of the FLT3-ligand and downstream signaling. Preclinical data using LY301228 demonstrates anti-leukemia activity which appears to be mediated via antibody dependent cell-mediated cytotoxicity (ADCC).   Methods', '    We conducted a phase 1 trial to determine the safety, pharmacokinetics, and preliminary efficacy of LY3012218 in patients with relapsed/refractory acute myeloid leukemia (AML). Patients were eligible if they were  18 years, had a performance status < 3, adequate organ function, a life expectancy of > 3 months, and were not candidates for higher intensity therapy. Exclusion criteria included stem cell transplant within < 3 months, central nervous system leukemia or isolated extramedullary disease. Patients were treated in 4 dose cohorts (5 mg/kg (n = 3), 10 mg/kg (n = 13), 20 mg/kg (n = 3), 30 mg/kg (n = 5)) and received the drug intravenously weekly on days 1, 8, and 15 for cycle 1 and days 1, 8, 15, and 22 for subsequent cycles.  Results', '    31 patients were screened and 24 patients were treated. 14 patients were male (58.3%), the median age was 70.3 years (range 26-82), the median number of prior therapies was 2 (range 1-6) and 26% had a baseline FLT3 mutation. 12 patients reported 20 serious AEs with the most frequent including', ' pneumonia (n = 6, 25%), neutropenia (n = 3, 12.5%) and sepsis (n = 2, 8.3%). Dose limiting toxicities of infection, vomiting (10 mg/kg), and increased transaminases (30 mg/kg) were observed, although these were not clearly related to LY3012218. No MTD was defined. The serum trough concentrations for 5 to 30 mg/kg treatments (mean of Cmin', ' 41.9 to 739 g/mL) following the third infusion were above the target trough concentration (33 g/mL) associated with antitumor activity in preclinical models. Twenty one patients were evaluated for response and all were classified as treatment failures.  Conclusions', '    Treatment with LY3012218 appears safe but did not demonstrate clinical activity as a single agent in relapsed/refractory AML. The lack of efficacy may be due to an absence of ADCC with LY3012218 or the presence of ligand-independent activation of signaling pathways down-stream of FLT3. Clinical trial information', ' NCT00887926']",
        "Doc_id":"ASCO_150588-156",
        "Doc_title":" Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia.",
        "_version_":1606188995888283649},
      {
        "Meeting_name":" AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status",
        "Background":"['FLT3 is a member of the class III receptor tyrosine kinase family that includes C-KIT, C-FMS and platelet derived growth factor receptor (PDGFR). FLT3 is primarily expressed in early myeloid and lymphoid progenitors and plays an important role in their proliferation and differentiation. In human leukemia, FLT3 is expressed on 70-90% acute myeloid leukemia (AML) and most B-acute lymphoblastic leukemia (B-ALL). FLT3 genetic aberrations are commonly detected in patients with AML. The most common aberration is internal tandem duplication (ITD), which occurs in 25-30% of AML patients and causes constitutive activation of FLT3. Point mutation in codon D835 of the FLT3 tyrosine kinase domain is reported in 7-10% of AML patients and also causes constitutive activation of the receptor. FLT3 small molecule inhibitors targeting the kinase domain are predominantly active against FLT3 activated AML. The restricted normal tissue expression profile and higher differential in leukemic specimens makes FLT3 amenable to antibody-based therapeutics, requiring only target expression independent of kinase activation status. Therefore, development of an antibody-drug conjugate (ADC) may provide a therapeutic alternative for AML patients.Here, we report the development of the first FLT3specific ADC, AGS62P1, employing site-specific conjugation using the non-natural amino acid, p-acetyl phenylalanine (pAF). AGS62P1 comprises a human gamma one antibody including an inserted pAF residue in each of the heavy chains. The antibody was conjugated to a potent cytotoxic payload via an oxime bond at the pAF sites, thus creating a nearly homogeneous drug distribution, with approximately 2 drug molecules per antibody. Strong binding affinity (0.1-0.9 nM) and potent in vitro cytotoxic activity (IC50 = 0.2-12 nM) was achieved in AML cell lines. The anti-FLT3 ADC was highly efficacious in AML tumor xenografts, leading to statistically significant tumor growth inhibition of both FLT3 ITD and non-ITD models. Additional characterization of both the antibody and ADC was performed, including ligand receptor interaction, degradation, internalization, and apoptosis.In summary, we have developed a site-specific ADC targeting FLT3 that exhibits potent anti-tumor activity in xenograft models regardless of FLT3 activation status. This drug can potentially offer a new and more versatile approach in targeting FLT3-expressing leukemia through a mechanism independent of FLT3 genetic aberration.']",
        "Doc_id":"AACR_2016-574",
        "Doc_title":" AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status",
        "_version_":1606189033430450176},
      {
        "Meeting_name":" Effects of the Flt3 ITD on response to chemotherapy in a murine model of acute myeloid leukemia.",
        "Background":"['Background', ' Acute myeloid leukemia (AML) is an aggressive, genetically heterogeneous malignancy. This heterogeneity is thought to underlie the divergent responses to treatment observed and contribute to relapse. The Flt3 receptor tyrosine kinase containing an internal tandem duplication (Flt3 ITD) is a common mutation in AML and associated with a poor prognosis; however, its effect on chemotherapy response is currently unknown. Methods', ' Murine AML was generated by retroviral transduction of an MLL-ENL fusion protein into fetal liver cells and subsequent transplantation into syngeneic mice. Blasts were harvested from moribund animals and myeloid lineage confirmed by immunophenotyping. Flt3 ITD sequence was inserted into a GFP tagged vector. Blasts were infected with Flt3 ITD or control virus. For competition assays mixtures of infected and uninfected blasts were exposed to chemotherapy for 72 hours. Among the remaining viable cells, percentages of infected blasts were determined by flow cytometry. For in vivo competition assays animals were injected with mixtures of blasts, treated with chemotherapy and percentages of Flt3 ITD positive blasts as well as total leukemic burden in femoral bone marrow was assessed. Results', ' Presence of the Flt3 ITD confers an advantage to doxorubicin (dox) in vitro. After exposure to dox at 5ng/mL more infected blasts remained viable when compared to controls (p = 0.0001). Presence of the Flt3 ITD increased sensitivity to cytarabine (Ara-C). After exposure to 50 nM Ara-C fewer Flt3 ITD blasts remained viable (p = 0.0293). Flt3 ITD confers sensitivity to Ara-C in vivo. Bl6 mice were injected with 1x106 blasts, 10% containing Flt3 ITD. After 12 days mice were treated for 5 days with either Ara-C at 200mg/kg, dox at 3mg/kg or observation. Ara-C treated animals had fewer Flt3 ITD blasts than controls (p = 0.0030) or dox treated animals (p < 0.0001) and lower leukemic burden (p < 0.0001). In contrast there was no difference in leukemic burden between Ara-C treated, dox treated or control animals in AML without Flt3 ITD (p = 0.2833). Conclusions', ' The Flt3 ITD confers resistance to doxorubicin in vitro and sensitivity to Ara-C in vitro and in vivo. These results suggest AML patients with Flt3 ITD may benefit more from high-dose cytarabine regimens then anthracyclines.']",
        "Doc_id":"ASCO_31795-65",
        "Doc_title":" Effects of the Flt3 ITD on response to chemotherapy in a murine model of acute myeloid leukemia.",
        "_version_":1606189041746706432},
      {
        "Meeting_name":" Effect of vorinostat use on survival in patients with acute myeloid leukemia (AML) with FLT3 ITD mutations.",
        "Background":"['Background', '  Novel treatment strategies for patients with AML remain an unmet need. Treatment with vorinostat for three days prior to idarubicin and cytarabine has resulted in high rates of durable responses in patients with FLT3 ITD positive AML in a prospective phase II study. The aim of the current study is to compare the survival of patients with AML treated with or without vorinostat in the FLT3 ITD positive and negative patient groups.  Methods', '  We retrospectively identified patients with AML and known FLT3 ITD mutation status treated at MD Anderson Cancer Center from 2000 to 2012. We compared the survival of patients who received vorinostat as part of their induction chemotherapy with the patients who did not receive vorinostat in the FLT3 ITD mutation positive and negative patient groups.  Results', '  Data on 1043 patients were collected. FLT3 ITD mutation status was known for 817 including 134 patients positive and 683 patients negative for FLT3 ITD mutation. There were 48 patients with known FLT3 ITD status who received vorinostat during induction. There was no difference in survival in the unselected population for the vorinostat and the the non vorinostat group. The vorinostat and non vorinostat groups were balanced in terms of age, gender, cytogenetics, complete response rate and performance status (PS) in both the FLT3 ITD positive and FLT3 ITD negative group. Among patients with FLT3 ITD mutations, 8 patients received vorinostat and 126 patients did not receive vorinostat. There was a survival benefit for the former group (HR 0.26, 95% CI 0.04-0.82, p = 0.04) independent of age and performance status (PS) (Cox proportional model including age and PS; adjusted HR 0.24, 95% CI 0.04-0.79). We did not find a difference in survival for patients with no FLT3 ITD mutation.  Conclusions', '  Vorinostat use was associated with favorable overall survival in patients with FLT3 ITD mutations known to have unfavorable prognosis.']",
        "Doc_id":"ASCO_153350-156",
        "Doc_title":" Effect of vorinostat use on survival in patients with acute myeloid leukemia (AML) with FLT3 ITD mutations.",
        "_version_":1606188999247921152},
      {
        "Meeting_name":" Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia",
        "Background":"['Background', ' The purine nucleoside analogues fludarabine and clofarabine are effective agents in the treatment of acute myeloid leukemia (AML). This study evaluated the efficacy and safety of combining idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) in adults with newly diagnosed AML. Methods', ' Using a Bayesian adaptive design, patients (pts) deemed suitable for intensive chemotherapy were randomized to receive CIA (n = 106) or FIA (n = 76). All pts received idarubicin 10 mg/m2 IV daily on Days 1-3 and cytarabine 1 g/m2 IV daily on Days 1-5. Clofarabine and fludarabine were given at 15 mg/m2 and 30 mg/m2, respectively, IV daily on Days 1-5. Pts with FLT3 mutations could receive sorafenib. Up to 6 cycles of consolidation were allowed for responding pts. Results', ' Baseline characteristics were similar comparing CIA to FIA with a median age of 53 years (range, 20-66) vs 49 years (range, 18-66) respectively and ELN risk intermediate-2/adverse of 57% and 58% respectively. With a median follow-up of 27 months (range, 1-58), the CIA and FIA arms had a similar CR/CRp rate (80% and 82%, respectively). MRD negativity rate by multiparameter flow cytometry at the time of CR/CRp was higher comparing CIA to FIA (80% vs. 65%, respectively, P = 0.07). The median EFS were 13 months and 12 months, respectively (P = 0.91), and the median OS were 24 months and not reached, respectively (P = 0.23). There were more adverse events (all grades) associated with CIA, particularly AST/ALT elevation (29% vs 4%), hyperbilirubinemia (26% vs 9%) and rash (31% vs 9%). Early mortality was similar in the 2 arms (60-day mortality', ' 4% for CIA vs 1% for FIA; P = 0.32). Comparing the 2 arms to a historical cohort of pts treated with IA showed similar response rates, EFS and OS excluding pts with FLT3 mutations from this analysis. However, in pts < 50 years of age, FIA was associated with improved survival compared with IA (2-year EFS rate', ' 58% vs 30%, P = 0.05; 2-year OS rate', ' 72% vs 36%; P = 0.009). Conclusions', ' CIA and FIA have similar efficacy in younger pts with newly diagnosed AML. FIA is associated with a better toxicity profile and may improve survival compared to IA in pts < 50 years of age. Clinical trial information', ' NCT01289457']",
        "Doc_id":"ASCO_194203-199",
        "Doc_title":" Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia",
        "_version_":1606188993709342721},
      {
        "Meeting_name":" Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib.",
        "Background":"['Background', '  The outcome of patients with relapsed acute myeloid leukemia (AML) with FLT3-ITD mutation is poor. Sorafenib is an inhibitor of FLT-3 kinase activity in nanomolar concentrations. We conducted this phase II study to evaluate the efficacy and tolerability of the combination of Sorafenib and 5-Aza for the treatment of patients with refractory or relapsed AML with the particular emphasis on those with FLT3-ITD mutation.  Methods', '  Patients were eligible if they had relapsed or refractory AML and were 18 years of age or older.  They received 5-Aza 75 mg/m2 daily x 7 together with Sorafenib 200 mg BID X 28 days; cycles were repeated in approximately 1-month intervals. Responses were assessed after first cycle and then at the discretion of the treating physician at the time of the best peripheral blood response.  Results', '  32 patients with AML with a median age of 61 years (range, 24-87) were enrolled. They included 13 (41%) with diploid cytogenetics, 9 (28%) with complex cytogenetics, and 10 (31%) with miscellaneous chromosomal abnormalities.  FLT-3-ITD was detected prior to the initiation of treatment in 30/32 patients.  Patients had received a median of 2 prior treatments (range, 1-6). 12 (38%) patients had received 3 prior regimens and 11 had failed therapy with a FLT3 kinase inhibitor (6 with AC220, 1 with PKC412, and 5 with sorafenib, either as monotherapy or with plerixafor); 2 had failed 2 prior FLT3 inhibitors. 10 patients were inevaluable as they never received therapy or discontinued it before response assessment at one month.  The overall CR/CRi rate among the 22 evaluable patients is 50%, including 9 (41%) with CRi and 2 (9%) with CR; with a median of 3 (range, 1-9) treatment cycles. The median time to achieving CR/CRi was 3 months (range, 1-4) and the median duration of CR/CRi was 3 months (range, <15.5).  Three patients proceeded to allogeneic stem cell transplant. The most common study drug-related adverse events were rash and fatigue with no deaths attributable to study medications.  Conclusions', '  Combination of 5-Aza and Sorafenib is promising for the treatment of patients with relapsed and refractory AML with FLT-3-ITD mutation and may allow them to proceed to stem cell transplant.']",
        "Doc_id":"ASCO_94902-114",
        "Doc_title":" Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib.",
        "_version_":1606189011959808000},
      {
        "Meeting_name":" Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.",
        "Background":"['Background', ' Gilteritinib, also known as ASP2215, is a selective FLT3 inhibitor in development for the treatment of acute myeloid leukemia (AML). In ongoing trials, gilteritinib has demonstrated antileukemic activity and has been well tolerated in FLT3-mutation positive subjects with relapsed/refractory (R/R) AML. Methods', ' Gilteritinib pharmacokinetics (PK) and pharmacodynamics (PD) were evaluated in adult subjects (  18 years) with R/R AML in an ongoing phase 1/2 dose-escalation/dose-expansion study (NCT02014558). Gilteritinib was administered once daily (20-450 mg) and blood samples were collected for safety, PK, and PK/PD assessments. Results', ' As of October 31, 2015, data were available from 252 subjects (n = 23, dose escalation; n = 229, dose expansion) for preliminary PK and PK/PD analyses. Gilteritinib PK was generally dose proportional from 20-450 mg with a median time to maximal concentration of 26 hr and a median half-life ~45159 hr. Increased efficacy was observed in subjects with gilteritinib steady-state trough concentrations  100 ng/mL, exposure levels that can be achieved in patients dosed at 120 mg gilteritinib once daily. Although QTcF is positively correlated to gilteritinib concentration, the preliminary model-averaged predicted median maximal QTcF (5.8 msec) and 1-sided upper 95% CI (8.7 msec) were less than 10 msec at the mean exposure associated with the 120 mg therapeutic dose. Furthermore, a low incidence of subjects (4.1%) had a maximum post-baseline QTcF interval > 500 msec. While concentration-related increases in CK and AST were observed, < 10% of subjects experienced a  Grade 3 increase in CK or AST. Conclusions', ' The gilteritinib PK and safety profile support QD oral administration. At 120 mg QD, gilteritinib concentrations associated with increased efficacy are readily achieved and substantial QTc prolongation is not anticipated. Concentration-related increases in CK and AST did not translate to high frequency of incidences  Grade 3 and are clinically manageable. Clinical trial information', ' NCT02014558']",
        "Doc_id":"ASCO_164597-176",
        "Doc_title":" Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.",
        "_version_":1606188990965219328},
      {
        "Meeting_name":" Mechanisms of action of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia cells.",
        "Background":"['Pim kinase proteins (Pim-1, -2 and -3) are a family of conserved proto-oncogenes that are upregulated in leukemias and lymphomas and are involved with leukemogenesis. Pim kinase substrates include transcription, translation, cell cycle, and survival proteins. Increased Pim expression in acute myeloid leukemia (AML), especially in FLT3-ITD activating mutation, provides a rationale to evaluate Pim kinase inhibitors in AML. AZD1208 is a small molecule pan-Pim kinase inhibitor [IC50', ' Pim-1 (0.4 nM), Pim-2 (5.0 nM) and Pim-3 (1.9 nM)]. AZD1208 treatment resulted in growth inhibition in AML cell lines including FLT3-WT (OCI-AML-3, KG-1a, MOLM-16) and FLT3-ITD mutated (MOLM-13, MV-4-11), with greater sensitivity measured in MOLM-16, followed by KG-1a and MV-4-11. The effects of AZD1208 on cell survival were investigated and there was limited apoptosis induction (<10% increase) in the AML cell lines evaluated as measured by flow cytometry and annexin-V/propidium-iodide staining after 24 h with up to 3 M AZD1208. This was consistent with a lack of decline in Mcl-1 protein levels, suggesting that growth inhibition is not through apoptosis induction. Preliminary data also indicated that there was limited change in cell cycle profile in OCI-AML-3 or MV-4-11 cells treated with AZD1208 for up to 72 h, suggesting that growth inhibition is not attributed to cell cycle arrest.To elucidate the mechanism of AZD1208, Pim kinase target protein phosphorylation was evaluated. With 3 M AZD1208 for 24 h, there was a decrease in Bad (Ser112) phosphorylation relative to total Bad only in KG-1a and MOLM-16 cells. Similarly, there was significant decline in histone H3 (Ser10) phosphorylation only in MOLM-16. However, several mTOR signaling pathway proteins were modulated by AZD1208. Pim-1 target PRAS40 (Thr246) phosphorylation decreased in KG-1a, MOLM-13, MV-4-11 and MOLM-16 within 6 h of exposure to 3 M AZD1208. Similarly, Pim-2 target 4E-BP1 (Ser65) phosphorylation decreased in all five cell lines by 24 h. Phosphorylation of downstream S6 (Ser235/236) was dramatically reduced in KG-1a and MOLM-16, and also declined in MV-4-11. Growth inhibition mediated by AZD1208 is similar in FLT3-WT (KG-1a) and FLT3-ITD (MV-4-11), however there is a varied response in Bad and S6 phosphorylation. These results indicate that although growth inhibition induced by AZD1208 is similar in cells with disparate FLT3 mutation status, the molecular events are divergent and may uncover signaling differences between Pim and FLT3-WT and FLT3-ITD. Taken together, Pim kinase inhibition by AZD1208 may be a valuable strategy to inhibit AML cell proliferation even in hard-to-treat AML with FLT3 activating mutations, and these investigations will be used to identify biomarkers during clinical trial that may be predictive of response in patients. There is a multi-center Phase I clinical trial with AZD1208 in AML currently underway and investigations are ongoing.']",
        "Doc_id":"AACR_2013-1050",
        "Doc_title":" Mechanisms of action of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia cells.",
        "_version_":1606189041317838848},
      {
        "Meeting_name":" Different characteristics of drug resistance in AML cell lines between a dual Flt3/CDK4 kinase inhibitor AMG 925 and Flt3 inhibitors.",
        "Background":"['Objectives', ' Flt3 inhibitors have shown clinical responses in Flt3 mutant acute myeloid leukemia (AML) but resistance develops rapidly. In order to improve the durability of clinical response of AMLFlt3 MUT, a small molecule inhibitor of Flt3 and CDK4/6 kinases, AMG 925, was developed. The primary purpose of this study is to compare the ability of AML cell lines to become resistant to AMG 925 and to other Flt3 inhibitors, and to elucidate the underlying molecular mechanisms.Methods', ' Drug resistant MOLM13 and Mv4-11 cell clones were isolated by prolonged exposure to increasing concentrations of AMG 925 and other Flt3 inhibitors. Cell proliferation was determined by CellTiter Glo. Protein expression levels were assessed by Western Blotting, IP Western Blotting and MSD assays. Flt3 mRNA levels were measured by RT-PCR.Results and Conclusions', ' Both MOLM13 and Mv4-11 cells developed resistance to all the inhibitors tested within 3-4 months. In contrast to AML cells resistant to other Flt3 inhibitors (IC50 increased by about 1000 fold), cells resistant to AMG 925 were only at much lower drug concentrations (IC50 increased by 3-5 fold). Mutations in the Flt3 kinase domains were found in cells resistant to the other Flt3 inhibitors but not in those resistant to AMG 925. P-Flt3 and P-STAT5 in AMG 925 resistant cells were less inhibited than in the sensitive parental cells, apparently as a result of an increased total Flt3 (2-3 fold) in the resistant cells. These results are consistent with the hypothesis that it is more challenging for AML cells to develop drug resistance against combined inhibition of Flt3 and CDK4/6 (AMG 925) than against inhibition of Flt3 alone.']",
        "Doc_id":"AACR_2013-5636",
        "Doc_title":" Different characteristics of drug resistance in AML cell lines between a dual Flt3/CDK4 kinase inhibitor AMG 925 and Flt3 inhibitors.",
        "_version_":1606189006191591424},
      {
        "Meeting_name":" The indolocarbazole derivative Go6976 suppresses the growth of leukemia cells with FLT3 mutations",
        "Background":"['The FMS-like tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase involved in hematopoietic progenitor cell development. Mutations of FLT3 have been reported in about a third of patients with acute myeloid leukemia (AML), and inhibitors of FLT3 are of clinical interest. Go6976 is an indolocarbazole inhibitor of the calcium-dependent isozymes of protein kinase C (PKC). In the present study, we demonstrated that Go6976 possesses a potent inhibitory activity against recombinant FLT3 using in vitro kinase assay. We also showed that Go6976 is a potent inhibitor of Aurora-B kinase. Go6976 significantly inhibited proliferation of leukemia MV4-11 cells having FLT3-internal tandem duplication (ITD). Cell growth inhibition by Go6976 occurred in parallel with the drug inhibiting FLT3 and its downstream signal pathways such as extracellular signal-regulated kinase1/2, STAT-5 and p38. The FLT3-independent myeloid leukemia HL-60 and U937 showed strong resistance to Go6976 treatment. Induction of massive apoptosis were observed upon treatment with Go6976 in MV4-11 cells associated with significant down-regulation with Survivin and Mcl-1 protein. Interestingly, Go6976 treatment also inhibited Survivin phosphorylation on Thr34, which is critical for its anti-apoptotic activity. This inhibition of Survivin phosphorylation occurred due to the direct suppression of Aurora-B by Go6976 treatment. These data indicate that Go6976 may have a unique therapeutic potential for patients with FLT3-driven leukemias.']",
        "Doc_id":"AACR_2012-1806",
        "Doc_title":" The indolocarbazole derivative Go6976 suppresses the growth of leukemia cells with FLT3 mutations",
        "_version_":1606189037452787712},
      {
        "Meeting_name":" Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.",
        "Background":"['Background', ' Gilteritinib, a highly selective FLT3/AXL inhibitor, has displayed antileukemic activity in FLT3 mutation-positive (FLT3mut+) relapsed/refractory (R/R) AML in the CHRYSALIS Phase I/II study (NCT02014558), specifically at doses 80 mg/d. This exploratory analysis assessed molecular response to gilteritinib in a CHRYSALIS subpopulation. Methods', ' Molecular response was assessed from bone marrow aspirates obtained at baseline and at 1 additional time point from FLT3mut+ patients (18 y) treated with 120 or 200 mg/d gilteritinib. These doses were identified due to their ability to induce consistent, potent FLT3 inhibition and high clinical response rates. FLT3-ITD and total FLT3 were quantified by NGS to assess molecular response. A Cox regression model of overall survival (OS) by Kaplan-Meier estimation established a FLT3-ITD', 'total FLT3 ratio (ITD signal ratio) of 102as the threshold for improved survival. Results', ' Of 147 FLT3-ITDmut+ patients who received gilteritinib 120 or 200 mg/d, 80 were included in this analysis. Composite response rate for these 80 patients was 55%. During response, 20 patients (25%) had an ITD signal ratio of 102. Of these 20 patients, 18 had a ratio of 103 (major molecular response [MMR]) and 13 had a ratio of 104 (minimal residual disease [MRD] negative). Median time to achieve minimum signal ratio was 54 days. Elimination of morphologic leukemia was observed in 80% of patients with ITD signal ratios <102. Patients who had a signal ratio 102, MMR, or were MRD negative had significantly longer median OS than those who did not (Table). Conclusions', ' Molecular responses to gilteritinib in FLT3-ITDmut+ R/R AML correlated with clinical response and improved OS. This is the first demonstration of molecular response to a FLT3 inhibitor in AML. These data suggest ITD signal ratio may predict durable clinical benefit of gilteritinib. Clinical trial information', ' NCT02014558Molecular ResponseAchieved a Molecular ResponseDid not Achieve a Molecular ResponseP-valuenMedian OS, Days (95% CI)nMedian OS, Days (95% CI)ITD signal ratio 10220417 (246NA)60199 (142234)<.001MMR18417 (228NA)62213 (143264).003MRD negative13417 (228NA)67213 (144264).002']",
        "Doc_id":"ASCO_183517-199",
        "Doc_title":" Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.",
        "_version_":1606189017125093376},
      {
        "Meeting_name":" Integrated molecular profiles and guadecitabine response in relapsed/refractory acute myeloid leukemia.",
        "Background":"['Epigenetic patterns of DNA methylation are frequently altered in acute myeloid leukemia (AML). Guadecitabine is a novel next generation hypomethylating drug with a demonstrated clinical activity in elderly AML. In our previous study of guadecitabine, we identified in relapsed/refractory (r/r) AML patients a gene expression signature (high DNMT3B, low P15, and low CDA) associated with reduced LINE-1 demethylation and resistance to the drug. Since pharmacodynamics only explains a small portion of the variability in response to guadecitabine, we suggest that intrinsic genetic and epigenetic characteristics can distinguish responders from non-responders. We analyzed genome-wide methylation patterns and screened 54 genes frequently mutated in leukemia in DNA from pre-treatment blood or bone marrow from 119 patients with r/r AML enrolled in guadecitabine phase I/II trials. Blood samples from 49 healthy donors were used as controls. We also examined expression of a panel of genes (CDA, P15, P21, DNMT3B, DNMT3A, DNMT1, and CTCF) at baseline by quantitative RT-PCR. Global DNA methylation at pre/post treatment was estimated by bisulfite-pyrosequencing of the LINE-1 repetitive sequence. For comparing methylation profiles at CpG islands (CGI), we performed hierarchical clustering analysis of differentially methylated 2794 CGI sites in 119 r/r AML and 49 healthy controls. Hierarchical clustering split them into 3 main groups of normal-like cluster (n=36), intermediate (n=41) and CpG island methylator phenotype (CIMP) like cluster (n=42). Normal-like cluster had a higher response rate (39 %) compared to intermediate (17%) and CIMP- like cluster (15%) (p=0.025, Fisherâ€™s exact test). Demethylation rate of LINE-1 was lower in CIMP-like cluster than in normal-like and intermediate cluster (average demethylation -19 Â± 2 % in CIMP-like cluster vs. -31 Â± 2 % in normal-like vs. -23 Â± 2 % in intermediate cluster, p=0.0007, One-way ANOVA). Mutation screening revealed frequent alterations affecting signaling pathways (CSF3R, KIT, KRAS, NRAS and FLT3) in the CIMP-like cluster (62%) compared to normal-like (11%) and intermediate cluster (13%) (p<0.0001, Fisherâ€™s exact test). High number of hypermethylated sites per patient was prominent in the CIMP-like cluster and associated with a four gene expression classifier z-score (low CDA, low P15, low CTCF and high DNMT3B) (R=-0.637, p<0.0001) as well as resistance to guadecitabine (mean of 4 gene z-score 0.54 in non-responders vs. 2.31 in responders, p=0.001). We propose that DNA hypermethylation at CpG islands, mutations in signaling pathways and unfavorable gene expression signature can be developed as biomarkers predicting resistance to guadecitabine in r/r AML. This trials were registered at www.clinicaltrials.gov as NCT02293993 (Phase I) and NCT02197676 (Phase II).']",
        "Doc_id":"AACR_2017-4677",
        "Doc_title":" Integrated molecular profiles and guadecitabine response in relapsed/refractory acute myeloid leukemia.",
        "_version_":1606189033869803521},
      {
        "Meeting_name":" A phase I/II trial of combination of PKC412 and 5-azacytidine (AZA) for the treatment of patients with refractory or relapsed (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).",
        "Background":"['Background', ' Midostaurin (PKC412) is a FLT3 kinase inhibitor with activity in acute myeloid leukemia (AML). Hypomethylating agents play an important role in the treatment of AML and MDS. We investigated the safety (phase I) and clinical activity (phase II) of combination of 5-azacytidine (AZA) and PKC412 in pts with R/R AML and MDS.  Method', ' Pts 18 years with MDS, CMML or AML, who failed prior therapies with performance status <2, adequate liver (bilirubin < 2x ULN, ALT  2.5x ULN) and renal (creatinine < 2x ULN) functions were eligible. Pts received AZA 75 mg/m2 subcutaneously or intravenously for 7 days of each cycle (Days 1-7) and PKC412 at 25 mg (cohort 1) and 50 mg (cohort 2; target dose) orally twice daily for 14 days (Days 8-21). Pts were to receive up to 12 cycles if benefit from treatment. Supportive care was standard. Results', ' 14 pts were included in phase I. 1 pt was inevaluable for DLT (withdrawal before completing cycle#1). 6 pts treated in cohort 1 and 7 in cohort 2. 1 pt in cohort 2 received PKC412 dose as per cohort 1 dose by pt error. Pt characteristics and responses are summarized in  the Table. The overall response rate (ORR) was 3/13(21%) (2 with CRi, 1 pt dropped BM blasts form 27% to 7% after 2 cycles and went to transplant. 1/4 with FLT3-ITD achieved CRi, 2 of the non-responders received prior FLT3 inhibitors (1 had developed FLT3 D835).  All toxicities were grade 1 (nausea 1 pt, vomiting 1 pt, dry skin 1 pt, and rash 1 pt) with no difference between the 2 groups. No DLT was identified.  Conclusions', ' PKC412+AZA is safe and well tolerated at the intended doses with good ORR in high risk pts with R/R AML. Phase II study is enrolling pts with FLT3-ITD. Updated result will be presented.   Patients characteristics and responses.']",
        "Doc_id":"ASCO_98996-114",
        "Doc_title":" A phase I/II trial of combination of PKC412 and 5-azacytidine (AZA) for the treatment of patients with refractory or relapsed (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).",
        "_version_":1606188981251211264},
      {
        "Meeting_name":" Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.",
        "Background":"['Background', '  Advanced age and FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) in acute myeloid leukemia (AML) are associated with early relapse after standard chemotherapy and poor survival.  Quizartinib (AC220), an oral FLT3 inhibitor active against ITD mutant and wild type FLT3, has shown promising activity in Ph 1 and 2 studies.   Methods', '  Patients (pts) in a Ph 2 open label study (N = 333) of quizartinib monotherapy included 154 aged 60 y with known FLT3-ITD status and AML relapsed in <1 y or refractory to 1st line chemotherapy.  Median duration of treatment was 14.2 wks (range 0.170.6 wks) for FLT3-ITD(+) pts and 9.5 wks (range 1.177.0 wks) for FLT3-ITD(-) pts. The composite complete remission (CRc) rate included complete remission (CR), complete remission with incomplete platelet recovery (CRp), and complete remission with incomplete hematologic recovery (CRi).  Results', '   Of 110 FLT3-ITD(+) pts, 63 (57%) had a CRc (3 CR, 4 CRp, 56 CRi).  Of 44 FLT3-ITD(-) pts, 16 (36%) had a CRc (2 CR, 1 CRp, 13 CRi). Median overall survival (OS) in FLT3-ITD(+) pts was 25.3 wks and 16/110 (15%) survived >52 wks.  The median age of these pts surviving >52 wks was 69.5 y (range 6680 y) and median OS was 76.3 wks (range 56.996.0 wks). All of these pts responded to quizartinib (2 CR, 2 CRp, 8 CRi, 4 partial remission [PR]).  2 pts were still alive >1  y (OS 93.0 and 96.0 wks). Median OS in FLT3-ITD(-) pts was 19.1 wks and 6/44 FLT3-ITD(-) pts (14%) survived  >52 wks.  The median age of these pts was 70.0 y (range 6577 y) and their median survival was 76.6 wks (range 54.998.4 wks).  5 of these pts responded to quizartinib (1 CR, 3 CRi, 1 PR).   Conclusions', '  These data for an FLT3-targeted agent show encouraging survival in a subset of elderly pts with relapsed/refractory FLT3-ITD(+) AML.    Clinical trial information', ' NCT00989261.']",
        "Doc_id":"ASCO_113972-132",
        "Doc_title":" Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.",
        "_version_":1606189016729780224},
      {
        "Meeting_name":" Targeting the miR29b/Sp1/Dnmt pathway for curative therapy in Mll-PTD/Flt3-ITD acute myeloid leukemia.",
        "Background":"[\"The partial tandem duplication (PTD) of the MLL gene is a molecular defect in human myelodysplastic syndrome and acute myeloid leukemia (AML) and associates with poor patient outcomes, especially when other molecular prognostic markers are co-present such as the internal tandem duplication (ITD) of FLT3, i.e., FLT3-ITD. In human AML, MLL-PTD alters the epigenome via aberrant H3K4 methylation activity but is also associated with increased DNA methylation through an unknown mechanism (Whitman, et al, Blood 2008). Using a double knock-in mouse model of AML with Mll-PTD and Flt3-ITD, we analyzed the DNA methylome using a methyl binding protein (MBD2) pull down followed by next generation sequencing. Leukemic mouse bone marrow (BM, n=8) exhibited a 1.7 fold increase in global DNA methylation compared to non-leukemic controls (n=9, P=0.017). Consistent with this finding, DNA methyltransferases (Dmnt) 1, 3a, and 3b were overexpressed (1.5 fold P=0.03, 2.3 fold P=0.01, and 5.3 fold P=0.03, respectively). We previously showed that the non-coding microRNA 29b (miR-29b) expression directly downmodulates DNMT3a and 3b, but indirectly inhibits DNMT1 via miR-29b-driven SP1 suppression. In the murine Mll-PTD/Flt3-ITD AML, the precursor to the mature miR-29b (pri-miR-29b-2) was downregulated in leukemic BM (0.7-fold, P<0.001), whereas Sp1 mRNA was upregulated compared to wildtype (1.6-fold P=0.01). Bortezomib is a proteasome inhibitor that also downregulates Dnmt's (Liu, et al, Blood, 2008) by increasing the expression of miR-29b (Liu, et al, Cancer Cell, 2010). In vitro, bortezomib induced a dose-dependent reduction in proliferation of Mll-PTD/Flt3-ITD leukemic blasts (MTS assay, EC50 23.83nM) and apoptosis. Prior to cell death in bortezomib-treated cells, expression of pri-miR-29b-2 increased by 1.7 fold over vehicle treated cells (P=0.01) while Dnmt3b mRNA (P=0.001) and protein levels decreased to half of the vehicle treated level. Targeting of this pathway in vivo using liposomal-bortezomib (1mg/kg IV twice per week for 2 weeks followed by 2mg/kg IV twice per week for 2 weeks) significantly increased survival of AML transplanted mice, compared with vehicle or free-bortezomib with 80% alive 90 days post-transplant (P<0.001). At day 90, treated mice had normal spleen weights (mean 86mg) and absence of leukemic blasts in BM, liver, or spleen compared to vehicle-treated mice that showed significant blast infiltration (mean spleen weight 396mg, P<0.001). Taken together, these data support the miR-29b/SP1/DNMT pathway of epigenetic modulation as active in Mll-PTD/Flt3-ITD AML, and indicate bortezomib as a valuable treatment option to be explored in patients with MLL-PTD/FLT3-ITD-associated AML.\"]",
        "Doc_id":"AACR_2013-3249",
        "Doc_title":" Targeting the miR29b/Sp1/Dnmt pathway for curative therapy in Mll-PTD/Flt3-ITD acute myeloid leukemia.",
        "_version_":1606188970594533376},
      {
        "Meeting_name":" Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).",
        "Background":"['Background', ' Relapse remains the major cause of treatment failure in AML patients (pts) undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT). We aimed to identify prognostic factors for relapse and leukemia free survival (LFS) after allo-HCT in AML pts.  Methods', ' We retrospectively analyzed 987 consecutive pts who underwent their first allo-HCT for AML between January 2001 and June 2012. 124 pts had monosomal karyotype (MK+), 440 had other cytogenetic abnormalities (core-binding factor [CBF] n=67; MK-, n=373). 113 pts had diploid cytogenetics and FLT3 mutations (CN-FLT3+), 235 were diploid without FLT3 mutations (CN-FLT3-); FLT3 data was unavailable for 75 CN pts. Pts were stratified based on disease status at HCT', ' complete remission (CR, n=627) and active disease (n=360). Results', ' In this cohort, median age was 52 years (range', ' 19  76) and 191 pts (20%) had secondary AML (sAML). Conditioning intensity was non-myeloablative in 230 pts (23%). On multivariate analysis in pts with CR at HCT (adjusted for age, donor type and conditioning intensity) factors that predicted inferior LFS included', ' sAML (HR=1.5, 95% CI=1.1-2.2, p=0.009), >=CR2 vs. CR1 (HR=1.6, 95% CI=1.2-2.1, p=0.002), CN-FLT3+ (HR=1.7, 95% CI=1.1-2.5, p=0.02), MK- (HR=1.4, 95% CI=1.1-2.0, p=0.04) and MK+ disease (HR=2.1, 95% CI=1.4-3.2, p <0.001). Three-year LFS rates for CN-FLT3+ and MK+  were 45.3% and 34% vs. 53.3% for CN-FLT3- pts.  For pts with active disease; CN-FLT3+ (HR=2.6, 95% CI= 1.5-4.2, p<0.001) and MK+ (HR=2.3, 95% CI= 1.5-3.5, p<0.001) predicted worse 3-year LFS', ' 10% and 6% vs. 30.8% in pts with CN-FLT3- . For CR pts, cumulative incidence of relapse (CIR) was higher for those with CNFLT3+ (HR=1.9, 95% CI=1.1-3.1, p=0.01) and MK+ disease (HR=2.1, 95% CI=1.2-3.5, p=0.005). Among active disease pts, CN-FLT3+ (HR=2.5, 95% CI=1.4-4.3, p=0.002) and MK+ (HR=1.9, 95% CI=1.2-3.0, p=0.009) also predicted for higher CIR.  Conclusions', ' Although pts with CN-FLT3+ and MK+ represent a high risk group for decreased LFS with increased relapse incidence after allo-HCT, they may still enjoy LFS of 30% - 45% if transplanted in CR. Post-transplant strategies to minimize the risk of relapse should be investigated in this setting.']",
        "Doc_id":"ASCO_112613-132",
        "Doc_title":" Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).",
        "_version_":1606188993554153472},
      {
        "Meeting_name":" FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).",
        "Background":"['Background', '  FLT3 mutations occur in one third of acute myeloid leukemia (AML) patients (pts) and predict poor outcome. The incidence and impact of FLT3 in MDS/ CMML is unknown.  Methods', '  We conducted a retrospective review at MDACC to identify FAB MDS/ CMML pts with FLT3 mutations at diagnosis.  Results', '  From 1996 to 2010; 2052 MDS/ CMML pts had mutation analysis. 45 (2.2%) had FLT3 mutations (internal tandem duplication-ITD or D835) at diagnosis. 29 pts had MDS and 16 had CMML. Median (Med) age was 64 years (21 to 83) and 69% were males. FAB groups', ' 3 pts with refractory anemia (RA), 11 pts with refractory anemia-excess blasts (RAEB), 18 pts with refractory anemia-excess blasts in transformation (RAEB-T) and 13 pts with CMML. IPSS', ' 3 in Low (7%), 16 in Int-1 (36%), 11 in Int-2 (24%), and 15 in High (33%). Med white count, hemoglobin, platelet count and marrow blast percent at diagnosis were 5.2 x 109/l (1.2 to 211), 10.0 g/l (6.8 to 14.9), 78 x 109/l (8 to 429), and 14% (1 to 28), respectively. FLT3 ITD and FLT3 D835 mutations were present in 32 (71%) and 13 pts (29%), respectively. Karyotype was diploid in 30 (66%); -5/-7 in 5 (11%), 11q in 1 (2%), and others in 9 pts (19%). All 5 pts with -5/ -7 had the ITD mutation. Concurrent mutations were identified in RAS, NPM1 and C-Kit in 6 (13%), 3 (7%) and 1 (2%) pt, respectively.  Med overall survival (OS) for FLT3 pts was 15 months compared to 17 months for non FLT3 pts (P=0.9). 18 pts had RAEB-T', ' 13 (72%) received AraC-based therapy and 3 (17%) received hypomethylating therapy (HMT) with complete remission (CR) in 14 pts (78%). 14 pts had RA/ RAEB', ' 5 (36%) received AraC-based  therapy and 7 (50%) received HMT with CR in 5 (37%) and hematological improvement (HI) in 4 (28%). 13 pts had CMML', ' 4 (31%) received AraC-based therapy and 6 (46%) received HMT with CR in 3 (23%) and HI in 3 (23%). Repeat FLT3 was available on 16 pts achieving any response and was absent/ decreased in 14 (88%), stable in 1 (6%) and increased in 1 (6%). Notably, the 14 pts with absent/ decreased FLT3 had med OS of 27 months versus 12 months for remaining group (P=0.004).  Conclusions', '  FLT3 occurs in MDS/ CMML at a lower frequency than AML and does not predict poor outcome. Pts who achieve absent/ decreased FLT3 seem to have significantly improved overall survival.']",
        "Doc_id":"ASCO_100643-114",
        "Doc_title":" FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).",
        "_version_":1606188998995214336},
      {
        "Meeting_name":" Combination of bortezomib with a FLT3 inhibitor potentiates inhibition of proliferation and apoptosis of AML in vitro.",
        "Background":"['Background', ' FLT3 receptor tyrosine kinase activating mutations contribute to leukemogenesis and poor prognosis in approximately 30% of acute myeloid leukemia (AML). An internal tandem duplication (ITD) mutation in the juxtamembrane domain of FLT3 results in loss of autoinhibition that leads to constitutive, ligand-independent activation of the receptor, with subsequent activation of multiple downstream signaling pathways, including RAS/MAPK and STAT5. Early phase clinical trials of FLT3 inhibitors show a lack of durability of responses, suggesting combination therapy may work better. Methods', ' In the course of conducting a synthetic lethality screen with a FLT3 inhibitor on the Ba/F3 murine cell line stably expressing human FLT3 or FLT3-ITD, we identified bortezomib, a proteasome inhibitor, as having potent activity against FLT3-ITD cells. The effects of drugs on proliferation, apoptosis, and phosphosignaling were quantified in Ba/F3 cells and in the HL60 (WT FLT3) and MV4-11 (FLT3-ITD) human cell lines, using an MTS- based colorimetric assay, caspase 3 and 7 activity assays, and immunoblotting, respectively. Results', ' A highly potent and specific FLT3 inhibitor was shown to have an IC50 of 1.9 nM, inhibiting proliferation, inducing apoptosis, and abrogating downstream STAT5 and ERK phosphorylation in FLT3-ITD cells. The IC50 of bortezomib for FLT3-ITD cells was 10 nM as compared to an IC50 of 40 nM for WT FLT3 cells. Surprisingly, bortezomib abrogated tyrosine phosphorylation of FLT3, STAT5, and ERK within 60 min of adding drug. When the FLT3 inhibitor and bortezomib were used at IC25 concentrations, a more pronounced inhibition of cell proliferation was observed when they were used in combination than with either alone. Conclusions', ' Bortezomib preferentially kills FLT3- ITD cells, showing a four-fold more potent inhibition of cell proliferation, induces apoptosis, and abrogates activation of FLT3 and its downstream effector pathways. The combination of proteasome inhibition with FLT3 inhibition results in enhanced cytotoxicity. The mechanism by which bortezomib affects the FLT3-ITD signaling axis and the possible synergy with FLT3 inhibitors remains to be elucidated.']",
        "Doc_id":"ASCO_35470-65",
        "Doc_title":" Combination of bortezomib with a FLT3 inhibitor potentiates inhibition of proliferation and apoptosis of AML in vitro.",
        "_version_":1606189040918331392},
      {
        "Meeting_name":" The Pim kinase inhibitor AZD1208 sensitizes acute myeloid leukemia cells with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) to cytotoxic effects of chemotherapy drugs",
        "Background":"['Purpose', ' Internal tandem duplication (ITD) in the juxtamembrane domain of the fms-like tyrosine kinase 3 (FLT3) receptor is present in leukemia cells of approximately 30% of acute myeloid leukemia (AML) patients. These patients have a high remission rate, but short relapse-free and overall survival. Pim-1 kinase, a pro-survival oncogene, is transcriptionally upregulated downstream of FLT3-ITD and promotes FLT3-ITD signaling via a positive feedback loop. We proposed that Pim kinase inhibitors would enhance the cytotoxic effects of chemotherapy drugs in AML cell lines and patient samples with FLT3-ITD.Methods', ' AZD1208, a pan-Pim (Pim-1, Pim-2 and Pim-3) kinase inhibitor, was kindly provided by AstraZeneca. FLT3-ITD cell lines included MV4-11, MOLM-14 and Ba/F3-ITD. The topoisomerase 1 and 2 inhibitors daunorubicin, mitoxantrone, etoposide and topotecan and the nucleoside analog cytarabine were studied at their IC50 concentrations for each cell line. Apoptosis was measured by flow cytometric analysis of Annexin V/propidium iodide (PI) staining, percent cells in sub-G1 cell cycle phase using PI staining and mitochondrial membrane potential (MMP) using JC-1 dye, as well as flow cytometric and western blot measurements of cleaved poly (ADP-ribose) polymerase (PARP) and caspase-3.Results', ' Co-treatment with 1M AZD1208 and daunorubicin induced significantly more apoptosis than daunorubicin or AZD1208 alone (e.g., 65% vs. 25% and 7% in Ba/F3-ITD) in FLT3-ITD cell lines. At least two-fold increase in apoptosis was also seen when AZD1208 was combined with mitoxantrone, etoposide or topotecan, compared with each drug alone, but AZD1208 did not increase apoptosis induced by cytarabine. Chemosensitization of FLT3-ITD cells with the combination treatment was confirmed by a higher percentage of sub-G1 cells (e.g., 33% for AZD1208 and daunorubicin combination vs. 17% for daunorubicin alone in Ba/F3-ITD), more rapid loss of MMP and increased time-dependent cleavage of PARP and caspase-3. Apoptosis was significantly (P<0.0001) rescued by co-treatment with the pan-caspase inhibitor z-VAD. Cell lines with wild-type FLT3 were less sensitive to combined AZD1208 and chemotherapy-induced apoptosis. Finally, increased cytotoxicity of daunorubicin in the presence of AZD1208 was also seen in FLT3-ITD AML patient marrow samples, but not remission marrow samples.Conclusion', ' Our work supports clinical applicability of combining a Pim kinase inhibitor with chemotherapy to treat AML with FLT3-ITD. Ongoing work is directed toward determining the molecular mechanisms of sensitization of FLT3-ITD cells to chemotherapy by Pim kinase inhibition.']",
        "Doc_id":"AACR_2015-5332",
        "Doc_title":" The Pim kinase inhibitor AZD1208 sensitizes acute myeloid leukemia cells with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) to cytotoxic effects of chemotherapy drugs",
        "_version_":1606188992140673024},
      {
        "Meeting_name":" Mechanism of sorafenib resistance in acute myeloid leukemia",
        "Background":"['Activating mutations in FLT3 occur in up to 35% of patients with AML and correlate with poor prognosis. Therapy directed against FLT3 has been shown to induce response in patients with AML, but these responses are almost always transient. Dual PI3K/mTOR inhibitors have displayed promising results in the treatment of solid tumors, and of hematological cancers. In this report we describe that a dual PI3K/mTOR inhibitor is effective against sorafenib-responsive, and -resistant, AML cell lines both in vitro and in vivo. We generated two cell lines by sustained treatment with sorafenib. Parental cell lines carry the FLT3-ITD mutation and are highly responsive to FLT3 inhibitors, while sorafenib-resistant cell lines display resistance to multiple FLT3 inhibitors. Next generation sequencing did not show any significant difference in the mutational burden in between responsive and resistant cell lines. While next generation sequencing identified FLT3-D835Y with an allele-depth of 67', '37 in a resistant cell line, Sanger sequencing and protein mass-spectroscopy did not identify any acquired mutations in the kinase domain of FLT3 in the resistant cells. Moreover, sorafenib treatment effectively blocked FLT3 activation in resistant cells, while it was unable to block colony formation or cell survival, suggesting that the resistant cells are no longer dependent on FLT3. Gene expression analysis of sorafenib-sensitive and -resistant cell lines, as well as of blasts from patients with sorafenib-resistant AML, suggested an enrichment of the PI3K/mTOR pathway that correlated with the resistant phenotype, which was further supported by phospho-specific-antibody array analysis. The selective PI3K/mTOR inhibitor, gedatolisib, efficiently blocked proliferation, colony and tumor formation of resistant cell lines as well as induces apoptosis. Taken together, our data suggest that aberrant activation of the PI3K/mTOR pathway results in FLT3-inhibitors-resistance and a dual specific PI3K/mTOR inhibitor is an effective treatment in both tyrosine kinase inhibitor sensitive and resistant AML.']",
        "Doc_id":"AACR_2016-310",
        "Doc_title":" Mechanism of sorafenib resistance in acute myeloid leukemia",
        "_version_":1606189014016065536},
      {
        "Meeting_name":" Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220 in vitro",
        "Background":"['Background', ' Clinical outcomes associated with acute myeloid leukemia (AML) have not improved substantially in decades. Activating FMS-like tyrosine kinase-3 (FLT3) mutations are detected in 30% of AML cases with internal tandem duplication (ITD) mutations conferring worse prognosis. Recently, the potent FLT3 inhibitor AC220 has achieved composite complete remission in 45% of patients with relapsed/refractory FLT3-mutant AML (Cortes et al, EHA 2011). Translational studies from our laboratory implicate reactivation of FLT3-ITD through kinase domain mutations in the majority AC220 relapse cases (Smith et al, ASH 2011). Given that less than half of treated patients initially achieve deep remissions on AC220, we hypothesize that off-target (non-FLT3 mediated) resistance is responsible for primary resistance to AC220, and may mediate loss of response in a subset of patients. Results', ' To model and identify putative mechanisms of off-target resistance to AC220 in vitro, we cultured the FLT3-ITD+ patient derived cell lines MV4;11 and Molm14 in escalating concentrations of AC220. To date, we have isolated 8 Molm14 subclones that are resistant to at least 20nM AC220, which is >60-fold the IC50 of the parental line (0.3nM), while efforts to generate resistant MV4;11 cells have repeatedly failed. Analysis of FLT3 signaling revealed persistent FLT3 phosphorylation in 5 clones in the presence of 10nM AC220. Sequencing of the FLT3 kinase domain identified acquired secondary activation loop mutations suggesting on-target acquired resistance. The remaining 3 clones demonstrated off-target resistance as evidenced by the absence of a FLT3 mutation and loss of FLT3 phosphorylation with 10nM AC220 treatment. Despite FLT3 inhibition, the clones failed to undergo apoptosis and maintained ERK phosphorylation when treated with AC220. Sequencing of K- and NRAS revealed an NRAS G12C mutation in 2 clones and an NRAS Q61K mutation in the third clone, both of which are known activating RAS mutations. The AC220 IC50 values for the G12C mutant clones were determined to be 134nM and 329nM AC220 and the Q61K mutant was one of the most resistant of all clones with an IC50 of >1000nM AC220. Further, all 3 NRAS mutant clones showed increased sensitivity to the MEK inhibitor PD0325901 compared to the parental cells and on-target resistant clones. Conclusions', ' Generation of 8 independent AC220-resistant AML cell lines revealed evidence for on- or off-target resistance mechanisms. We have identified oncogenic RAS as a putative mechanism of acquired AC220 off-target resistance in vitro, suggesting that pathologic activation of the RAS/ERK pathway may result in failure of clinically active FLT3 inhibitor therapy in AML patients. Assessment for activating RAS mutations in patient samples with primary and acquired resistance to AC220 and other clinically effective FLT3 inhibitors is currently ongoing.']",
        "Doc_id":"AACR_2012-1893",
        "Doc_title":" Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220 in vitro",
        "_version_":1606189035821203456},
      {
        "Meeting_name":" A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia.",
        "Background":"['Background', ' The outcome of acute myeloid leukemia (AML) patients (pts) 60 years (yrs) old remains poor, with a median overall survival of a few months. Neither the addition of other drugs during induction of the traditional 7+3 regimen nor an increase of cytarabine or daunorubicin doses has improved their overall survival. We have therefore designed a combination of clofarabine and daunorubicin.  Aims', ' Determine the safety and efficacy of clofarabine and daunorubicin in pts  60 yrs of age. Methods', ' Induction-clofarabine 20 mg/m2 /d in a 1-hour IV for 5 days followed 3 hrs later by daunorubicin 50 mg/m2 IV over 5 minutes on days 1, 3, and 5. Pts who did not achieve complete remission (CR) or CR without platelet recovery (CRp) were eligible for a second round of induction as above. Consolidation - 2 cycles of clofarabine 20mg/m2 /d for 3 days and daunorubicin 50 mg/m2/day on days 1 and 3. Results', ' Twenty-one pts were enrolled. The median age was 69 (range 60-85) yrs. Seven pts (34%) had secondary AML and 52% had complex karyotype. Twenty-one pts completed one induction cycle, one pt received a second induction due to residual disease and 6 pts underwent consolidation therapy. The principal toxicity was grade 3 infections and prolonged thrombocytopenia and neutropenia, which occurred in 18% and 21% of pts, respectively. Three deaths were documented from treatment complications (sepsis and fungal infections). Eight (38.1%) pts achieved either a CR or CRp. Responses were observed in 5/11 (45.5%) pts with high risk features (complex karyotype and/or presence of FLT3). The median disease free-survival was 1.9 (range, 0.9-8) months and the median overall survival was 6.5 (range, 4.2-14.2) months. The 1-yr overall survival was 35%. Conclusions', ' These preliminary results suggest that clofarabine in combination with daunorubicin is safe, well-tolerated with minimal toxicity, and active for the upfront treatment of 60 yrs old AML pts, including those with adverse features.  Future trials will explore additional modifications to this regimen in order to optimize therapy for this group of pts with high risk features and frequent treatment failure.']",
        "Doc_id":"ASCO_93029-114",
        "Doc_title":" A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia.",
        "_version_":1606189030055084032},
      {
        "Meeting_name":" Signaling adaptation to FLT3 inhibition in FLT3/ITD leukemia results in a reactivation of ERK signaling that can be abrogated with MEK inhibition",
        "Background":"['The use of FLT3 tyrosine kinase inhibitors (TKIs) for the treatment of FLT3 mutant acute myeloid leukemia (AML) has been explored as a promising strategy for over a decade. However, FLT3 TKIs have thus far shown limited clinical benefit in patients with FLT3/ITD AML. We hypothesized that FLT3/ITD leukemia cells exhibit mechanisms of intrinsic signaling adaptation to FLT3 TKI treatment that are associated with an incomplete biologic response. If true, combined targeted therapeutic approaches that overcome the adaptive resistance to FLT3 inhibition could be used to maximize the efficacy of anti-leukemia treatment for those expressing this mutation.To evaluate this hypothesis, the FLT3/ITD AML cell lines Molm14 and MV4;11 were treated with FLT3 TKIs for up to 48 hours at concentrations sufficient for maximal FLT3 inhibition and downstream signaling was analyzed by immunoblotting. We identified a rebound in ERK phosphorylation discernible by six hours and continuing for the duration of treatment, despite continued drug presence. This rebound resulted in near baseline levels of phosphorylated ERK (pERK) and was coupled to a rebound in phosphorylation of elements both upstream and downstream of ERK as well as in the expression levels of ERK target genes, suggesting a global reactivation of the signaling cascade. Rebound was sensitive to a reduction in serum, suggesting a growth factor-dependent mechanism.To explore the consequences of this adaptation, the impact of combinatory targeting of ERK activity using selective small molecule inhibitors of MEK was evaluated. When Molm14 and MV4;11 cells were treated with inhibitors of both FLT3 and MEK in combination, little to no pERK rebound was observed. Additionally, the anti-leukemia effects were more pronounced for the combination compared to either drug alone, both in vitro and in vivo. In vitro, the addition of a MEK inhibitor (PD0325901 or trametinib) to FLT3 TKI (sorafenib) treatment synergistically increased cell death and decreased cell viability. This effect was most pronounced at mid-range sorafenib combined with low dose MEK inhibitor. In vivo, the addition of low-dose PD0325901 to sorafenib treatment resulted in a significant reduction of both peripheral blood and bone marrow blasts in a transplant model (p < 0.05).Together, these studies reveal that FLT3/ITD leukemia cells demonstrate an adaptive feedback mechanism capable of reactivating ERK signaling in response to FLT3 inhibition. This adaptation limits the efficacy of FLT3 TKI treatment and can be abrogated by the addition of a MEK inhibitor. Our data suggest that the addition of low-dose MEK inhibitor to FLT3 TKI treatment as a means to overcome signaling adaptation may improve outcomes for patients with FLT3/ITD AML.']",
        "Doc_id":"AACR_2016-4785",
        "Doc_title":" Signaling adaptation to FLT3 inhibition in FLT3/ITD leukemia results in a reactivation of ERK signaling that can be abrogated with MEK inhibition",
        "_version_":1606188998830587904},
      {
        "Meeting_name":" FGF2 from the bone marrow promotes resistance to FLT3 inhibitors in AML",
        "Background":"['Introduction', ' Activating mutations in the FLT3 kinase are present in 25% of newly diagnosed acute myeloid leukemia (FLT3+ AML) patients and confer a poor prognosis. Treatment with FLT3 inhibitors is initially effective, but residual leukemia cells survive in the bone marrow microenvironment and clinical resistance develops within months. We tested proteins from the bone marrow microenvironment for their ability to protect FLT3-ITD+ MOLM14 cells from AC220, and found that FLT3 ligand (FL) and fibroblast growth factor 2 (FGF2) were among the most protective.Results', ' Consistent with previous reports, FL restored downstream FLT3 phosphorylation and signaling in the presence of the FLT3 inhibitor quizartinib (AC220). In contrast, FGF2 activated FGFR1 and the MAPK pathway, circumventing the effects of AC220 on MOLM14 cells and increasing cell survival. To model the effect of prolonged contact with the bone marrow microenvironment, MOLM14 cells were cultured continuously in FGF2 and AC220. Under these conditions, 4/4 cultures developed AC220 resistance and resumed exponential growth after 7 weeks. Development of FGF2-mediated resistance was accelerated compared to MOLM14 cultured continuously in AC220 alone (only 2/4 resistant cultures,12 weeks). Long-term resistant cultures grown in FGF2 were protected from AC220 across a wide range of concentrations, but concurrent treatment with the FGFR inhibitor PD173074 synergistically overcame FGF2-mediated protection.Serial bone marrow biopsies of patients on the AC220 phase II clinical trial were analyzed by immunohistochemistry. Quantification of FGF2 revealed a significant increase in AC220 during treatment (34% to 51% after one month, p<0.01) and FGF2 expression peaked at 61% after 4 months (p<0.01), indicating that residual leukemia cells exist in a microenvironment abundant in FGF2. To test if FGFR inhibition could overcome FGF2-mediated protection from bone marrow stroma, we grew MOLM14 cells in co-culture with an FGF2-expressing stromal cell line (HS-5). HS-5 co-culture increased viability in MOLM14 in AC220 treatment, however concurrent PD173074 treatment abrogated stromal cell protection suggesting that combination of FLT3 and FGFR inhibitors may overcome resistance mediated by the microenvironment.Conclusions', ' FGF2 ligand-induced activation of the FGFR1/MAPK pathway leads to protection from AC220 in vitro and eventual development of resistance. FGF2-mediated resistance can be overcome by concurrent FLT3 and FGFR inhibition. Consistent with our in vitro model, patients treated with AC220 had increasing FGF2 in their bone marrow, which peaked prior to resistance and relapse, suggesting that combined FLT3 and FGFR inhibitors may improve the durability of response. Our results provide an approach to develop rational inhibitor combinations that cirucumvent ligand-mediated pathways of resistance.']",
        "Doc_id":"AACR_2015-984",
        "Doc_title":" FGF2 from the bone marrow promotes resistance to FLT3 inhibitors in AML",
        "_version_":1606188995484581889},
      {
        "Meeting_name":" The prognostic impact of combined NPM1+/FLT3- mutational status in newly diagnosed acute myeloid leukemia (AML) patients with intermediate risk cytogenetics according to age and treatment modality.",
        "Background":"['Background', '    Combined NPM1+/FLT3- is associated with a favorable prognosis in adults with AML, treated with standard chemotherapy. The impact of this on outcome is however not well defined according to age and different treatment modalities, including chemotherapy with or without hematopoietic cell transplantation (HCT), and hypomethylating agents (HMA).  Methods', '    Out of 620 newly diagnosed AML pts treated between 2007 and 2014, 169 with intermediate risk cytogenetics and known NPM1/FLT3 were analyzed.  Results', '    Estimated 3-yr overall survival (OS) according to age, NPM1/FLT3 status, and treatments are shown in the table. Among adults and elderly treated with chemotherapy alone, those with NPM1+/FLT3- had a superior OS compared to those without this mutational status (P=0.004 and 0.0008, respectively). Adults without NPM1+/FLT3- had a significantly improved OS when treated with HCT in addition to chemotherapy (P<0.0001), and a comparable OS to those with NPM1+/FLT3- (P=0.43), when treated with chemotherapy alone. Similarly, elderly without NPM1+/FLT3- had a superior OS when treated with chemotherapy followed by HCT (P=0.028), and a comparable OS to those with NPM1+/FLT3- (P=0.83), when treated with chemotherapy alone.  Among elderly pts without NPM1+/FLT3-, those treated with HMA alone (n=12) had a similar OS to those treated with chemotherapy without HCT (P=0.86).  Conclusions', '    Combined NPM1+/FLT3- is associated with a favorable prognosis, irrespective of age, in newly diagnosed AML pts with intermediate risk cytogenetics, treated with chemotherapy. In pts without NPM1+/FLT3-, the OS improves with the addition of HCT to standard chemotherapy, irrespective of age. HMA seems to be comparable to chemotherapy alone in elderly pts without NPM1+/FLT3-.    Elderly (>60 yrs.)N=84*Adults (18-60 yrs.)N=85Chemo aloneN=51Chemo + HCT N=12Chemo aloneN=37Chemo + HCTN=48NPM1+/FLT3-N=17OtherwiseN=34NPM1+/FLT3-N=1OtherwiseN=11NPM1+/FLT3-N=13OtherwiseN=24NPM1+/FLT3-N=5OtherwiseN=43Estimated 3-yr OS59%20%-40%64%16%-51%P=0.005P<0.0001*Other treatments', ' N=21.']",
        "Doc_id":"ASCO_151021-156",
        "Doc_title":" The prognostic impact of combined NPM1+/FLT3- mutational status in newly diagnosed acute myeloid leukemia (AML) patients with intermediate risk cytogenetics according to age and treatment modality.",
        "_version_":1606188980581171200},
      {
        "Meeting_name":" Hypoxia selectively confers resistance to the survivin-targeting compound YM155 in acute myeloid leukemia and Ewings sarcoma cell lines",
        "Background":"['BackgroundHypoxia is characteristic of almost all types of solid tumors and is an important component of the bone marrow microenvironment. It is an adverse prognostic indicator in cancer as it is associated with tumor progression and chemoresistance. Cells may adapt to hypoxia in different ways; including growth arrest, stimulation of angiogenic factors, inhibition of apoptosis, induction of the ER stress program, or modification of the cellular energy metabolism. YM155 inhibits survivin gene expression by suppressing promoter activity and subsequent gene expression. The role of hypoxia and its clinical implications in childhood cancer remain largely unknown. Therefore, studying the drug response of cancer cells within a hypoxic environment is critical for the accurate prediction of patients response to therapy.The aims of the present study were (1) to perform screening of the effects of 5 molecularly targeted compounds on a large panel of pediatric cancer cell lines including acute myeloid leukemia (AML), Ewings sarcoma (ES), osteosarcoma (OS), and neuroblastoma (NB), under normoxia and hypoxia, and (2) to determine the potential mechanisms of drug resistance under hypoxia.Methods and ResultsIn the present study the IC50 values were determined for the following targeting agents', ' linsitinib, picropodophylin (insulin-like growth factor-1 receptor), YM155 (survivin), AZD 8055 (mTOR), dovitinib (FLT3, c-kit, FGF4), and Palbociclib (CDK4/CDK6) in a panel of 15 AML, 4 ES, 2 OS and 2 NB cell lines using Cell Titer Glo assay. The effect of hypoxia was differential. It depended on the cell line and the compound used. However, hypoxia induced universal resistance to YM155 in all cell lines tested. YM155 had significant cytotoxicity in AML cell lines (IC50 between 2.5-1775 nM) in normoxia, however, the IC50 values in hypoxia were in the micromolar range, with an increase of > 100 fold. The effect of hypoxia on YM155 response in ES cell lines was less pronounced with (IC50s between 1-10 nM) in normoxia compared to (IC50 between 6 and 350 nM) in hypoxia. We studied the effect of hypoxia on the cell cycle using propidium iodide and flow cytometry in MV4-11 AML cells. Treatment with YM155 for 24 h in normoxia induced a pronounced decrease in the percentage of cells in S phase and G2/M phase and an increase in the sub-G1 phase. However, no change in cell cycle phases was detected under hypoxia. Ongoing studies are focusing on determining the mechanisms of hypoxia-induced YM155 resistance through studying the expression of proteins regulating hypoxia, cell cycle, and apoptosis using western blot.ConclusionThese data demonstrate that hypoxia induced different effects in a panel of pediatric cancer cell lines. However, it conferred pronounced resistance to YM155 in AML and ES cell lines. Hypoxia is likely a key factor in programming treatment resistance and, thus, relapse and poor outcomes.']",
        "Doc_id":"AACR_2016-2791",
        "Doc_title":" Hypoxia selectively confers resistance to the survivin-targeting compound YM155 in acute myeloid leukemia and Ewings sarcoma cell lines",
        "_version_":1606188986434322432},
      {
        "Meeting_name":" Diverse non-FLT3 molecular mechanisms of crenolanib resistance.",
        "Background":"['FMS-like tyrosine kinase 3 (FLT3) activating mutations are primary molecular targets for the treatment of acute myeloid leukemia (AML) due to high prevalence and unfavorable prognosis. Several type II FLT3 inhibitors have shown clinical benefits but acquisition of secondary FLT3 mutations was reported as a common mechanism of resistance. Previous studies showed that crenolanib, a type I FLT3 inhibitor, had clinical activity without acquisition of secondary FLT3 mutations. To identify the molecular mechanisms associated with crenolanib sensitivity and resistance, we performed exome sequencing on crenolanib treated patients with FLT3-mutant multiply relapsed or refractory AML. Baseline mutational analysis revealed distinct mutational profiles in patients with prior FLT3 inhibitor exposure, especially in the following pathways', ' NRAS, IDH1, WT1 and RUNX1.']",
        "Doc_id":"AACR_2017-3199",
        "Doc_title":" Diverse non-FLT3 molecular mechanisms of crenolanib resistance.",
        "_version_":1606189003547082752},
      {
        "Meeting_name":" The FLT3 inhibitor AC220 (quizartinib) inhibits drug transport by ABCG2 at pharmacologically relevant concentrations and sensitizes cells to ABCG2 substrate chemotherapy drugs.",
        "Background":"['The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3) is expressed on acute myeloid leukemia (AML) cells and is mutated, most commonly by internal tandem duplication (ITD), in 30% of cases, resulting in constitutive signaling and short disease-free survival following chemotherapy. FLT3 inhibitors have activity in AML with both FLT3-ITD and wild-type FLT3, but first-generation inhibitors have not had optimal potency, selectivity or pharmacokinetic properties. The second-generation bis-aryl urea FLT3 inhibitor AC220 inhibits FLT3-ITD and wild-type FLT3 at 0.1 and 0.5 M, respectively, in vivo, has excellent kinase selectivity and pharmacokinetic properties, has shown very good tolerability and activity in single-agent phase I and II trials, and will be tested in combination with chemotherapy. We therefore sought to characterize interactions of AC220 with ATP-binding cassette proteins associated with drug resistance in AML, including ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Uptake of fluorescent substrates and apoptosis were measured by flow cytometry, binding to ABCB1 and ABCG2 by effects on [125I]iodoarylazidoprazosin ([125I]-IAAP) photolabeling, and cell viability by the WST-1 colorimetric assay. AC220 (Selleck Chemicals, Houston, TX) inhibited transport of the fluorescent ABCG2 substrate pheophorbide A in ABCG2-overexpressing drug-selected 8226/MR20 and transfected K562/ABCG2 cells in a concentration-dependent manner, between 100 nM and 5 M, and inhibited transport of the fluorescent ABCB1 substrate DiOC2(3) in ABCB1-overexpressing drug-selected HL60/VCR and transfected K562/ABCB1 cells in a concentration-dependent manner between 500 nM and 10 M. AC220 inhibited [125I]-IAAP photolabeling of ABCG2 and ABCB1 with IC50 values of 0.27 M and 3.3 M, respectively. Co-incubation with AC220 at 0.1, 0.5 and 1 M sensitized K562/ABCG2 cells to the ABCG2 substrate chemotherapy drug mitoxantrone 1.6-, 3.3- and 6- fold, respectively, in the cell viability assay. Finally, co-incubation with AC220 at concentrations of 0.5, 1, 5 and 10 M increased apoptosis of K562/ABCG2 cells induced by fixed concentrations of the ABCG2 substrate chemotherapy drugs mitoxantrone and topotecan by 28, 45, 48 and 60% and 27, 61, 76, and 85%, respectively. We conclude that AC220 is a potent inhibitor of ABCG2-mediated drug transport at pharmacologically relevant concentrations. AC220 inhibition of ABCG2 should sensitize ABCG2-overexpressing AML cells to ABCG2 substrate chemotherapy drugs, but may also cause clinically significant pharmacokinetic interactions. These effects should be considered in the design and evaluation of regimens combining AC220 with chemotherapy drugs.']",
        "Doc_id":"AACR_2013-947",
        "Doc_title":" The FLT3 inhibitor AC220 (quizartinib) inhibits drug transport by ABCG2 at pharmacologically relevant concentrations and sensitizes cells to ABCG2 substrate chemotherapy drugs.",
        "_version_":1606189032693301248},
      {
        "Meeting_name":" Potent in vivo activity of the aurora kinase inhibitor ABT-348 in human acute myeloid leukemia and myelodysplastic syndrome xenograft models",
        "Background":"['The Aurora kinases are a family of serine/threonine kinases that mediate essential functions in cell division. Aurora A depletion results in accumulation of cells in the G2/M phase and apoptosis. Inhibition of Aurora B/C results in abnormal cell division, polyploidy, resulting in apoptosis, therefore, Aurora kinases present an attractive target for chemotherapy. Cells treated with aurora inhibitors enter mitosis with normal kinetics but fail to undergo cytokinesis due to mitotic spindle checkpoint disruption. ABT-348 is a novel adenosine triphosphate (ATP)-competitive inhibitor of Aurora A, Aurora B, and Aurora C (Enzyme IC50 A=116, B=5, C= 1 nM) and a potent inhibitor of all members of the VEGF and PDGF family of receptor tyrosine kinases (RTKs). Despite significant advances in the epidemiological, genetic and biological understanding of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), the basic therapeutic approach has not substantially changed for the last 10-15 years, so most patients still die of this disease. Here we demonstrate profound in vivo efficacy (with regressions) of ABT-348 in both AML (MV-4-11, FLT3 mutant expressing the internal tandem duplication with constitutive kinase activation) and MDS (SKM-1) xenograft models. MV-4-11 tumor-bearing SCID mice were treated at 6.25, 12.5 and 25 mg/kg/day, p.o., q7d x 3 (%TGI ratios on day 30 were 80, 86 and 94%, respectively). SKM-1 tumor-bearing SCID mice were treated at 6.25, 12.5 and 25 mg/kg/day, p.o., q7d x 3 (% tumor growth inhibition or TGI ratios on day 30 were 38, 59 and 80%, respectively). In addition, ABT-348 provided additive effects when combined with cytarabine, decitabine or doxorubicin compared to cytotoxic monotherapies. The treatments were well tolerated with no animal health concerns observed indicating the feasibility of ABT-348 combination strategies in the clinic. Currently ABT-348 is being evaluated (monotherapy and in combination with cytotoxic therapies) in the HL-60 acute promyelocytic leukemia xenograft model in vivo. Dose/scheduling studies for combination therapies in the SKM-1 and HL-60 xenografts are ongoing. Pharmacokinetic/pharmacodynamic biomarker analyses in these xenograft models were evaluated using phospho-H3 (an Aurora B substrate, proliferation) and cleaved caspase-3 (apoptosis) by IHC at various timepoints post single dose (1/2 hr to 5 days). A general decrease in proliferation and increase in apoptosis consistent with the mechanism of action was observed which coincided with the potent in vivo efficacy in xenograft models. Overall, ABT-348 is a potent, oral Aurora kinase inhibitor, demonstrating robust in antitumor activity in AML and MDS xenograft models with a good safety profile that warrants investigation in the clinic. ABT-348 is currently undergoing Phase I clinical trials in advanced hematologic malignancies.']",
        "Doc_id":"AACR_2012-858",
        "Doc_title":" Potent in vivo activity of the aurora kinase inhibitor ABT-348 in human acute myeloid leukemia and myelodysplastic syndrome xenograft models",
        "_version_":1606189005843464193},
      {
        "Meeting_name":" Insertion mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the D835Y mutation in acute myeloid leukemia.",
        "Background":"['Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for a large number of deaths. Mutation in FMS-like tyrosine kinase 3 (FLT3) is one of the most prevalent factor in this heterogeneous disease. The major mutations in FLT3 can be categories as internal tandem duplications (ITD) and point mutations. Recent studies suggest that ITDs are subdivided in to two groups depending on their location', ' the juxtamembrane domain (ITD-JM) and the tyrosine kinase domain (ITD-TDK). Although, ITD-JM has been characterized well the ITD-TKD has not yet been studied well due to its recent discovery. For this reason, we compared ITD mutations in TKD and JM, as well as the most frequently occurring point mutation located in the TKD, D835Y. The purpose of this study was to understand whether it is the mutationâ€™s nature or location that plays the driving role in leukemogenesis. We used a cytokine-dependent mouse pro-B cell line, BaF3, to overexpress different FLT3 mutants. We first examined the colony formation capacity in semisolid cytokine- and serum-free medium. The assay resulted in indistinguishable number and size of colonies for both ITD-JM and ITD-TKD, while D835Y-TKD transfected cells failed to form colonies suggesting that the ITD-TKD mutations have stronger transforming potential than other TKD mutations. In addition to colony formation assays, cell proliferation and survival was significantly higher in ITD-TKD expressing cells compared to cells expressing D835Y-TKD. Finally, we showed that phosphorylation of STAT5 and AKT is increased in ITD-TKD, while other FLT3 downstream signaling remained unaffected. All together, our data suggest that ITD-TKD displays higher oncogenic potential than other TKD mutants.']",
        "Doc_id":"AACR_2017-2380",
        "Doc_title":" Insertion mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the D835Y mutation in acute myeloid leukemia.",
        "_version_":1606189039966224385},
      {
        "Meeting_name":" Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML).",
        "Background":"['Background', ' AML is a disease with a high number of various mutations and genomic abnormalities; most of them have a proved prognostic value. We focused on FLT3 gene, which shows a high heterogeneity of mutations, to assess how difference in mutations affect prognosis. Methods', ' In a cohort of 459 consecutive patients, we analyzed at the diagnosis FLT3 gene with qualitative PCR, Denaturing High Pressure Liquid Chromatography, and Sanger sequencing in positive patients. Survival analysis was performed with Kaplan-Meier method using Mantel-Cox test. Results', ' At diagnosis, 55 out of 459 patients (12.0%) harbor ITD mutation, 22/459 (4.8%) TKD mutation; 4/459 (.9%) ITD mutated patients had concomitant TKD mutation. Median survival was 13.2 months in ITD group, 6.5 months in TKD group, and 27.2 months in ITD/TKD group. There were no statistical difference between these groups. In 3 TKD patients, ITD mutation was detected after first course of therapy; we cannot define if it is due to detection limit, or to a de novo mutation in a sub-clone. In 1 patient a TKD mutation emerged after several week of treatment with a FLT3 inhibitor, with concomitant loss of therapy response. This finding can underline a mechanism of resistance to FLT3 inhibitors drugs. In ITD mutant patients, we considered the number of nucleotide duplicated. Fifteen out of 55 patients harboring ITD involving a low number of nucleotides (ITD < 30 nucleotides) showed a better outcome in term of overall survival compared with 40/50 patients harboring ITD involving high number of nucleotides (ITD 30 nucleotides)(p = 0.009). Median OS was 33.8 and 12.6 months in the 2 groups, respectively. Conclusions', ' In AML, FLT3 mutation defines a poor prognosis. Particularly in the ITD group, we proved that patients with worst prognosis is identified by ITD major or equal to 30 nucleotides. In the era of personalized medicine, we should check biological impact of every peculiar mutation to better define treatment strategy tailored on single patients. Acknowledgments', ' founded by ELN, AIL, AIRC, Progetto Regione-Universit 2010-12 (L.Bolondi), FP7 NGS-PTL project']",
        "Doc_id":"ASCO_170267-176",
        "Doc_title":" Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML).",
        "_version_":1606189018887749632},
      {
        "Meeting_name":" Preclinical and pharmacological activities of protein arginine methyltransferase 5(PRMT5) enzyme inhibition in acute myeloid leukemia .",
        "Background":"['With standard cytotoxic chemotherapy the majority of patients with Acute Myeloid Leukemia (AML) fail to achieve long term remission. Protein Arginine Methyltransferase 5 (PRMT5) can catalyze methylation of arginine residues in target proteins like histones and P53. The epigenetic marks of PRMT5 on histones H3 (S2Me-H3R8) and H4 (S2Me-H4R3), directly lead to transcriptional silencing of genes. Overexpression of PRMT5 has been reported in hematologic and solid malignancies and represents a promising therapeutic target. Thus, we hypothesized that inhibition of PRMT5 enzymatic activity using a first in class, selective small molecule inhibitor BLL1 would result in antileukemic activity and novel methods to treat AML.PRMT5 was upregulated in AML-derived cell lines and primary patient samples. PRMT5 in complex with co-repressors like histone deacetylase (HDAC)s and DNA methyltrasferase (DNMT)s is involved in epigenetic silencing of tumor suppressor genes. Using Co-IP assay we captured PRMT5 in association with DNMT3a and HDAC2 in AML cells, in which treatment with BLL1 (25M) resulted in disruption of this interaction. We confirmed the ability and specificity of BLL1 by detecting the loss of unique epigenetic mark of PRMT5, S2Me-H3R8. We previously reported that pharmacologic inhibition of DNMTs (by decitabine) and HDACs (by AR42) or the disruption of their repressor complexes (by bortezomib) can inhibit critical oncogenes in AML, KIT and FLT3, by upregulating miR-29b and consequently lead to better clinical response in AML. Similar to these epigenetic-targeting compounds, BLL1 upregulated miR-29b (>7 fold; MV411, FLT3 ITD+ cells) and resulted in downregulation of FLT3 RNA (>4 fold) and protein (3.8 fold). We examined the in vitro antileukemic activity of BLL1 in AML and demonstrated a dose-dependent inhibition of cell proliferation (MTS assay) in AML cell lines (MV411; IC50=6M & Kasumi1, KITmut, IC50=11M) and primary patient blasts (#1, FLT3 ITD+, NPM1+, CD34; IC50=8M & #2, FLT3 ITD+, CD34+; IC50=7.5M). Colony forming ability was significantly decreased (p<0.001) in BLL1 (2M) treated AML cells compared to controls. We observed a BLL1-dependent increase in apoptosis measured by AnnexinV staining (25 & 50M, MV411; 8.6 fold & Kasumi1; 4 fold) within 48 hrs. BLL1 treatment promoted cell maturation measured by increased monocyte differentiation marker CD11b in AML cells (50M, MV411; 11.5 fold & Kasumi1; 6.8 fold) and primary patient blasts (25M, #1; 4 fold).In conclusion, our data suggest that inhibiting PRMT5 activity interferes with the production or activity of oncoproteins and, subsequently, disrupts leukemogenic and proliferation pathways in AML. Given the substantial antileukemic potential of PRMT5 inhibitor compound on AML cells and primary patient blasts, an assessment of therapeutic implications of this novel drug in vivo is highly warranted.']",
        "Doc_id":"AACR_2013-1128",
        "Doc_title":" Preclinical and pharmacological activities of protein arginine methyltransferase 5(PRMT5) enzyme inhibition in acute myeloid leukemia .",
        "_version_":1606189014752165888},
      {
        "Meeting_name":" Molecular characterization of normal karyotype acute myeloid leukemia in Korean patients.",
        "Background":"['Background', ' Recent advances in molecular characterization of AML have led to molecular classification of normal karyotype (NK) AML. Studies from the Western countries have shown favorable prognostic impact of NPM1 gene mutations. We investigated clinical implications of the NPM1 mutations as well as other gene alterations in Korean patients with NK AML. Methods', \" Patients included in this retrospective study had NK AML, received standard induction chemotherapy ('7+3' regimen), and had DNA samples from leukemic blasts at diagnosis. Polymorphisms of 4 genes (GSTT1, GSTM1, GSTA1, MDR1 [C3435T]) and mutations of 2 genes (FLT3, NPM1) were analyzed using PCR (GSTT1, GSTM1, FLT3- ITD), RFLP (GSTA1, MDR1 [C3435T]), and direct sequencing (NPM1). Clinico-laboratory data were retrieved from the Asan Medical Center Leukemia Registry. Results\", ' One hundred and two patients, 63 males and 39 females, were included. Median age was 44 years (range, 15-80). Null genotype of GSTM1 and GSTT1 was observed in 41.2% and 52.0% of the patients, respectively. Genotype of GSTA1 was CC in 75.3% and CT in 24.7%, and C3435T polymorphism of MDR1 gene was CC in 52.2%, CT in 39.1% and TT in 8.7%. FLT3-ITD was detected in 22.8% and NPM1 was mutated in 36.5%. For total patients, CR rate was 78.9%, and survival probabilities at 5-year were 39.9% for OS, 57.9% for RFS, and 42.5% for EFS. Multivariate analyses demonstrated independent prognostic factors for clinical outcomes of NK AML as followings', ' (1) for the induction of CR, no independently significant factor, (2) for OS, age (RR 2.710, P=0.003) and FLT3-ITD (RR 1.947, p = 0.025), (3) for RFS, age (RR 6.333, p < 0.001), FLT3-ITD (RR 3.658, p = 0.002), and uric acid level (RR 2.833, p = 0.027), and (4) for EFS, age (RR 3.422, p = 0.003), FLT3-ITD (RR 2.655, p = 0.005), and C3435T of MDR1 (RR 0.449, p = 0.013). Conclusions', ' Mutations of the NPM1 gene did not show significant impact on clinical outcomes in Korean patients with NK AML, whereas presence of a FLT3-ITD mutation was significantly associated with inferior survivals. Racial differences in clinical significance of genetic alterations should be considered before molecular classification is established in NK AML.']",
        "Doc_id":"ASCO_52314-74",
        "Doc_title":" Molecular characterization of normal karyotype acute myeloid leukemia in Korean patients.",
        "_version_":1606189003487313920},
      {
        "Meeting_name":" Improved sensitive detection method of FLT3 (FMS-like tyrosine kinase) internal tandem duplication (ITD) mutation using next-generation sequencing technology and nested PCR",
        "Background":"['Sensitive detection of internal tandem duplication (ITD) mutation of FLT3 is very important in acute myeloid leukemia. To increase detection sensitivity of FLT3-ITD, we developed new detection algorithm using next generation sequencing (NGS) data. We validated results using nested polymerase chain reaction (PCR) methods. We compared results of NGS data, nested PCR and conventional PCR methods.First, using whole exome sequencing data of 83 AML patients, we applied calling algorithm for FLT3-ITD. Briefly, to detect ITDs with NGS data, the reads are aligned to a reference sequence (UCSC hg19), with BWA which is a read aligner allowing soft-clipping. Some reads can be an indication of the occurrence of ITD and BWA aligns those reads as soft-clipped.Second, we deigned two types of primer for Nested PCR. The first primer was targeted wildly for between exon14 and exon15 of FLT3 gene. Nested PCR primer was deigned to target previously reported regions which are frequently occurred ITD mutation. PCR reactions of two steps were performed using the PCR primers sequentially.In these 83 patients, FLT3-ITD was positive only in 7 patients when tested by conventional PCR methods. When NGS detection method was applied, this resulted in positive FLT3-ITD in 11 patients (11/83, 13%). When validation was performed using nested PCR, FLT3-ITD was confirmed in all of 11 patients. Nested PCR detected additional 4 patient positive for FLT3-ITD in this population. For 68 patients, FLT3-ITD was negative by both NGS and nested PCR method. Overall, NGS method improved sensitivity of FLT3-ITD detection by 57% in this population. And the concordance rate of NGS method and nested PCR was 95.2% (79/83).Then we investigated clinical significance of sensitive FLT3-ITD detection. For this, we performed nested PCR and conventional PCR at the same time in 238 AML patients to detect FLT3-ITD. Positive rate for FLT3-ITD was 20% (48/238) and 10% (24/238) by nested PCR and conventional PCR respectively. When survival analysis was performed, among patients with negative FLT3-ITD result by conventional PCR, patients who showed positive for FLT3-ITD by nested PCR had shorter overall survival compared to those who showed negative for FLT3-ITD by nested PCR. (p = 0.03). This implies that sensitive FLT3-ITD detection using nested PCR is clinically meaningful.Diagnosis of FLT3-ITD is very important genetic factor, leading a therapeutic direction for AML patient. Here we report that we have developed alternative more sensitive detection methods for FLT3-ITD based on nested PCR and NGS. Sensitive detection of FLT3-ITD was clinically meaningful, suggesting that these methods should be incorporated in a future clinical practice. Also, we want to note that, NGS method is capable of quantifying FLT3-ITD size and amount in AML patients.']",
        "Doc_id":"AACR_2016-3186",
        "Doc_title":" Improved sensitive detection method of FLT3 (FMS-like tyrosine kinase) internal tandem duplication (ITD) mutation using next-generation sequencing technology and nested PCR",
        "_version_":1606188996704075777},
      {
        "Meeting_name":" Next generation sequencing in acute myeloid leukemia",
        "Background":"['Acute myeloid leukemia (AML) represents a heterogeneous group of aggressive myeloid malignancies characterized by the accumulation of blasts in the bone marrow. The prognosis of AML is variable, likely reflecting its diversity at a genetic level. The pathogenesis of AML has not been completely defined; however it is clear that recurrent chromosomal abnormalities (e.g., translocations and numeric abnormalities) and genetic events (e.g., point mutations and indels) are necessary for disease development. Genetic changes are diverse and consist of large genomic changes such as rearrangements and ploidy anomalies, as well as submicroscopic changes, including point mutations and indels. Few studies have correlated cytogenetically detected anomalies with molecularly detected mutations in AML. Here we describe our experience using a hematological next generation sequencing (heme-NGS) panel in conjunction with conventional cytogenetic studies to interrogate diagnostic AML specimens in a routine clinical setting. Next generation sequencing was done using a custom designed amplicon panel and Illumina TruSeq Custom Amplicon (TSCA) capture. Using a customized bioinformatics pipelines we were able to detect single nucleotide variants (SNV) and small insertion/deletion (indel) to a lower limit of 5% with 100% sensitivity and specificity. 28 genes recurrently mutated in myeloid malignancies were examined including targeted regions of NPM1, FLT3, KIT, PTPN11, NRAS, IDH1, IDH2, JAK2, DNMT3a, EZH2, PTEN, CEBPA, TP53, WT1, RUNX1, TET2, ATM, BRAF, CBL, MPL, SF3B1, ASXL1, HRAS, KRAS, PHF6, GNAS, ETV6 and MYD88. Over 100 specimens were analyzed by NGS and cytogenetics , with only a single case being normal by both tests. Comparison of mutation-positive AML demonstrated more mutations present in cytogenetically normal cases, compared with those with chromosome abnormalities detected. Conversely, in 11 cases no mutations were detected by heme-NGS, with 10/11 of these cases showing recurrent cytogenetic abnormalities. In those cases where NGS mutations were identified, comparison of cases with normal (CN-AML) and abnormal (CA-AML) cytogenetic studies demonstrated different mutation frequencies, with more mutations detected in CN-AML. Interestingly, TP53 was the most commonly mutated gene in CA-AML and least mutated in CN-AML. These results illustrate the complementary information gained from NGS sequencing performed with conventional cytogenetic studies in diagnostic AML specimens, providing a comprehensive picture of the genomic landscape in this disease. A complete description of these combined cytogenetic and molecular abnormalities seen in AML and correlation with clinical features will be presented.']",
        "Doc_id":"AACR_2014-5609",
        "Doc_title":" Next generation sequencing in acute myeloid leukemia",
        "_version_":1606189028160307200},
      {
        "Meeting_name":" Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML",
        "Background":"['FMS-like receptor tyrosine kinase-3 (FLT3), a member of the class III tyrosine kinase receptor family, is expressed by immature hematopoietic cells, and highly associates with acute myeloid leukemia (AML). While acquired resistance to selective FLT3 inhibitors, the treatment became inefficient. Many literatures suggested that dual FLT3-Aurora inhibition may overcome selective FLT3 inhibitor resistance, in part due to inhibition of Aurora kinase, and may benefit patients with FLT3-mutated AML. Thus, utilizing dual FLT3-Aurora inhibitors may be the viable therapy for the treatment of AML.Recently, our group reported a novel AURKA inhibitor by using high-throughput parallel synthesis and structure-based drug design (SBDD). Based on this, we wanted to modify the selective AURKA inhibitor to maintain its Aurora A inhibition as well as improve its FLT3 activity to develop dual FLT3-Aurora kinase inhibitors. Through rapid construction of the platform of FLT3 virtual screening, the lead was quickly and efficiently identified. Proceeding investigation of structure-activity relationship could lead to 6-phenyl pyrrolopyrimidine analogue, showing FLT3 inhibition with an IC50 of 101 nM as well as Aurora kinase A inhibition with an IC50 of 33 nM. To further increase the level of inhibition of FLT3, binding energy calculations and docking study of FLT3 model were introduced to select terminal groups of the side chain with high priority. The selected compounds were synthesized and evaluated the bioactivity. The dramatic antiproliferation of the dual FLT3-AURKA inhibitor against MOLM-13 and MV4-11 (FLT3-ITD (+) human AML cell lines) was observed, and its biologic mechanism of inhibition of FLT3 and Aurora kinase A was proved the by significant evidence of biomarker. For this finding, this novel inhibitor holds potential for further development of preclinical investigations as an anti-AML drug candidate.']",
        "Doc_id":"AACR_2014-2530",
        "Doc_title":" Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML",
        "_version_":1606189029724782592},
      {
        "Meeting_name":" FLT3/ITD acute myeloid leukemia (AML) cells show C-MYC- and PIM-1-mediated CDC25A overexpression despite the presence of intrinsic DNA damage",
        "Background":"['Activating mutations of FLT3 occur in 30% of patients with AML, and are associated with poor prognosis. It has been reported that FLT3/ITD AML cells are sensitive to MDM2 inhibition-induced apoptosis (Blood 2010;116', '71) and indeed, FLT3 inhibition synergizes with MDM2 inhibition in the induction of apoptosis in FLT3/ITD AML (Leukemia 2010;24', '33). Considering the rarity of TP53 mutations in FLT3/ITD AML, use of MDM2 inhibitors in AML with mutant FLT3 may offer clinical benefits. We investigated the FLT3/ITD-specific p53 signaling profile that may be associated with high susceptibility of FLT3/ITD cells to MDM2 inhibition. [Methods] The MDM2 inhibitor Nutlin-3a was used. Murine pro-B cells stably transfected with expression vectors that encoded wild-type human FLT3 (Ba/F3-FLT3 cells) or human FLT3 containing an ITD mutation (Ba/F3-ITD cells) were provided by Dr Donald Small and AML samples were obtained from patients after informed consent. Apoptosis was quantified by Annexin binding assay and cells were transfected by the Amaxa Nucleofector I. Statistical analysis was performed using t test or Mann-Whitney U test. [Results] Ba/F3-ITD cells were more susceptible to Nutlin-induced apoptosis but not to AraC or doxorubicin than Ba/F3-FLT3 cells; high Nutlin-3a sensitivity was associated with efficient BAX activation (P < .001). Basal levels of total and phospho p53 were 7 times higher in Ba/F3-ITD than in Ba/F3-FLT3 cells; levels of H2AX, a DNA damage marker, were 6 times higher in Ba/F3-ITD than in Ba/F3-FLT3 cells, and reactive oxygen species levels were also high in Ba/F3-ITD cells (26.2  3.2% vs 6.1  0.1%; P < .001). Although steady state p53 activation was not sufficient to inhibit cell growth or induce cell death in Ba/F3-ITD cells, Nutlin-3a potently activated p53 signaling and induced apoptosis. Interestingly, CDC25A, which is specifically degraded in response to DNA damage, was 30 times higher in Ba/F3-ITD cells compared to Ba/F3-FLT3 cells, despite the presence of DNA damage. Among patient AML samples (n=37), CDC25A levels were significantly higher in samples with mutant FLT3 (n=16) than those with wild-type FLT3 (n=21) (1.7  1.2 vs 17.1  6.7; P < .001). Knockdown experiments showed that CDC25A over-expression was partially induced by C-MYC and PIM-1. Nutlin-3a reduced CDC25A mRNA levels by 63.9  0.4 % (P < 0.01). The proteasome inhibitor MG132 or the pan-caspase inhibitor Z-VAD-FMK did not rescue the CDC25A reduction. [Conclusion] CDC25A over-expression was closely associated with FLT3/ITD in AML. FLT3/ITD cells showed C-MYC- and PIM-1-mediated CDC25A over-expression despite the presence of intrinsic DNA damage. CDC25A over-expression has been reported in a variety of human cancers, and CDC25A has been considered a therapeutic target. CDC25A down-regulation may be potential mechanism by which MDM2 inhibition induces cell death in FLT3/ITD AML cells.']",
        "Doc_id":"AACR_2012-3021",
        "Doc_title":" FLT3/ITD acute myeloid leukemia (AML) cells show C-MYC- and PIM-1-mediated CDC25A overexpression despite the presence of intrinsic DNA damage",
        "_version_":1606189004197199872},
      {
        "Meeting_name":" Single center experience treating adults with FLT3-mutated acute myeloid leukemia (AML).",
        "Background":"['Background', ' Activating mutations of the fms-like tyrosine kinase-3 (FLT3) gene are common in AML. Depending upon the allele mutation fraction, these mutations have been associated with poor outcomes in prospective multi-center trials. Methods', ' We studied a consecutive series of adults with FLT3-mutated leukemia at our institution since we began testing in 2006 through Sept 2011. Clinical characteristics and patient (pt) outcomes were extracted through a retrospective chart review and analyzed using logistic regression and Cox proportional hazard models. Results', ' We identified 73 pts with a FLT3 mutation (71 with AML and 2 with myelodysplasia with <20% blasts). 62 (85%) presented to our institution at initial diagnosis; 11 (15%) were diagnosed elsewhere and seen by us only at relapse. 44 (60%) were men and 51 (70%) were white. Median age was 62 yrs (range, 19-90); 48% were <60 yrs old. 63 (86%) had an internal tandem duplication (ITD) mutation, 9 (12%) had the D835 point mutation (TKD), and 1 had both. An NPM1 mutation was also present in 26 (36%).  Median white blood cell count at diagnosis was 53 x 103/L (range, 0.8 - 466). 34 (47%) had monocytic morphology (M4 or M5). 8 (11%) pts had favorable karyotypes; 50 (68%) had normal karyotypes; 13 (18%) had unfavorable karyotypes. 58 (79%) received standard induction therapy (anthracycline + cytarabine for most; ATRA + arsenic trioxide for 3 with APL); 46/58 (79%) achieved a complete remission (CR). Including the 15 pts who received only low intensity therapies, 40/64 (63%) with an ITD and 6/9 (67%) with a TKD mutation achieved CR. 31 (42%) pts received an allogeneic transplant, 21 in first CR (CR1) and 10 after relapse. Median overall survival (OS) for the whole group was 417 days (95% CI', ' 291-780); it was 684 days for those diagnosed at our institution and 285 days for those seen only after relapse. Median disease-free survival (DFS) in CR1 was 417 days. Median OS for pts transplanted in CR1 was 1262 days from initial diagnosis and 416 days for those transplanted after relapse. DFS did not differ with or without a transplant (median, 526 vs 305 days; p=.64).  Conclusions', ' FLT3-mutated AML is heterogeneous. Our single center experience is similar to that reported from multi-center trials.']",
        "Doc_id":"ASCO_95630-114",
        "Doc_title":" Single center experience treating adults with FLT3-mutated acute myeloid leukemia (AML).",
        "_version_":1606189010667962368},
      {
        "Meeting_name":" Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).",
        "Background":"['Background', ' RAS-RAF-MEK-ERK pathway is activated in >75% of AML patients (pts). Selumetinib (AZD6244) is an orally bioavailable small molecule inhibitor of the MEK kinase. We report here the results of a phase II multicenter trial using selumetinib in advanced AML pts. Methods', ' Pts 18 years (yrs) with relapsed/refractory AML or 60 yrs old with untreated AML who were not candidates for standard chemotherapy were eligible. Pts received selumetinib 100mg twice daily. Pts were screened for KRAS, NRAS and FLT3 mutations. Analysis for p-ERK (downstream of MEK) was performed by flow-cytometry. Results', ' 47 pts (27 men) were enrolled. Median age was 69 yrs (range, 26-83). 85% were 60 yrs. Disease stage included previously untreated AML (13 pts, all were  60 yrs; 11 had prior therapy for antecedent hematologic disease), primary refractory AML (14 pts), 1st relapse (8 pts) and beyond first relapse (12 pts). Overall, 51% pts had secondary AML. Median number of prior therapies was 2 (range, 0-6). 51% had poor-risk cytogenetics. 10 pts had a FLT3 ITD, 3 pts had an NRAS mutation and one pt had a KRAS mutation. Selumetinib was well tolerated. Median number of cycles administered was 1 (range, 1-21). 49% received 2 cycles. Grade 3 adverse events possibly related to the drug included fatigue, dyspnea, and nausea occurring in 9%, 9% and 6% respectively. 1 pt has partial response, 3 pts had minor response (>50% decrease in blood and/or marrow blasts lasting >4 weeks), 2 pts had unconfirmed minor response (uMR', ' >50% decline in marrow blasts without a follow up confirmatory biopsy), 4 pts had stable disease (median', ' 16.5 weeks, range', ' 9-85). No pt with FLT3 ITD or NRAS mutation responded. The sole pt with KRAS mutation had uMR with hematologic improvement in platelets. Analysis of p-ERK showed baseline activation in 15/21 (71%) pts, but no difference in baseline levels in the responders vs non-responders (p=0.27). Conclusions', ' Administration of selumetinib in advanced AML is associated with modest antileukemic activity, which is independent of baseline p-ERK levels. Given its favorable toxicity profile, combination with drugs that target relevant signaling pathways in AML should be considered. (Sponsored by NCI grant NO1-CM-62201)']",
        "Doc_id":"ASCO_98251-114",
        "Doc_title":" Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).",
        "_version_":1606189030651723777},
      {
        "Meeting_name":" The novel retinamide VNLG-152, which targets translation by promoting degradation of MAPK-interacting kinases, has preferential activity in acute myeloid leukemia with FLT3-ITD",
        "Background":"['Purpose', ' Acute myeloid leukemia (AML) with internal tandem duplication (ITD) mutations of the fms-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase has a poor prognosis, with short disease-free survival following both chemotherapy and allogeneic hematopoietic stem cell transplantation. FLT3 inhibitors are active, but their activity is limited and transient. New treatments and approaches are needed. The novel retinamide (NR) VNLG-152, targets translation by promoting degradation of MAPK-interacting kinases (Mnks), thereby inhibiting phosphorylation of eukaryotic translation initiation factor 4E (eIF4E), a downstream target of FLT3-ITD. eIF4E aids in translation by recruiting ribosomes to mRNA, a process that is upregulated in AML with FLT3-ITD. The association of the eIF4E protein complex is the rate- limiting step in translation initiation. We characterized the effects of VNLG-152 in AML cell lines and patient samples with FLT3-ITD and with wild-type FLT3.Methods', ' Cell lines studied included human MV4-11 and MOLM-14, with endogenous FLT3-ITD expression, HL60 and U937, with wild-type FLT3, and Ba/F3-ITD and Ba/F3-WT, which are murine Ba/F3 cells transfected with human FLT3-ITD and wild-type FLT3, respectively. Cytotoxicity was measured in a WST-1 colorimetric assay, proliferation by carboxyfluorescein diacetate succinimidyl ester (CFSE) staining, and apoptosis by Annexin V-FITC and propidium iodide labeling, measured by flow cytometry. AML patient samples obtained on an IRB-approved protocol were studied in cytotoxicity assays.Results', ' VNLG-152 was cytotoxic to the human FLT3-ITD AML cell lines MV4-11 and MOLM-14 with low micromolar IC50 concentrations, while IC50 concentrations were greater than 10 M in the wild-type FLT3 AML cell lines HL60 and U937. IC50s in Ba/F3-ITD and Ba/F3-WT cells were 3.6 M (95% CI, 3.0-3.9 M) and 5.7 M (95% CI, 5.0-6.4 M), respectively. The cellular effects of VNLG-152 were evaluated further in Ba/F3-ITD cells. Concentration-dependent slowing of proliferation was seen at low micromolar concentrations, while concentration-dependent pro-apoptotic effects occurred at higher concentrations. VNLG-152 was also cytotoxic to blasts isolated from FLT3-ITD AML patient samples at IC50 concentrations <1 M, whereas its IC50 concentrations in blasts from AML patient samples with wild-type FLT3 were > 5 M.Conclusion', ' We conclude that the novel Mnk degrading agent VNLG-152 is active in AML with FLT3-ITD. Subsequent work will examine combinations with FLT3 inhibitors and with chemotherapy drugs in this prognostically unfavorable AML subtype.']",
        "Doc_id":"AACR_2015-5408",
        "Doc_title":" The novel retinamide VNLG-152, which targets translation by promoting degradation of MAPK-interacting kinases, has preferential activity in acute myeloid leukemia with FLT3-ITD",
        "_version_":1606189031209566208},
      {
        "Meeting_name":" Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.",
        "Background":"['Background', ' We investigated the clinical activity, PK, safety and resistance mechanisms to single-agent crenolanib patients (pts) with refractory/relapsed acute myeloid leukemia (R/R AML) with FLT3 ITD. Methods', ' From Aug 2012 to May 2015, 69 pts (65 evaluable) with R/R FLT3+ AML (29 ITD, 11 D835, 29 ITD+D835) were treated with crenolanib 100 mg TID (42) or 200 mg/m2/d in 3 divided doses (27). Results', ' Crenolanib therapy resulted in a 39% CRi and 11% PR amongst the 18 pts (6 D835, 9 ITD, 3 ITD+D835) with R/R FLT3 AML who had not received prior FLT3 inhibitors (Cohort A). OS was 234d (238d in pts with  2 prior therapies and 133d in  3 prior therapies). Activity was seen in FLT3 ITD (OS 238d), TKD (OS 185d), and TKD+ITD (128d). Pts < 60 had a higher survival (OS 234d) than those  60 (OS 185d). 36 pts received crenolanib after progressing on prior TKIs (Cohort B), sorafenib (28), quizartinib (11), midostaurin (3), pexidartinib (4), gilteritinib (2) and FLX-925 (1). 10 pts had received  2 prior TKIs. FLT3-TKD mutations were acquired in 25 pts following TKI exposure', ' 19/36 had dual mutations with FLT3-ITD and FLT3-D835 (15 ITD, 2 D835). Overall RR was 31% (6 CRi, 5 PRs). OS was 94d in this cohort (158d in ITD, 63d in the dual ITD+D835 mutants). Cohort C consisted of 11 pts who developed FLT3+ AML after prior MDS (8 pts), and 1 pt each after prior myelofibrosis, polycythemia vera and systemic mastocytosis. These pts had only transient benefit from crenolanib, with OS of 55d. Crenolanib had predictable PKs (tmax 2 hrs, T1/2 7.5 hrs), with no accumulation seen with repeated dosing. Median Day 15 trough level was 352 nM documenting therapeutic drug levels. Common AEs included nausea/vomiting, transaminitis and fluid retention (majority Grade 1/2). Only 2 pts discontinued crenolanib due to related AEs. No pt acquired a secondary FLT3 mutation at the time of relapse following crenolanib. Conclusions', ' Encouraging single-agent activity, safety and PK is observed with crenolanib in multiply relapsed FLT3+ AML (including 40 pts with FLT3 D835 mutations). Crenolanib isnow being assessed in combination with standard chemotherapy in newly diagnosed and R/R AML. Clinical trial information', ' NCT01657682 and NCT01522469']",
        "Doc_id":"ASCO_170782-176",
        "Doc_title":" Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.",
        "_version_":1606189033688399872},
      {
        "Meeting_name":" First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for the treatment of hematological malignancies",
        "Background":"['Despite huge effort spent on understanding acute myeloid leukemia (AML), current standards of care are still based on the same chemotherapy agents as two decades ago - typically based on cytarabine chemotherapy with an anthracycline. Although patients aged <60 years may achieve remission to induction therapy, most patients will relapse. One of primary reasons for that is high heterogeneity of the disease. Recently one of the most extensively investigated approaches to the treatment of AML, are targeted therapies, especially inhibition of certain kinases. Probably mostly investigated up to date are inhibitors of FLT3 with most advanced clinical compound - AC220 (Quizartinib). FLT3 inhibitors are very effective in killing cancer lines with a major drawback of the therapy being fast development of resistance.PIM kinases are expressed in various cancers including AML but also other liquid tumors as well as in some solid tumors. Inhibition of PIM kinases which are downstream in the FLT3 signaling cascade have already shown influence on cancer cell survival. In addition there are great hopes related to the fact that PIM kinases were shown to contribute in resistance to FLT3 inhibitors. This leads to the conclusion that combined inhibition of PIM and FLT3 may be a rational strategy.Selvita has developed series of inhibitors combining activity against PIM and FLT3 kinases. Selected clinical candidate SEL24-B489 - has shown excellent anticancer efficacy. It is active against broad panel of AML cell lines and primary blasts, but also against other hematological cancers', ' DLBCL, CLL, HL - both in vitro on cell lines, patient samples and in vivo. Head to head comparison of SEL24-B489 with PIM (AZD1208) and FLT3 (AC220) inhibitors currently in clinical development will be presented. Comparison shows strong activity of SEL24-B489 against broader panel of cell lines in vitro and in vivo (in xenograft models) than AZD1208 or AC220. SEL24-B489 is currently in preclinical development and details of toxicology profile will also be discussed.']",
        "Doc_id":"AACR_2015-5394",
        "Doc_title":" First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for the treatment of hematological malignancies",
        "_version_":1606189042110562304},
      {
        "Meeting_name":" Decitabine response in FLT3-negative AML is associated with mitochondrial priming",
        "Background":"[\"To date, acute myeloid leukemia (AML) remains a poor-prognosis disease with only approximately 25% of patients surviving five years after being diagnosed (SEER  2005-2011). There are a wide variety of treatment options ranging from intense chemotherapy to targeted therapies. Beyond tolerability, identifying the ideal treatment strategy for each patient remains a difficult task. Mitochondrial profiling of AML patient samples using Bcl-2 homology domain (BH3) mimetics has proven to accurately identify patients that respond to several therapies in AML. In this method, cancer cells are exposed to BH3 mimetics designed to test for susceptibility to induction of apoptosis. The readout, called BH3-Priming indicates anti-apoptotic protein dependencies in cancer cells.In this study, samples from AML patients that were treated with at least one cycle of the hypomethylating agent, decitabine, at The Ohio State University were collected and BH3 profiled (n = 64). The patients were assessed for a complete response to the drug and were characterized by several molecular biomarkers including FLT3 mutational status. We found that the FLT3 mutation negative patients (n = 32) who responded to decitabine had significantly higher mitochondrial responses to the BIM and HRK mimetics (p = 0.04) compared with non-responders. We also found that FLT3 mutant patients (n = 12) had significantly (p = 0.02) higher priming than those patients lacking those lesions. Surprisingly, despite being apparently more predisposed towards apoptosis, these patients are less likely to respond to decitabine (42% versus 20%) in vivo than those without these mutations. This could indicate that additional non-mitochondrial inhibitory mechanisms are present in those FLT3 mutant leukemias that prevent response to decitabine.To further examine the interaction between FLT3 and mitochondrial priming, we profiled engineered cell lines with and without FLT3 mutations. We found that mitochondrial priming was significantly lower (p = 0.03) in BAF3 cells with unmutated FLT3 compared with five BAF3 cell lines containing FLT3 mutations (ITD and TKD mutations). Further, we examined the Broad Institute's Cancer Therapeutics Response database (CTRP v 2.0) for cancer cell line response to decitabine and found that wild type FLT3 cell lines that responded to decitabine had significantly higher mitochondrial priming than those that did not respond to the drug (p = 0.04), consistent with the patient data.Taken together, we have discovered that response to decitabine in AML cell lines and AML patient samples depends on mitochondrial dependencies and FLT3 mutational status. Genetic lesions in FLT3; however, may be able to over-ride mitochondrial responsiveness to pro-apoptotic factors, illustrating the probable need to measure multiple attribute types including genetics and ex vivo functional testing to accurately determine the likelihood of response to AML therapies.\"]",
        "Doc_id":"AACR_2016-2282",
        "Doc_title":" Decitabine response in FLT3-negative AML is associated with mitochondrial priming",
        "_version_":1606189000448540672},
      {
        "Meeting_name":" Dual inhibitors of Flt3 and c-Fest tyrosine kinases potently inhibit proliferation of AML cells expressing an active Flt3 mutant.",
        "Background":"['Acute myelogenous leukemia (AML) is a hematologic cancer associated with advancing age and relatively poor prognosis. Although diverse genetic changes are associated with AML, about one-third of cases involve activating mutations in the receptor tyrosine kinase, Flt3. Clinical trials of most Flt3 tyrosine kinase inhibitors have been disappointing, indicating that additional signaling pathways contribute to the transformed phenotype. Previous studies have linked the c-Fes protein tyrosine kinase to Flt3 in AML, and RNAi-knockdown studies suggest that c-Fes may be required for Flt3 function. Recently, our laboratory reported several classes of inhibitors with favorable selectivity profiles for c-Fes both in vitro and in cell-based assays. In this study, we tested c-Fes inhibitors from four different chemical classes for their growth-suppressive activity against myeloid leukemia cells lines with an activating mutation in Flt3 (MV4-11 cells) vs. wild-type Flt3 (THP-1). All c-Fes inhibitors tested potently inhibited the growth of MV4-11 AML cells, but were far less active against THP-1 cells. The IC50 values for inhibition of MV4-11 cell proliferation by c-Fes inhibitors of the diaminopyrimidine, phenoxyquinazoline and pyrrolopyrimidine classes ranged from 25-140 nM, rivaling the potency of the clinical Flt3 inhibitors lestaurtinib and tandutinib. In contrast, two pyrazolopyrimidine c-Fes inhibitors were less potent in MV4-11 cells, with IC50 values for growth arrest in the low micromolar range. KINOMEscan analysis, an indirect binding assay which provides a relative measure of inhibitor selectivity across the kinome, suggested that the more potent compounds may have dual specificity for both Flt3 and c-Fes while the less potent compounds may be more selective for c-Fes alone. To test this idea, we performed in vitro kinase assays with recombinant purified c-Fes and Flt3 proteins. We observed that the most potent inhibitors of MV4-11 AML cell proliferation inhibited both c-Fes and Flt3 kinase activity, with IC50 values in the 0.2-1.5 M range for c-Fes and in the 0.2-4.0 M range for Flt3. For example, the phenoxyquinazoline analog TL02-59 showed similar potency against both c-Fes (IC50 of 1.0-1.5 M) and Flt3 (IC50 of 0.6-4.0 M) in vitro, and potently blocked MV4-11 cell proliferation (IC50 of 26.5 nM) and induced apoptosis. In contrast, the pyrazolopyrimidine inhibitor WZ4-49-8, which exhibited 20-fold greater selectivity for c-Fes over wild-type Flt3 in vitro, was less active against MV4-11 cell proliferation (IC50 of 1.86 M) and produced a lower apoptotic response than TL02-59. Interestingly, the established Flt3 inhibitor lestaurtinib was also a relatively potent inhibitor of c-Fes, yielding IC50 values in the 0.4-0.8 M range. These results suggest that dual inhibition of both Flt3 and c-Fes may provide a therapeutic advantage for the treatment of AML.']",
        "Doc_id":"AACR_2013-2086",
        "Doc_title":" Dual inhibitors of Flt3 and c-Fest tyrosine kinases potently inhibit proliferation of AML cells expressing an active Flt3 mutant.",
        "_version_":1606188996142039040},
      {
        "Meeting_name":" Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies.",
        "Background":"['Despite huge effort spent on understanding the pathogenesis of acute myeloid leukemia (AML), current standards of care are still based on the same chemotherapy agents as two decades ago - combinational treatment of cytarabine with an anthracycline. Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in AML. Although FLT3 inhibitors initially exhibit clinical activity, resistance to treatment inevitably occurs within months. PIM kinases are thought to be major drivers of the resistance phenotype and their inhibition in relapsed samples restores cell sensitivity to FLT3 inhibitors. Thus, simultaneous PIM and FLT3 inhibition represents a promising strategy in AML therapy. Selvita has developed a potent and selective first-in-class, dual PIM/FLT3 kinase inhibitor, the SEL24-B489 compound, and profiled its activity for in vitro and in vivo AML models showing significantly broader anti-tumor activity of SEL24-B489 than selective FLT3-ITD or PIM inhibitors. We compared SEL24-B489 head-to-head with a selective PIM inhibitor (AZD1208) and a selective FLT3-ITD inhibitor (AC220) in a panel of AML cell lines with FLT3-ITD or unmutated kinase (FLT3-WT) as well as peripheral AML cells and CD34+ bone marrow blasts. SEL24-B489 exhibited a significantly broader activity, irrespective of FLT3 status, than either of the selective inhibitors. Since PIM kinases have emerged as important mediators of FLT3-inhibitor resistance, we hypothesized that the dual specificity of SEL24-B489 might overcome the phenotype of resistance. We utilized previously developed MOLM-14 cells transduced with either FLT3-WT or FLT3 alleles containing TKD point mutations to show that neither of the these mutations decreased the cellular sensitivity to SEL24-B489. Higher cellular activity and biomarker response of SEL24-B489 than competitive inhibitors was shown by inhibition of specific biomarkers such as S6 and STAT5 phosphorylation at nanomolar concentrations in both FLT3-ITD positive and FLT3-WT cell lines in vitro. We have also demonstrated SEL24-B489 superior potency of SEL24-B489 in xenograft models in vivo. Consistent with the experiments in vitro showing marked synergy between SEL24-B489 and AraC, a combination of these agents resulted in almost completely blocked tumor growth in vivo. Most importantly, SEL24-B489 has been selected as a clinical candidate and is currently in phase I clinical trials.']",
        "Doc_id":"AACR_2017-4087",
        "Doc_title":" Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies.",
        "_version_":1606188977359945728},
      {
        "Meeting_name":" Characterization of novel STAT5 inhibitors to interfere with the oncogenic activities of STAT5 in hematopoietic diseases.",
        "Background":"['Activation of the transcription factor STAT5 is essential for the pathogenesis of acute myeloid leukemia (AML) containing the FLT3 internal tandem duplication (ITD). FLT3 ITD is a constitutively active tyrosine kinase (TK) that drives the activation of STAT5 leading to the growth and survival of AML cells. Although there has been some success in identifying TK inhibitors that block the function of FLT3 ITD, treatment options are still limited. This is mainly due to drug resistance development by mutations that allow for the continued activation of STATs. Since STAT5 represents a critical mediator of malignant cellular behavior and sits at the convergence point of many kinase pathways, the direct targeting of STAT5 may be an effective means of overcoming this resistance to TK inhibitors. First, we screened a library of potential STAT5 inhibitors for specific SH2 domain binders using a fluorescent polarization assay. Thereby, we identified small inhibitory molecules, called AC-3-019 and AC-4-130, that bind to the SH2 domain of STAT5, subsequently resulting in the disruption of the reciprocal STAT5-phosphopeptide interactions. They efficiently blocked kinase-mediated phosphorylation, dimer formation, nuclear translocation, DNA binding and STAT5 mediated target gene expression. Further, we observed a time- and dose-dependent impairment of proliferation, blocked cell cycle progression and increased apoptosis. Studies with human AML patient-derived samples similarly showed an induction of apoptotic cell death and decreased colony forming capabilities. A combinatorial drug screen revealed synergistic effects with TK inhibitors, as well as with drugs standardly used in the treatment of AML patients, e.g. Cytarabine. Finally, AC-3-019 and AC-4-130 significantly suppressed tumor growth in vivo without general toxicity in healthy organs. Overall, our findings indicate that AC-3-019 and AC-4-130 are potent and selective inhibitors of STAT5. These compounds provide lead structures for further chemical modifications and clinical development for the identification of compounds to improve existing therapies.']",
        "Doc_id":"AACR_2017-1184",
        "Doc_title":" Characterization of novel STAT5 inhibitors to interfere with the oncogenic activities of STAT5 in hematopoietic diseases.",
        "_version_":1606189033676865536},
      {
        "Meeting_name":" Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML).",
        "Background":"['Background', ' S is an oral multi-kinase inhibitor with activity against the Raf/ERK/MEK pathway and FLT3. It selectively induces apoptosis in FLT3-mutant human AML cell lines at nM concentrations. Methods', ' Objectives of this study are to determine the tolerability and efficacy of combination of S with chemotherapy. Ara-C 1.5 g/m2 over 24 hrs daily x 4 (x 3 for pts over 60) and Ida 12 mg/m2 daily x 3 are administered with S. In the phase I part, pts with relapsed AML were treated with escalating doses of S (400 mg qod, 400 mg daily, 400 mg bid) for 7 days during induction, and 400 mg bid was established as safe. Pts achieving CR receive up to 5 courses of consolidation with Ida 8 mg/m2 daily x 2 and Ara-C 0.75 g/m2 daily x 3 in addition to S 400 mg bid for up to 28 days per cycle repeated every 4 to 6 weeks. Maintenance is with S 400 mg bid for up to a year. Results', ' 10 pts (median age 34, range 21-58) with relapsed AML (median prior therapy 2, range 1-6) were treated in the phase I . 7 were FLT3-ITD positive. 4 achieved CR; 6 failed. In the phase II part, 45 pts (12 with FLT3-ITD and 2 with FLT3-TKD) were treated. Median age is 53 (range 18 - 65). Cytogenetics were diploid in 19, +8 in 5, -5/-7 in 5, 11q23 in 2, other in 14. Median presentation WBC was 4.9 x 109/L (range 0.6 - 122.7 x 109/L). 8 pts were FLT3-ITD+/NPM1-. 40 pts are evaluable for response and 85% achieved CR (n = 30) or CRp (n = 4) (13 of 14 FLT3 mutated pts); 5 pts are too early (1 FLT3 mutated). Most frequent grade 3 and higher related adverse events', ' hyperbilirubinemia (5), rash and hand-foot syndrome (3), raised transaminases (2), diarrhea (2), hypertension (2). With a median f/u of 5.4 mo (range, 0.5 - 11.3), the probability of survival at 6 mo is 81.6%. 5 pts have relapsed; median CR duration has not been reached, (range; 0.2+ - 10.6+ mo). Among pts with FLT3 mutation, 4 have relapsed and 9 remain in CR. Plasma inhibitory assay was performed using day 7 samples from 10 pts; mutant FLT3 was suppressed by all with 5-fold more potent suppression against mutant versus wild-type FLT3. Conclusions', ' S can be safely combined with IA; it has a high CR rate in frontline therapy of younger pts with AML, in particular those with FLT3 mutations. Correlative studies confirm potent activity of S against FLT3 signaling.']",
        "Doc_id":"ASCO_32234-65",
        "Doc_title":" Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML).",
        "_version_":1606188990172495872},
      {
        "Meeting_name":" Targeting Src-family kinases to combat acquired inhibitor resistance in FLT3-ITD+ AML.",
        "Background":"['Activating internal tandem duplication (ITD) mutations in the FMS-like receptor tyrosine kinase 3 (Flt3) are found in approximately 30% of acute myeloid leukemia (AML) patients. Flt3-ITD expression is associated with aggressive, chemotherapy-resistant disease and decreased overall survival. Multiple selective Flt3 kinase inhibitors have been developed as targeted therapy for Flt3-ITD+ AML. However, the clinical utility of these kinase inhibitors has been limited by the rapid recurrence of drug-resistant disease that often results from Flt3 kinase domain mutations that prevent inhibitor action. Recent studies revealed that multiple non-receptor tyrosine kinases are over-expressed in AML, including the myeloid Src-family kinases Hck, Lyn and Fgr, and may cooperate with Flt3 to drive disease. These observations suggest that kinase inhibitors with specificity profiles targeting Flt3 and these AML-associated cytoplasmic kinases may be less prone to acquired resistance. In the present study, we determined the contributions of Hck and Fgr kinase activities to Flt3-ITD+ AML cell growth using a chemical genetics approach. While RNAi-mediated knockdown of each of these kinases reduces proliferation and increases apoptosis in primary AML cells, the impact of pharmacologic inhibition of their kinase activities on AML cell growth is not known. Because no selective Hck or Fgr inhibitors exist, we developed kinase domain mutants that desensitize each kinase to the broad-spectrum SRC-family kinase inhibitor, A-419259. Examination of a previous crystal structure of Hck with A-419259 bound to the active site suggested a role for the â€˜gatekeeperâ€™ residue in compound binding. Substitution of the gatekeeper threonine of Hck and Fgr with methionine conferred 3-fold resistance to A-419259 in vitro without diminishing kinase activity. When expressed in human TF-1 myeloid cells transformed with Flt3-ITD, these inhibitor-resistant Hck and Fgr mutants conferred resistance to growth inhibition by A-419259 to a similar extent, while expression of the corresponding wild-type kinases was without effect. The sensitivity of the TF-1/Flt3-ITD cell lines to A-419259 correlated with inhibition of mutant Hck and Fgr kinase activity in the cells. Our findings suggest that suppression of AML cell growth by A-419259 is due in part to inhibition of Hck and Fgr, and identify these AML-associated kinases as therapeutic targets. Ongoing studies are addressing the role of Hck and Fgr as inhibitor targets in Flt3-ITD+ AML cell lines and patient samples as well as the propensity of A-419259 and other multi-targeted inhibitors of AML-associated kinases for acquired drug resistance.']",
        "Doc_id":"AACR_2017-2363",
        "Doc_title":" Targeting Src-family kinases to combat acquired inhibitor resistance in FLT3-ITD+ AML.",
        "_version_":1606189015608852481},
      {
        "Meeting_name":" Induction of acute myeloid leukemia (AML) with idarubicin, cytarabine and cladribine (ICC).",
        "Background":"['Background', ' Seven plus 3 has long been considered the standard of care for the induction of AML. The addition of Cladribine to Daunorubicin 60 mg/m2 and Cytarabine has been shown to increase complete remission (CR) rate and median overall survival (OS) but whether the addition of Cladribine to 7 + 3 with other anthracyclines is beneficial is unknown.  Methods', ' A retrospective study was conducted evaluating patients with AML induced with ICC between January 2010 and December 2014 at Methodist University Hospital in Memphis, TN. Approval for the study was obtained from the IRB. Patient and disease characteristics and outcomes were analyzed with GraphPad Prism, Microsoft Excel and SPSS version 19.0.  Results', ' Twenty-two patients diagnosed with AML that received ICC were identified. Patient and disease characteristics are summarized in table 1. Twelve patients (54.5%) had at least 1 high-risk feature. All patients achieved hypoplastic bone marrows on Day 14 and seventeen (77.3%) achieved CR. Thirty day mortality was 9.1% (2 patients). One patient died from typhlitis and the other patient died secondary to complications from pulmonary leukostasis which was present upon presentation prior to initiation of induction chemotherapy. Twenty-four month OS and disease-free survival were 53.4% and 35.4%, respectively.  Conclusions', ' Induction of AML with ICC was associated with a high CR rate and OS in our older and high-risk population. Further studies of ICC are reasonable.   Patient and Disease CharacteristicsTotal Number of Patients', ' 22Median age ', ' 58 years (range 24-68)CharacteristicsNo. of Patients (%)Males/Females14 (63.6)/ 8 (36.4)White/Black10 (45.5)/ 12 (54.5)History of MDS5 (22.7)CytogeneticsFavorable2(9.1)Intermediate13(59.1)Poor4(18.2)Unknown3(13.7)Flt3 Positive*1 (4.5)NPM1 Positive**2 (9.1)*Isolated occurrence with intermediate risk cytogenetics  **Isolated occurrence with intermediate risk cytogenetics']",
        "Doc_id":"ASCO_149043-156",
        "Doc_title":" Induction of acute myeloid leukemia (AML) with idarubicin, cytarabine and cladribine (ICC).",
        "_version_":1606188999288815616},
      {
        "Meeting_name":" NGS-based detection of FLT3-ITDs with Anchored Multiplex PCR",
        "Background":"['FLT3 internal tandem duplications (ITDs) are found in > 20% of pediatric and adult acute myeloid leukemia (AML) cases and are generally associated with a poor prognosis. Nevertheless, detection of FLT3-ITDs presents a challenge to NGS-based approaches, as many variant callers fail to identify the highly variable repeated sequences associated with FLT3-ITDs.We have developed a novel targeted assay, the Archer VariantPlex Core AML Panel, that utilizes Anchored Multiplex PCR (AMP) with probes in multiple locations proximal to exons 13, 14, and 15 of FLT3. These exons encompass the commonly mutated juxtamembrane domain and tyrosine kinase domain 1. This panel yields high-complexity, dual-strand coverage of known FLT3-ITD locations. Because AMP probes, unlike traditional PCR probes, function independently of each other, we are able to produce multiple overlapping snapshots of the region of interest, thereby enhancing the ability to confidently identify complex mutation types. The sequenced reads are assembled using a novel de novo assembly algorithm in the Archer Analysis bioinformatics pipeline, in which the resulting consensus is annotated and events that involve FLT3 exons 13 14 or 15 are marked as FLT3 abnormalities.In order to assess Archer Analysis and the VariantPlex Core AML panel, we tested it on >20 patient-derived samples with known FLT3-ITDs. In addition, we generated over two thousand in silico datasets, representing the spectrum of known ITDs, to further test our panel design and analysis algorithm. Each in silico dataset was constructed to simulate reads originating from probes in VariantPlex Core AML Panel. This methodology permitted rigorous optimization of both the VariantPlex Core AML Panel and the analysis algorithm.The VariantPlex Core AML Panel, in conjunction with our novel detection algorithm, showed both exceptional sensitivity and specificity in the detection of FLT3-ITDs. FLT3-ITDs were successfully identified in all patient samples tested, and no false positives were detected. Our in silico datasets showed similarly high sensitivity and specificity.These data indicate that AMP libraries targeting the FLT3-ITD region are ideal for the detection of this complex mutation type, largely because of the overlapping and anchored read structure. Therefore, the Archer VariantPlex Core AML panel, in conjunction with Archer Analysis represents a reliable platform for the detection of FLT3-ITDs, in addition to other mutations commonly found in AML.']",
        "Doc_id":"AACR_2016-3618",
        "Doc_title":" NGS-based detection of FLT3-ITDs with Anchored Multiplex PCR",
        "_version_":1606189038202519552},
      {
        "Meeting_name":" Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS).",
        "Background":"['Background', ' Elderly patients (pts) with acute myeloid leukemia (AML) may not be suitable for intensive chemotherapy. Low-dose cytarabine (LDAC) is superior to supportive care in these pts (Burnett, 2007). In a phase I study of sorafenib, a multi-targeted kinase inhibitor with FLT-3 inhibitory activity, in AML/myelodysplastic syndrome (MDS) pts we observed modest activity (Crump, 2004) which seemed more prominent in AML pts with FLT3 mutations. The NCIC Clinical Trials Group initiated a multicentre phase I/II study of the combination of LDAC with sorafenib in elderly pts with AML or high risk MDS. Methods', ' Eligible pts were age > = 60 yrs and unsuitable for intensive chemotherapy regimens. Phase I dose escalation proceeded in cohorts of 3 pts based on toxicity in cycle 1. Phase II was a Simon 2-stage design; 2/15 complete remissions were required in stage 1 to accrue an additional 17 pts in stage 2. FLT3 mutational status was determined in all pts. Results', ' 21 pts were enrolled', ' 4 MDS, 17 AML (9 with prior MDS). Median age was 77 (range 63-83). The recommended phase II dose (RP2D) was LDAC 10 mg bid days 1-10 and sorafenib 300 mg bid days 2-28. Further escalation was not possible due to fatigue, sepsis, diarrhea and skin rash at this dose. In 15 evaluable pts at the RP2D, 1 CR, 1 PR, 2 SD, 2 PD, 9 treatment failures were seen. Duration of response in CR, PR, and SD pts was 2.8, 3.9, 2.5, and 8.7 mos. FLT3 internal tandem duplication (FLT3- ITD) was found in 1 pt (this pt had the PR), and tyrosine kinase domain mutation (FLT3-TKD) in 2 pts. The CR was seen in a pt without FLT3 mutation. Conclusions', ' The study did not meet the prespecified criteria to complete the second stage of phase II accrual. The response rate might have been affected by', ' (i) the low frequency of FLT3 mutation in the study population compared to historical estimates; (ii) the dose of LDAC achievable in combination; (iii) the response criteria requirement for platelet recovery', ' a challenge with continuous dosing of sorafenib plus intermittent LDAC. We conclude that this combination of sorafenib and LDAC has limited activity in an unselected cohort of elderly pts in which pts with FLT-3 mutations seem underrepresented.']",
        "Doc_id":"ASCO_50468-74",
        "Doc_title":" Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS).",
        "_version_":1606189018997850113},
      {
        "Meeting_name":" BMI-1 inhibition by PTC-209 induces mitochondrial apoptosis in acute myeloid leukemia cells",
        "Background":"['Leukemia stem cells play important roles in leukemia initiation, progression, and relapse, and represent a critical target for therapeutic intervention. BMI-1 is essential for the self-renewal of normal hematopoietic and leukemia stem cells. High expression of BMI-1 has been associated with poor prognosis in AML. PTC-209 is a novel transcriptional inhibitor of BMI-1, which has been reported to exhibit antitumor activity against cancer-initiating cells in colorectal cancer. We investigated anti-leukemia effects of the BMI-1 inhibitor PTC-209 on AML cells. A total of 8 AML cell lines (MOLM-13, OCI-AML3, MV4-11, NB4, HL-60, U-937, MOLM-14, OCI-AML2) were treated with different concentrations of PTC-209 for 48 hours and the IC50 values (concentration at which cell growth is inhibited by 50% at 48 hours of exposure) and the ED50 values (effective concentration inducing 50% killing as measured by Annexin V positivity) were determined. The IC50 values were 0.38  0.07 M (mean  SEM), indicating high anti-proliferation effect. The ED50 values ranged from 1.2 to 2.6 M in 7 cell lines (1.97  0.22 M) and the remaining cell line (NB4) showed relative resistance to PTC-induced apoptosis (> 10 M). PTC-209 exhibited dose- and time-dependent anti-proliferative and cytotoxic activities, by inducing G1-S transition delay and apoptosis. PTC-209 induced conformational change of BAX (i.e., BAX activation), loss of mitochondrial membrane potential (MMP), caspase-3 activation and DNA fragmentation in addition to phosphatidylserine (PS) externalization, indicating mitochondrial apoptosis. PTC-209 induced Annexin V in primary AML cells (23.4  4.6% after 48-hour treatment with 1 M PTC-209, n = 23) in a dose-dependent manner, which is more prominent in immature CD34+CD38- population (33.7  6.0%; P = 0.0036). In accordance with its high anti-leukemia activity, PTC-209 strongly reduced cellular BMI-1 levels in CD34+CD38- AML cells. Higher reduction of BMI-1 expression was positively correlated with higher susceptibility to PTC-209 in CD34+CD38- AML cells (r = 0.88; P = 0.047). The apoptotic activity was observed independent of p53 or FLT3 mutational status of the leukemia cells. Our data suggest that BMI-1 inhibition by small molecule inhibitors may be developed into a novel therapeutic strategy for AML. (Drs M. Andreeff and S. Kimura are co-senior authors with equal contribution to the work)']",
        "Doc_id":"AACR_2015-2938",
        "Doc_title":" BMI-1 inhibition by PTC-209 induces mitochondrial apoptosis in acute myeloid leukemia cells",
        "_version_":1606188988570271744},
      {
        "Meeting_name":" Crenolanib",
        "Background":"['Every year in the US there are approximately 12,000 new cases of acute myeloid leukemia (AML). Amongst these patients, 25% have internal tandem duplications (ITDs) of the type III receptor tyrosine kinase, FLT3, causing constitutive activation of the receptor. This mutation has been associated with a poor survival rate, thus making the FLT3/ITD an important target in the treatment of AML. Treatment with small molecule tyrosine kinase inhibitors (TKIs) has shown high response rates in AML patients.1 However, this response is often temporary due to the development of resistance-conferring point mutations.2 Furthermore, QTc prolongation has proven to be a dose-limiting toxicity with some FLT3 TKIs.1 Crenolanib is a TKI with activity against PDGFR and FLT3 and is currently being tested in trials involving patients with a variety of solid tumors. We have determined that crenolanib has potent activity in vitro against FLT3. Crenolanib is cytotoxic to the FLT3/ITD-expressing leukemia cell lines Molm14 and MV411, with an IC50 of 7 nM and 8 nM, respectively. In immunoblots, crenolanib inhibited phosphorylation of both the wild type FLT3 receptor (in SEMK2 cells) and the FLT3/ITD receptor (in Molm14 cells) in culture medium with an IC50 of 1-3 nM. Importantly, the IC50 of crenolanib against the D835Y mutated form of FLT3 was 8.8 nM in culture medium. Using primary AML patient samples, we determined that crenolanib was cytotoxic to FLT3/ITD-expressing samples in a manner comparable to agents such as sorafenib and AC220. Furthermore, crenolanib had cytotoxic activity against primary samples that were obtained from patients who had developed D835 resistance mutations while receiving FLT3 TKIs. In vitro, the IC50 of crenolanib for inhibition of FLT3/ITD in plasma was found to be 34 nM, indicating a relatively low degree of plasma protein binding. From pharmacokinetic studies of crenolanib in solid tumor patients, steady state trough plasma levels of roughly 500 nM were found to be safe and tolerable, suggesting that crenolanib could potentially inhibit the target in vivo as effectively as AC220. Unlike AC220, crenolanib has no significant activity against c-KIT, which may be an advantage in that myelosuppression can be avoided. Furthermore, there was no evidence of QTc prolongation in patients treated with crenolanib. In summary, crenolanib offers a number of advantages over other FLT3 TKIs. Clinical trials of crenolanib in AML patients with FLT3 activating mutations are planned. References', ' 1) Cortes et al. (2011) A Phase II Open-Label, AC220 Monotherapy Efficacy Study in Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia', ' Updated Interim Results. American Society of Hematology Abstract no. 2576. 2) Smith et al (2011) Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia. American Society of Hematology Abstract no. 937.']",
        "Doc_id":"AACR_2012-3660",
        "Doc_title":" Crenolanib",
        "_version_":1606189018963247104},
      {
        "Meeting_name":" Mutation analysis in 35 cases of newly diagnosed therapy-related acute myeloid leukemia (AML) by next-generation sequencing (NGS)",
        "Background":"['Background', ' AML has numerous mutations that predict response to treatment and overall survival. We aimed to assess various mutations in newly diagnosed therapy related AML cases by NGS and their association with clinicopathologic parameters. Methods', ' We performed molecular studies on DNA extracted from bone marrow aspirate specimens in 35 newly diagnosed treatment nave therapy related AML (WHO 2008 criteria) patients (8/2013 to 8/2015). Entire coding sequences of 28 genes (ABL1, ASXL1, BRAF, DNMT3A, EGFR, EZH2, FLT3, GATA1, GATA2, HRAS, IDH1, IDH2, IKZF2, JAK2, KIT, KRAS, MDM2, MLL, MPL, MYD88, NOTCH1, NPM1, NRAS, PTPN11, RUNX1, TET2, TP53, WT1) were sequenced using TruSeq chemistry on Illumina MiSeq platform. FLT3 and CEBPA mutation analysis were detected by PCR. Results', ' Median age was 71 years with 49% males and 51% females. Twelve (34.3%) and 3 (8.6%) patients had prior MDS and MDS/MPN respectively. CBC', ' [median (range)]', ' Hb 9 g/dL (4.9-12.9), platelets 48 K/L (3-378), WBC 4.6 K/L (0.4-156.6), ANC 1.3 K/L (0-27.21), AMC 0.2 K/L (0-14.2). BM blast % [median (range)]', ' 35% (5-92). Karyotype (n = 35)', ' 7 (20%) diploid, 9 (25.7%) 1, 3 (8.6%) had 2, 1 (2.9%) had 3, 15 (42.9%) > three abnormalities, 17 (48.6%) monosomies, 10 (28.6%) trisomies. Three cases (8.6%) had t(8;21) , 3 (8.6%) t(9;11)(p22;q23), 1 (3%) t(15;17), 1 (3%) t(1;22). MRC risk categories were', ' favorable 4 (11.4%), intermediate 14 (40%), adverse 17 (48.6%). Mutations are detailed in Table 1. 13 (37.1%) had mutations in 1, 9 (25.7%) in 2, 4 (11.4%) in 3 and 2 (5.7%) in > 3 genes. Positive associations identified were', ' WBC and ASXL1, platelet count and JAK2, ASXL1, PTPN11, and peripheral blood (PB) blast % and FLT3.Conclusions', ' Therapy related AML is heterogeneous at the genetic level and multiple mutations likely indicate clonal evolution. With longer follow-up, we could use this data to refine prognostic models for AML. GenesNo. of cases% of casesTP531234.29%DNMT3A617.14%TET2617.14%FLT3514.29%NRAS514.29%IDH138.57%RUNX138.57%ASXL125.71%KRAS25.71%NPM125.71%PTPN1125.71%GATA112.86%JAK212.86%IDH212.86%KIT12.86%WT112.86%']",
        "Doc_id":"ASCO_171437-176",
        "Doc_title":" Mutation analysis in 35 cases of newly diagnosed therapy-related acute myeloid leukemia (AML) by next-generation sequencing (NGS)",
        "_version_":1606188992551714816},
      {
        "Meeting_name":" Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies",
        "Background":"[\"PIM kinases represent an emerging therapeutic target in multiple hematological malignancies, as exemplified by currently ongoing phase I clinical trials by Astra Zeneca (AZD1208) and Novartis (LGH447) in acute myeloid leukemia and multiple myeloma. Selvita has developed a potent and selective dual PIM/FLT3 mutant kinase inhibitor - SEL24-B489 showing high inhibitory activity on all three PIM kinase isoforms and FLT3 kinase mutants. We have previously reported that PIM kinases are important downstream effectors of FLT3 signaling and play a crucial role in cell survival and inhibition of apoptosis upon expression. Due to heterogeneous nature of AML, dual inhibition of FLT3 mutant kinase and PIM kinases led to improved efficacy of our compound in comparison to selective inhibitors of either PIM of FLT3 kinases.Herewith, we would like to report further progress of characterizing the B489 inhibitor beyond AML. We assessed PIM kinase expression levels in a panel of lymphoid malignancies and found that PIM1 and PIM2 exhibit high expression levels in a fraction of mantle cell lymphoma (MCL), diffuse large-B-cell lymphoma (DLBCL), follicular lymphoma (FL), Hodgkin's lymphoma (HL), chronic lymphocytic leukemia (CLL) and mucosa associated lymphoid tissue-type (MALT) lymphoma cell lines and primary tumors . High levels of PIM kinases were associated with certain established adverse prognostic factors and clinical outcome of the patients and correlated with aggressiveness of the disease in some of these tumors. Inhibition of PIM kinases with tool inhibitors was shown to influence cellular proliferation and, translational inhibition of 4EBP1 as reported in the literature. In addition, SEL24-B489 inhibited NFB activity and decreased CXCR4 expression. Comparison of SEL24-B489 to competitive PIM inhibitors revealed higher cellular activity and biomarker response, as shown by inhibition of phospho-S6 phosphorylation in sub-microM concentrations. The presented data will further validate SEL24-B489 as a successful example of rational drug design and present a promising therapeutic approach in multiple hematological malignancies, both stand alone and in combination with standard of care and targeted therapies in clinical development.\"]",
        "Doc_id":"AACR_2014-1749",
        "Doc_title":" Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies",
        "_version_":1606188992296910848},
      {
        "Meeting_name":" Mutational analysis for IDH1 and IDH2 in pediatric leukemia",
        "Background":"['Recently, mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that NADP+dependent isocitrate dehydrogenase (IDH)1/2-mutated AMLs display global DNA hypermethylation and a specific hypermethylation signature, suggesting a shared proleukemogenic effect. To explore the involvements of IDH1/2 in the pathogenesis in pediatric hematological malignancies. We analyzed mutations that involve the activation sites of IDH1/2 using polymerase chain reaction amplification/sequencing in a total of 244 samples of pediatric myeloid malignancies as well as infantile leukemia including 17 AML-derived cell lines, 115 primary cases of AML, 28 primary cases of MDS, 15 primary cases of juvenile myelomonocytic leukaemia (JMML), 6 chronic myeloid leukemia (CML)-derived cell line, 18 primary cases of CML and 45 infantile leukemia(6 AML and 39 acute lymphoblastic leukemia (ALL) patients). Moreover, to assess whetherIDH1/2 mutations overlap with known gene abnormalities, such as FLT3, c-KIT, and NPM1 mutations, mutational analyses of FLT3, c-KIT, and NPM1 were also performed. The common IDH2 R140Q mutation was detected in a single AML case, whereas no IDH1 mutation was detected in samples of myeloid malignancies. Although no IDH2 mutation was detected in infantile leukemias, novel P127S, H133I and I130V of IDH1 mutations were detected in 4 of 45 (8.9%) infantile ALL cases. No IDH1 and IDH2 mutations were detected in the JMML, MDS, or CML samples examined. Six AML samples including one cell line had c-KIT mutations (D816V, N822K, or D419fs), 12 AML cases had FLT3-ITD and 10 infantile leukemia cases had FLT3 mutations (D835E or I836). The NPM1 mutation was detected in 2 of 132 AML samples. The AML case harboring the IDH2 mutation, Case 39 was a 12-year-old boy diagnosed as AML-M2 according to the French-American-British cooperative group classification system having t(8;21)(q22;q22), showed no abnormalities of NPM1, c-KIT, and FLT3. Remarkably, among 4 infantile ALL cases with IDH1 mutations, 3 cases showed mixed lineage leukemia(MLL) rearrangements with t(4;11). The FLT3-D835 mutation was found in 1 of 4 patients with IDH1 mutations. These results suggest that although the involvements of IDH1/2 mutations in the pathogenesis of pediatric myeloid malignancies are extremely rare, closely positioned to near activation site, R132 IDH1, these IDH1 mutations are the candidate second genetic events in a subset of MLL-leukemia.']",
        "Doc_id":"AACR_2012-71",
        "Doc_title":" Mutational analysis for IDH1 and IDH2 in pediatric leukemia",
        "_version_":1606188980913569792},
      {
        "Meeting_name":" Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).",
        "Background":"['Background', ' In contrast to the poor prognosis associated with hyperleukocytosis, the prognostic significance of leukopenia at the time of diagnosis of AML is unknown. Methods', ' Single institution retrospective analysis of 225 consecutive, newly diagnosed AML patients (pts), homogeneously treated between July 1996 and February 2005; and divided into 2 groups based on presenting WBC', ' < 2,000/uL (30) and > 2,000/uL (195). Simultaneously obtained peripheral blood and marrow blasts were analyzed for cell surface expression of CD34, cKit, CXCR4, PCAM, VLA-2, VLA-3, VLA-4, VLA-5, and FLT3 using flow cytometry. Results', \" Patients' characteristics (gender, secondary vs. de novo, and cytogenetic [CTG] risk) were comparable between the 2 groups. Leukopenic AML pts were older (median 56 vs. 53 years, p = 0.02), and had lower induction complete remission [CR] rates\", ' 63% vs. 81% (p = 0.03) by univariate analysis. Induction mortality was 0% for leukopenic and 5% for non-leukopenic pts. In primary refractory pts, median survival was longer for leukopenic (11) vs. non-leukopenic (34) pts', ' 137 vs. 81 d (p = 0.026). Median follow-up was 22 mos. Event-free (EFS), disease-free (DFS), and overall survivals (OS) were lower in the leukopenic group', ' 12 vs. 14; 14 vs. 17; and 17 vs. 19 mos, respectively; but did not reach statistical significance. By multivariate analysis, age (p < 0.0001) and CTG risk group (p < 0.0001) were independent predictors of OS, while CTG risk group predicted RFS (p < 0.0001). The level of expression of cell surface adhesion molecules on blood and marrow blasts was comparable for the 2 groups. Conclusions', ' AML pts presenting with leukopenia have comparable outcomes to those presenting with normal or high WBC despite a lower likelihood of achieving remission. Leukopenic AML did not have over-expression of cell surface adhesion molecules.']",
        "Doc_id":"ASCO_34078-65",
        "Doc_title":" Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).",
        "_version_":1606188996403134464},
      {
        "Meeting_name":" FLX925 (AMG 925) is a rationally designed FLT3, CDK4/6 inhibitor that retains potency against clinically relevant secondary resistance mutations in FLT3",
        "Background":"['Acquired secondary resistance mutations to clinically active kinase inhibitors remains a key obstacle between valid therapeutic hypotheses and meaningful patient benefit. In AML, evidence suggests that inhibition of FLT3 (particularly in FLT3-ITD mutated cancers) can be efficacious; however, relapse from complete remission is common and often rapid. As with other cancers driven by key oncogenic kinase mutations (e.g. BCR-ABL in CML), a primary mechanism of resistance is the acquisition of secondary resistance mutations in the oncogenic kinase themselves. Multiple strategies have been pursued to address such resistance, including the development of kinase inhibitors that either bind their respective targets differently or by targeting multiple important pathways simultaneously. Herein we describe a rationally conceived next generation FLT3 inhibitor, FLX925 (previously AMG 925), that was prospectively designed to address or avoid common resistance mechanism to earlier FLT3 inhibitors with its unique binding mode and potent activity against CDK4/CDK6.FLX925 is a potent and selective type 1 inhibitor of FLT3 that retains its cellular potency against clinically relevant secondary resistance mutations in FLT3 occurring with quizartinib or sorafenib treatment (FLX925 IC50', ' MOLM13ITD, 15 nM; MOLM13ITD/D835, 28 nM; MV4-11ITD, 16 nM; MV4-11ITD/D835, 19 nM; MV4-11ITD/N841, 16 nM; MV4-11ITD/F691, 73 nM). Indeed, while compounds currently in the clinic became more than 200-fold less potent against a number of mutants, FLX925 remained relatively equipotent (+/- 5-fold the parental cell line IC50) in these same resistant clones. This is in stark contrast to the striking cross-resistance observed with quizartinib in sorafenib resistant cells. Moreover, the few clones that grew out of a screen for resistance to FLX925 displayed a persistence phenotype with modestly reduced sensitivity to FLX925 (5-fold IC50 shift) that was rapidly reversible. This persistence was associated with higher FLT3 protein levels and no detectable secondary mutations in FLT3.In addition to its suppression of FLT3 signaling, FLX925 potently inhibits CDK4/CDK6, central components of the cell cycle machinery. This unique profile may reduce the likelihood of emergent resistant clones and extends the therapeutic potential of FLX925 to other malignancies dependent on these pathways (e.g. MCL). Indeed, the addition of PD0332991 (a selective CDK4/6 inhibitor) to a relatively selective FLT3 inhibitor reduced the frequency of acquired resistance in a cell based screen, relative to a FLT3 inhibitor alone. These data suggest the unique profile of FLX925 makes it an ideal inhibitor for the treatment of cancers driven by FLT3 signaling, such as AML. A phase I clinical trial evaluating the safety, tolerability pharmacokinetics and pharmacodynamics effects of FLX925 in patients with AML is ongoing.']",
        "Doc_id":"AACR_2015-787",
        "Doc_title":" FLX925 (AMG 925) is a rationally designed FLT3, CDK4/6 inhibitor that retains potency against clinically relevant secondary resistance mutations in FLT3",
        "_version_":1606189028281942016},
      {
        "Meeting_name":" Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia",
        "Background":"['Acute myeloid leukemia (AML) is an aggressive malignancy of hematopoietic progenitors with poor clinical outcomes. Despite the power of next-generation DNA sequencing to describe AML genomes and to identify recurrent mutations, our fundamental understanding of the genomics of leukemogenesis is incomplete. Founder mutations in the majority of AML cases are unknown because pre-leukemic cells are clinically silent and are outcompeted by their malignant descendants. Our limited knowledge of founder mutations comes from infrequent cases of AML arising secondary to antecedent clonal bone marrow disorders or rare instances of inherited syndromes. Importantly, recent advances in AML stem cell biology now enable the prospective separation of residual non-leukemic hematopoietic stem cells (HSC) from AML cells. We previously showed that non-leukemic HSC contain clonal antecedents of AML in patients in long-term remission post-therapy, and have proposed a model in which serial acquisition of mutations occurs in self-renewing HSC. Here, we investigated this model and the nature of founder mutations through the genomic analysis of de novo AML and patient-matched residual non-leukemic HSC. Using exome sequencing, we identified mutations present in eight individual AML genomes (mean 10 mutations per patient) and screened for them in the residual HSC. We identified several mutations present in residual HSC that retained normal multilineage differentiation in vivo. These putative early mutations detected in residual HSC include NPM1c, mutations in TET2, and novel AML mutations in genes involving the cell cycle and mRNA biogenesis. Putative late mutations absent from residual HSC and only found in leukemic cells include FLT3 ITD and IDH1 R132H. Finally, through single cell analysis, we determined that as we hypothesized, a clonal progression of multiple mutations occurs in non-leukemic HSC. Quantitative genetic analyses of the HSC compartment enabled us to reconstruct the subclonal architecture of normal and pre-leukemic stem cells. Consistent with mouse models, pre-leukemic HSC with TET2 mutations outcompeted their normal counterparts. However, in most cases, normal HSC were 6-50 times more numerous than pre-leukemic HSC. In two cases where sequential populations of pre-leukemic HSC were identified, the less mutated pre-leukemic HSC population was 10-25 times more numerous than its more mutated descendent. This result contrasts with the classical model of a linear succession of dominant pre-leukemic subclones. These pre-leukemic HSC reveal the clonal evolution of AML genomes from founder mutations, suggest a potential mechanism contributing to relapse, and constitute a cellular reservoir that may need to be targeted for more durable remissions.']",
        "Doc_id":"AACR_2012-3303",
        "Doc_title":" Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia",
        "_version_":1606188977783570432},
      {
        "Meeting_name":" Efficacy and safety of quizartinib (AC220) in patients age  70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).",
        "Background":"['Background', '  Advanced age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in AML are each associated with early relapse after standard chemotherapy and poor survival.  Quizartinib, an oral FLT3 inhibitor active against ITD mutant and wild type FLT3, has shown promising activity in Ph 1 and 2 studies.  Methods', '  We provide detailed analysis from a Ph 2 study (N = 333) of quizartinib monotherapy, focusing on patients (pts) aged  70 y with AML that relapsed and/or was refractory to prior therapy.  Results', '  A total of 83 pts age 70 y included 60 (72%) FLT3-ITD(+) and 23 (28%) FLT3-ITD(-).  Median duration of treatment was 14.6 wks for FLT3-ITD(+) pts and 5.9 wks for FLT3-ITD(-) pts. Composite complete remission (CRc) rate included complete remission (CR), complete remission with incomplete platelet recovery (CRp), and complete remission with incomplete hematologic recovery (CRi).  Of 60 FLT3-ITD(+) pts, 32 (53%) had a CRc (1 CR, 3 CRp, 28 CRi).  Of 23 FLT3-ITD(-) pts, 10 (43%) had a CRc (2 CR, 1 CRp, 7 CRi). 12/27 FLT3-ITD(+) pts (44%) and 5/10 FLT3-ITD(-) pts (50%) refractory to prior therapy responded to quizartinib, and 12/83 (14%) survived >1 y.  The most common (10%) Grade 3 or 4 treatment-related adverse events (TRAEs) were febrile neutropenia (22%), anemia (20%), transient QT interval prolongation (17%; no Grade 4), and thrombocytopenia (12%). 15 pts (18%) had TRAEs resulting in discontinuation.  Conclusions', '  Because AML in the elderly, particularly in those aged 70 y, is genetically heterogeneous and often follows a myelodysplastic syndrome, there is a wide assumption that it may be less amenable to FLT3-targeted therapy than AML in younger pts. Our data argue against these conclusions and show that pts aged 70 y with chemotherapy-resistant AML have preserved high response rates, and promising survival to quizartinib.    Clinical trial information', ' NCT00989261.']",
        "Doc_id":"ASCO_114013-132",
        "Doc_title":" Efficacy and safety of quizartinib (AC220) in patients age  70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).",
        "_version_":1606189029804474369},
      {
        "Meeting_name":" Characterization of a novel FLT3 inhibitor in AML cell lines",
        "Background":"['Acute myeloid leukemia (AML) is a hematologic malignancy that is characterized by increased myeloproliferation and a block in differentiation of progenitor cells, leading to infiltration of immature blasts in the bone marrow and peripheral blood. FMS-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase expressed in hematopoietic progenitor cells. Approximately 30% of AML cases harbor a mutation in the FLT3 gene leading to constitutive activation of FLT3. The most commonly observed mutation occurs in the juxtamembrane domain as an internal tandem duplication (FLT3-ITD) of variable length sequence repeats. In addition, activating mutations in the kinase domain are observed in 7-10% of patients. The presence of FLT3-ITD mutations confers a poor prognosis, and thus many studies are directed at developing and testing novel FLT3 inhibitors for the treatment of AML. A number of clinical trials are now underway studying tyrosine kinase inhibitors (TKI) that target FLT3. There have been limitations in the responses observed in patients on these trials related to insufficient achievement of FLT3 inhibition and the development of drug resistance through a variety of mechanisms. This includes resistance conferring point mutations that appear in patients following drug treatment, as well as selection for cells with activation of parallel signaling pathways. Therefore, the search for novel TKIs that overcome some of these mechanisms and the discovery of additional targets for the treatment of AML are necessary to improve the cure rate of this disease. TTT-3002 is a multi-targeted kinase inhibitor that has activity against FLT3-ITD. Here we report the results of the characterization of this compound in a panel of AML cell lines. TTT-3002 has potent activity against FLT3 phosphorylation in FLT3-ITD cell lines at subnanomolar concentrations and significantly decreases cell viability through the induction of apoptosis. Interestingly, TTT-3002 is highly active against cell lines with known activating or resistance mutations in the FLT3 gene, indicating the potential for broad clinical application. Furthermore, through analysis of TTT-3002 potency in cell lines cultured in human plasma preparations from healthy donors, we observed a 10-20 fold shift in IC50 values for FLT3 phosphorylation compared to cell culture media. These results suggest that TTT-3002 has reasonable protein binding, and may require lower doses than many other TKIs to achieve an effective concentration of free drug in plasma. Finally, we have found that 6 mg/kg bid in a solid dosing form is well tolerated in BALB/c mice, and it is sufficient to eliminate luciferase expressing Ba/F3 cells containing a FLT3-ITD mutation after 4 days of treatment. Continual dosing with TTT-3002 significantly prolongs tumor free survival over vehicle control treated mice (p<0.0001, n=10). These findings demonstrate the potential of TTT-3002 as a promising targeted therapeutic in the treatment of AML.']",
        "Doc_id":"AACR_2012-1807",
        "Doc_title":" Characterization of a novel FLT3 inhibitor in AML cell lines",
        "_version_":1606188983828611072},
      {
        "Meeting_name":" BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors",
        "Background":"['The BET (bromodomain and extra terminal) protein antagonists, e.g., JQ1, disrupt the binding of the bromodomains of BRD4 to acetylated lysines, displacing the BET proteins, along with the associated transcript initiation and elongation factors, from the chromatin. JQ1 treatment also induces hexamethylene bisacetamide (HMBA)-inducible protein 1 (HEXIM1), which binds and sequesters pTEFb, thereby inhibiting its kinase activity for RNAP II. This inhibits the pause release of RNAP II, thereby attenuating the elongation and expression of the mRNA of oncogenes, e.g., c-MYC and BCL2, and their target genes, leading to growth inhibition and apoptosis of AML cells. Although the second generation FLT3 tyrosine kinase inhibitors (TKI), such as AC220 induce remissions in the aggressive sub-type of AML expressing FLT3 mutations, resistance-causing gatekeeper (F691I/L), activation loop (AL) (D835V/Y/F) or compound FLT3-ITD/F691I mutations are known to impair the in vitro and in vivo activity of the FLT3-TKIs. We have recently determined that JQ1, but not its inactive enantiomer R-JQ1 potently induced apoptosis of not only Ba/F3/FLT3-ITD but also Ba/F3/FLT3-ITD expressing the highly FLT3 TKI-resistant mutations F691L and D835V (IC50 values for JQ1 were 697, 1588 and 909 nM, in the three cell lines, respectively). JQ1 dose-dependently induced apoptosis of human cultured AML MOLM13 and MV4-11 cells, as well as of primary AML cells, all expressing FLT3-ITD. Concomitantly, JQ1 treatment attenuated c-MYC, BCL2 and CDK6, while inducing p21, p27, BIM and cleaved PARP levels. Following engraftment of NOD/SCID mice with MOLM13 xenografts, treatment with JQ1 (50 mg/kg, daily x 5 days per week x 3 weeks), versus treatment with vehicle control, significantly improved survival of the mice (p < 0.01), without causing any toxicity. Co-treatment with JQ1 and AC220 or the pan-histone deacetylase (HDAC) inhibitor (HDI) panobinostat (PS) synergistically induced apoptosis of cultured (MV4-11 and MOLM13) and primary AML cells expressing FLT3-ITD. We also determined the effects of JQ1 against MOLM13/TKIR cells that were generated under the continuous selection pressure of FLT3-TKI, and exhibited > 50-fold resistance to AC220. As compared to the parental MOLM13, the TKI-resistant cells express higher levels of BRD4, c-MYC and class I HDACs. Importantly, as compared to the parental MOLM13, the MOLM13/TKIR cells were significantly more sensitive to JQ1-induced apoptosis (p < 0.001). Additionally, co-treatment with JQ1 and PS, but not AC220, synergistically induced apoptosis of MOLM13/TKIR cells. This was associated with marked attenuation of c-MYC levels. Collectively, these findings support further in vivo testing of BRD4 antagonist-based combinations with AC220 or PS against FLT3 TKI-sensitive, and of BRD4 antagonist with PS against FLT3 TKI-refractory AML expressing FLT3-ITD.']",
        "Doc_id":"AACR_2014-1721",
        "Doc_title":" BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors",
        "_version_":1606188984033083392},
      {
        "Meeting_name":" JAK2 and PTPN11 mutations as potential biomarkers for BCL-xL inhibition as monotherapy and in combination therapy for acute myeloid leukemia.",
        "Background":"['Acute Myeloid Leukemia (AML) is a heterogeneous disease where many distinct functional mutations have been identified. While mutations in FLT3, NRAS, NPM1, and IDH genes have been well characterized in de novo AML, a subset of AML associated with leukemic transformation of chronic myeloproliferative neoplasms (MPNs) are enriched in mutated JAK2 and PTPN11. MPNs are a set of disorders characterized by the chronic and abnormal overproduction of blood cells which can ultimately progress to AML. Targeted therapy against mutated JAK2 and PTPN11 with small molecule inhibitors against the JAK-STAT and RAS-ERK pathways, respectively, are being actively investigated in AML. However, acquired resistance and non-durable responses are already being demonstrated in monotherapy treatment. Thus, AML that has arisen from leukemic transformation of MPNs remains an area of unmet medical need. This need is underscored by the fact that these patients suffer from poor outcomes and low response rates to standard chemotherapy. Together, these results indicate the need for rational combinations in this population.']",
        "Doc_id":"AACR_2017-3812",
        "Doc_title":" JAK2 and PTPN11 mutations as potential biomarkers for BCL-xL inhibition as monotherapy and in combination therapy for acute myeloid leukemia.",
        "_version_":1606188986179518464},
      {
        "Meeting_name":" A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.",
        "Background":"['Background', ' Gilteritinib, a highly selective, potent FLT3/AXL inhibitor, showed antileukemic activity with favorable tolerability in a Phase 1/2 trial of FLT3 mutation-positive (FLT3mut+) relapsed/refractory AML. In FLT3mut+ AML cell lines, gilteritinib plus azacitidine (AZA) inhibited growth, and induced apoptosis and differentiation. This ongoing Phase 2/3 trial will examine the efficacy, safety, and tolerability of gilteritinib alone, gilteritinib plus AZA or AZA alone in newly diagnosed FLT3mut+AML patients ineligible for intensive induction chemotherapy. Methods', ' This open-label, 3-arm, 2-stage randomized trial (NCT02752035) will enroll ~540 newly diagnosed adults with FLT3mut+ (FLT3-ITD or -TKD) AML; those with APL, BCR-ABL+, or active CNS leukemia will be excluded. Before initiation, the safety and tolerability of gilteritinib plus AZA will be assessed in a Safety Cohort to establish the appropriate gilteritinib dose for combination therapy. Subjects will then be randomized 1', '1', '1 to receive oral gilteritinib alone (120 mg daily; Days 128), AZA alone (75 mg/m2 by subcutaneous injection or intravenous infusion on Days 17), or AZA (75 mg/m2; Days 17) plus oral gilteritinib (daily on Days 128 at the dose determined from the Safety Cohort), and stratified by age ( < 75 vs 75 years). Subjects will continue treatment until a discontinuation event occurs. The primary endpoint is overall survival of subjects receiving gilteritinib or gilteritinib plus AZA versus AZA alone; the key secondary endpoint is event-free survival. Additional secondary endpoints', ' complete remission rate, leukemia-free survival, remission duration, composite remission rate, tolerability, and fatigue. Dose changes and interruptions are allowed in all treatment arms. A formal interim futility analysis by an Independent Data Monitoring Committee is planned when ~50 subjects in each treatment arm have either discontinued therapy or completed 2 treatment cycles. Enrollment began on November 21, 2016; as of January 31, 2017, the Safety Cohort is ongoing. Clinical trial information', ' NCT02752035']",
        "Doc_id":"ASCO_183262-199",
        "Doc_title":" A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.",
        "_version_":1606188999672594433},
      {
        "Meeting_name":" A transducer module consisting of Toll-like receptor 9 and Bruton's tyrosine kinase triggers acute myeloid leukemia blast proliferation",
        "Background":"[\"Acute myeloid leukemia (AML) is a genetically heterogeneous disease and mutations occur in various genes including those encoding for signaling molecules. A well characterized example is the tyrosine kinase Flt3, which harbours internal tandem duplications in about one third of AML patients that render the kinase constitutively active. AML cells often become addicted to such constitutively activated survival inducing signaling pathways that can be therapeutically exploited by using small molecule kinase inhibitors.By screening bone marrow biopsies of AML patients for kinase expression profiles, we detected Bruton's tyrosine kinase (Btk) in AML blasts in 26 out of 30 analyzed cases. Btk acts as an oncogene in chronic lymphocytic leukemia as well as in certain B-cell lymphoma subtypes. As compared to diseases of lymphoid origin far less is known about the role of Btk in myeloid neoplasias.Here, we show that Btk is often constitutively activated in AML and moreover, that genetic as well as pharmacological inhibition of Btk in AML cell lines as well as primary patient-derived AML cultures strongly diminishes AML cell growth. By applying quantitative mass spectrometry, we identified a signalosome consisting of Btk and Toll-like receptor 9 that is needed to constitutively transduce proliferation signals through the NFkB pathway. This newly identified TLR9/Btk signaling axis is of clinical interest as it is effectively druggable by Btk inhibitors which have so far only indications for the treatment of lymphoid malignancies.\"]",
        "Doc_id":"AACR_2014-4203",
        "Doc_title":" A transducer module consisting of Toll-like receptor 9 and Bruton's tyrosine kinase triggers acute myeloid leukemia blast proliferation",
        "_version_":1606189022534696960},
      {
        "Meeting_name":" Identifying AML-specific key targeted drugs using high-throughput drug sensitivity and resistance testing profiles of AML cells.",
        "Background":"['Introduction', ' Conventional cytotoxic chemotherapy regimens for adult acute myeloid leukemia (AML) are effective in curing less than 50% of the patients, and there is a major need for targeted drugs with better anti-cancer selectivity. Here, our aim was to i) identify potential clinically used or emerging cancer drugs by quantitative drug sensitivity and resistance testing (DSRT) of 16 AML cell lines ii) compare the cell line data with results obtained from tested 24 ex vivo AML patient specimens iii) identify genomic correlations potentially explaining drug responsiveness.Methods', ' The cancer pharmacopeia-wide drug collection is composed of 119 FDA approved and 90 investigational chemical compounds including cytotoxic agents and cell signaling molecule inhibitors. Each drug was tested over a 10,000-fold concentration range and that has generated quantitative five point dose-response curves. AML cells were plated in 384 well plates (where the drugs were pre-printed using an acoustic nano-dispensing technology, Labcyte) and incubated in standard cell culture conditions. Cell viability was measured by Cell Titer Glow luminescence assays. Analysis of dose response curves using Dotmatics software resulted in IC50 values. Moreover, the genomic profiles of the AML cell lines were determined by microarrays and/or next-gen sequencing data for further integration with drug responses.Results', ' Comprehensive data analysis of 16 AML cell lines indicated that specific targeted drugs were selectively killing AML cells. The data analysis revealed relatively strong responses for MEK inhibitors in most AML cell lines (e.g. refametinib 87%, trametinib 82%, selumetinib 75%) while 21% of ex vivo AML patient samples were sensitive to these MEK inhibitors. In case of rapalog sensitivity, 80% of AML cell lines (e.g. temsirolimus 82%, everolimus 71%, sirolimus 81%) and 25% of ex vivo AML patient cases were responsive to the mTOR inhibitors. The AML cell lines carrying FLT3-ITD mutations were extremely sensitive to FLT3 inhibitors (e.g. quizartinib, lestaurtinib, tandutinib, and sorafenib) but very few responses to FLT3 inhibitors were observed in AML patients carrying an ITD mutation in the FLT3 kinase.Summary', ' Systematic DSRT profiling of AML cell lines illustrates drug sensitivity patterns to classify the cell lines as sensitive or resistant to specific classes of drugs. mTOR and MEK inhibitors were among the most effective inhibitors for most cell lines and also in some ex vivo patient cases suggesting that these drugs may have potential as therapeutic agents in AML. Also, bioinformatics predictions can be used to identify key synergistic combinations of tested drugs for effective AML therapy. Further integration of molecular profiles and functional responses of AML cell lines will help provide better understanding of drug efficacy based on known genetic background of the disease.']",
        "Doc_id":"AACR_2013-5220",
        "Doc_title":" Identifying AML-specific key targeted drugs using high-throughput drug sensitivity and resistance testing profiles of AML cells.",
        "_version_":1606189024321470464},
      {
        "Meeting_name":" Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients",
        "Background":"['Background', ' Genomic alterations are proved to initiate cancer and related to prognosis in AML. We tested 101 consecutive AML patients (pts) at diagnosis to find prognostic implications of new genomic analysis techniques. Methods', ' We performed traditional cytogenetic and SNP 6.0 or Cytoscan HD Array (Affymetrix). SNP Array data were analyzed by a bio statistical tool (Nexus Copy Number v7.5). All the patients were tested for FLT3 and P53 mutational status. Survival analysis was performed with Kaplan-Meier method using Mantel-Cox test. Results', ' Outof 101 patients, 22 patients (21.8%) had a mutation of TP53, 27 patients had secondary AML. Seventy of 101 patients were treated with intensive chemotherapy, 13/101 were treated with 5-azacitidine, 3/101 were inserted in clinical trials, and 12/101 did not receive specific therapies. By karyotype analysis, 3/101 patients had t(8;21) or inv(16) (LR), 51/101 Normal Karyotype or other alterations (SR), and 47/101 had at least one alteration between -5, del(5q), -7, del(7q), t(6;9), t(9;22), abn(3q), (11q), (20q), (21q), (17p), or complex karyotype (HR). With SNP array 8/101 patients showed chromothripsis events involving different chromosomes. This group of patients had median age of 68.5 years (range 56-76), and all had complex karyotype. All these patients harbored TP53 mutation. TP53 is significantly more mutated in chromothripsis patients than in those with HR karyotype without chromothripsis (p < 0.001). In our set, chromothripsis defines a group of patients with poor prognosis compared with all other patients (p < 0.001), median survival 2.57 months vs 18.53 months. Chromothripsis define patients with worst prognosis even in HR group (p = 0.01). Moreover, we identified as abnormal several pathways regulating', ' cytoskeleton, histone acetyltransferase microtubules, telomere and positive regulation of cell cycle (p < 0.001). Conclusions', ' Our data suggest that chromothripsis independently defines a group of patients with poor prognosis. Chromotripsis is highly associated with TP53 mutation. Genomic characterization of those patients could reveal underlying mechanisms.']",
        "Doc_id":"ASCO_170279-176",
        "Doc_title":" Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients",
        "_version_":1606189015325736960},
      {
        "Meeting_name":" Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.",
        "Background":"['Background', '     Induction chemotherapy is often not used in elderly patients with AML due to poor prognosis and inferior outcomes.  We present here our experience in treating 20 patients age>70yrs with an induction regimen consisting of high dose cytarabine and mitoxantrone (HiDAC/MITO).  Methods', '     We analyzed all patients age > 70 years who underwent induction with HiDAC/MITO at our institution from January 2009 to December 2011.  20 patients received HiDAC at 3 g/m2 daily  on days 1-5 and mitoxantrone 80mg/m2* once on day 2(*one patient received 60mg/m2).  The end points analyzed were complete remission (CR) and induction mortality at day 30, overall survival and progression free survival.  Results', '    Median age was 75 years (70-83).  11 (55%) patients were male and 9 (45%) patients were female.  Median duration of follow up of 10 (50%) patients who are still alive at the time of this analysis is 439 days (38-1095).  High risk cytogenetics was noted in 11 (55%) patients including two patients with FLT3 mutated cytogenetics.  Intermediate risk cytogenetics was noted in 9 (45%) patients including 2 patients with NPM1 mutated FLT 3 WT AML. 12 (60%) patients had secondary AML.  The age unadjusted charlson comorbidity index (CCI) was 3 (2-9).  15 (75%) patients attained CR and 3 (15%) patients attained a CR with incomplete platelet recovery (CRp).  CR +CRp rate was 90%.  Two (10%) patients were refractory to induction and 5 (25%) patients relapsed at a later time point after induction.  Median duration of hospital stay was 28 days (22-60).  Median time to ANC >1K was 23.5 days (18-29), excluding 2 patients who had refractory disease.  Median time to platelet recovery >100K was 25 days (20-44), excluding 2 patients with refractory disease and 3 patients with CRp. Regimen related toxicity included cardiac toxicity in 4 patients and bacteremia in 11 patients.  Five (25%) patients were consolidated with stem cell transplant.  Median overall survival (OS) was 151 days (38-1095) and progression free survival (PFS) was 131 days (38-1049).  Conclusions', '     HiDAC/MITO induction is well tolerated by elderly patients with AML and demonstrates an overall response (CR+CRp) rate of 90% coupled with no induction deaths.']",
        "Doc_id":"ASCO_96941-114",
        "Doc_title":" Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.",
        "_version_":1606188993268940800},
      {
        "Meeting_name":" Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3",
        "Background":"['Background', ' FLT3+ AML patients (pts; 20%-30% of AML pts) often have rapid post-induction relapse, highlighting the need for therapies that improve the bridge to SCT. CPX-351 is a liposomal formulation that delivers a synergistic 5', '1 molar ratio of cytarabine (C) and daunorubicin (D). CPX-351 demonstrated efficacy versus 7+3 in a randomized, open-label, controlled phase III trial in pts aged 60-75 years with newly diagnosed, high-risk AML; our analysis investigated outcomes in the subset of FLT3+ pts. Methods', ' Pts were randomized 1', '1 to induction with 1-2 cycles of CPX-351 (100 u/m2 [C 100 mg/m2 + D 44 mg/m2] on Days 1, 3, and 5 [2nd induction', ' Days 1 and 3]) or 7+3 (C 100 mg/m2/day x 7 days [2nd induction', ' x 5 days] + D 60 mg/m2on Days 1, 2, and 3 [2nd induction', ' Days 1 and 2]). Pts with complete remission (CR) or CR with incomplete platelet or neutrophil recovery (CRi) could receive up to 2 consolidation cycles. Results', ' Of the pts who had FLT3 mutations assessed and received study treatment, 22/138 (16%) pts in the CPX-351 arm and 20/136 (15%) pts in the 7+3 arm had baseline FLT3 mutations. AML subtypes in FLT3+ pts were', ' tAML (19%); AML after MDS with (38%) or without (10%) prior hypomethylating agents; AML after CMMoL (12%); and de novo AML with MDS karyotype (21%). In FLT3+ pts, median OS was longer with CPX-351 (10.25 mo) versus 7+3 (4.55 mo; HR = 0.57 [95% CI', ' 0.24, 1.33]; P= 0.093) and the rate of CR+CRi was higher (68% vs 25%). A greater number of FLT3+ pts treated with CPX-351 were able to undergo SCT (n = 10/22 [45%]; 4 pts were alive as of this analysis, after a median post-SCT follow up of 692 days [range', ' 96-769]) compared with 7+3 (n = 2/20 [10%]; neither pt still alive). The on-study safety profile of CPX-351 in FLT3+ pts was comparable to 7+3 and consistent with the overall study population. Serious adverse events were experienced by 7 (32%) FLT3+ pts in the CPX-351 arm and 10 (50%) in the 7+3 arm. Conclusions', ' CPX-351 demonstrated numerical improvement in median OS in older pts with newly diagnosed, FLT3+ high-risk AML and allowed more pts to undergo SCT. The analysis was limited by small number of pts. Clinical trial information', ' NCT01696084']",
        "Doc_id":"ASCO_192604-199",
        "Doc_title":" Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3",
        "_version_":1606189032383971328},
      {
        "Meeting_name":" MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML).",
        "Background":"['Background', ' We showed recently that CEBPA mutations (mut) in CN AML are associated with better outcome and a unique microRNA expression profile, including miR-181a upregulation. Here we tested if miR-181a expression can predict outcome independently. Methods', ' We analyzed 187 de novo CN AML adult patients (pts) aged <60 years (y; median 45) similarly treated on CALGB 9621 and 19808. Of these, 122 had molecular high risk [FLT3-ITD or NPM1 wild type (wt)] and 65 low risk (no FLT3-ITD, NPM1 mut) CN AML. FLT3, NPM1, CEBPA, MLL, and WT1 mutations, and ERG and BAALC expression were analyzed centrally. miR-181a expression was measured in pretherapy marrow using OSUCCC v3.0 arrays. The mean of 2 miR-181a probe log intensities was used as a continuous variable for analyses. Results', ' Higher miR-181a levels (miR-181a) were associated with CEBPA mut, NPM1 wt, no FLT3-TKD, lower ERG expression, higher %FAB M1/M2, lower WBC and age, higher blood blasts, and lower % gum hypertrophy. miR-181a tended to associate with more complete remissions (CRs; p = .07) and significantly associated with longer disease-free (DFS; p = .05) and overall (OS; p = .01) survival (median follow-up 6.5 y for pts alive). A stronger prognostic impact of miR-181a was observed in the molecular high risk group, where miR-181a predicted more CRs (p = .03), and longer DFS (p = .0002) and OS (p = .0001). In multivariable analyses of the molecular high risk group, miR-181aindependently predicted CR, and longer DFS and OS (Table). For descriptive purposes, we dichotomized pts at the median miR-181a expression value. For high v low miR-181a expressers, CR rates were 84% vs 72% and 5 y DFS and OS rates 43% vs 18% and 48% vs 19%, respectively. Conclusions', ' miR-181a expression is a prognostic marker in CN AML, mainly in the molecular high risk group, where it predicts outcome independently of other variables including CEBPA mutations. As miR-181a confer better treatment response, novel approaches increasing miR-181a levels might benefit not only CN but also other AML pts. Multivariable analyses for outcome for high molecular risk pts Variables in final modelsCR OR* p DFS HR+ pOS HR+ p miR-181a, each 1 unit increase in log expression1.54.040.70.0080.71.001 CEBPA, wild type v mutated--2.8.0053.6.0004 NPM1, wild type v mutated--7.7.015.0.008 FLT3-ITD, positive v negative--4.9.023.5.05 WT1, wild type v mutated----0.5.02 Age, each 10-y increase WBC, each 50 x 10e09/L increase0.52 -.007 -- -- -- 1.4- .0007 Bone marrow blasts, each 1% increase--1.04.03-- Extramedullary involvement, absent v present----2.3.01*OR', ' Odds ratio. +HR', ' Hazard ratio. ORs > 1 (<1) mean higher (lower) CR rate for the first category listed for the dichotomous variables and for the higher (higher) values of the continuous variables. HRs < 1 (>1) indicate lower (higher) risk for an event for the first category listed for the dichotomous variables and for the higher (higher) values of the continuous variables. Variables considered in the models were those significant at  = 0.20 in univariable analyses.']",
        "Doc_id":"ASCO_32121-65",
        "Doc_title":" MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML).",
        "_version_":1606188973294616576},
      {
        "Meeting_name":" Variations in FLT3 ligand levels during the course of AML treatment.",
        "Background":"['Background', '  FLT3 ligand (FL) is a hematopoietic growth factor expressed in many tissues.  AML patients who are administered myeloablative therapy exhibit a marked and transient rise in plasma FL concentrations. Furthermore, the presence of high concentrations (1000 pg/mL) of FL impedes the efficacy of FLT3 tyrosine kinase inhibitors in vitro. However, the behavior of FL concentrations throughout the course of AML treatment remains unknown. This pilot study was undertaken to track the relationship between AML therapy and FL levels over time.  Methods', '  Ten AML patients were enrolled in an IRB-approved procurement protocol. Blood samples were collected at weekly intervals for one year, and plasma was isolated by centrifugation. Plasma FL and stem cell factor (SCF) concentrations were measured by ELISA.  Results', '  We observed four distinct patterns in FL fluctuations. First, in all cases where induction or consolidation chemotherapy resulted in an aplastic bone marrow (nine patients), FL concentrations rose markedly and consistently to levels >1000 pg/mL following the administration of chemotherapy. Second, in three of four patients whose leukemia was refractory to induction chemotherapy, FL concentrations remained below 500 pg/mL during induction. Third, in two patients receiving the FLT3 TKI sorafenib, FL concentrations did not rise above 500 pg/mL while on this medication. Fourth, in one patient receiving the hypomethylating agent 5-azacitidine, FL concentrations remained below 100 pg/mL throughout the course of therapy. SCF concentrations did not vary throughout the course of chemotherapy.  Conclusions', '  An FL surge was seen when cytotoxic chemotherapy resulted in aplasia. This FL surge was not seen with sorafenib or 5-azacitidine. In addition, the FL surge was attenuated in three patients whose leukemia was refractory to chemotherapy. These observations give rise to two new hypotheses regarding FL', ' 1) It is possible to maintain lower FL levels with targeted agents than with chemotherapy; and 2) Residual leukemia appears to inhibit the FL surge, providing indirect evidence of cross-talk between leukemia and the stromal microenvironment. This inhibition may be the explanation for why AML patients develop pancytopenia early in relapse.']",
        "Doc_id":"ASCO_110304-132",
        "Doc_title":" Variations in FLT3 ligand levels during the course of AML treatment.",
        "_version_":1606189040375169024},
      {
        "Meeting_name":" Bortezomib induces the degradation of FLT3-ITD tyrosine kinase in acute myeloid leukemia through an autophagy-dependent mechanism",
        "Background":"['Internal tandem duplication mutations of the Fms-like tyrosine kinase 3 (FLT3-ITD) are found in 30% of Acute Myeloid Leukemias and are associated with a very poor outcome. Although the activity of FLT3 inhibitors such as AC-220 is currently evaluated in phase II and III trials with promising results, some studies suggest that leukemic cells can develop various mechanisms of resistance including mutations of the tyrosine kinase domain (TKD).In the present work, we show that AML cell lines harboring FLT3-ITD mutation, MV4-11 and MOLM-14, are exquisitely sensitive to the proteasome inhibitor bortezomib. Importantly, although bortezomib induced apoptosis in all primary AML samples (n=24), FLT3-ITD mutated cells (n=13) are much more sensitive than non-mutated samples (n=11). Moreover we observed a positive correlation between FLT3-ITD mutation load (measured by the FLT3-ITD/FLT3wt ratio) and bortezomib activity among FLT3-ITD samples (p=0.0084, r=0.719). At the molecular level, bortezomib induced autophagy, as shown by an increase of LC3-II protein expression and by electron microscopy analysis. This autophagy was mainly cytotoxic as cell death was inhibited by the autophagy pharmacological inhibitor, 3-methyladenine. Before cell death occurs, we observed that bortezomib induced a downregulation of FLT3-ITD both in cell lines and primary samples. Accordingly, cell signalling dependent on FLT3-ITD (ERK/Akt/STAT5) was inhibited upon bortezomib treatment. Others proteasome inhibitors such as MG-132 or carfilzomib were also able to downregulate FLT3-ITD protein level. Interestingly, 3-methyladenine restored FLT3-ITD expression and signaling after bortezomib exposure, suggesting a role for autophagy in the downregulation of the mutated receptor. Using confocal microscopy, we showed a co-localization between FLT3-ITD and LC3 structures after bortezomib exposure. Electron microscopy analyses confirmed the presence of the receptor in autophagy vesicles. Furthermore, the membrane trafficking inhibitor dynasore inhibited autophagy, cell death and degradation of FLT3-ITD induced by bortezomib. We also showed that bortezomib overcomes the resistance to AC-220 in a MOLM-14 ITD/TKD model, by triggering the degradation of the receptor. Finally, in vivo studies using a mouse xenograft model, confirmed that bortezomib was able to decrease FLT3-ITD protein level and inhibit leukemic cell growth.Altogether, our results show that proteasome inhibitors induce a downregulation of the oncogenic tyrosine kinase FLT3-ITD in an autophagic-dependent manner, suggesting that they could be used as an alternative strategy in AML with FLT3-ITD mutations.']",
        "Doc_id":"AACR_2014-1336",
        "Doc_title":" Bortezomib induces the degradation of FLT3-ITD tyrosine kinase in acute myeloid leukemia through an autophagy-dependent mechanism",
        "_version_":1606188973923762176},
      {
        "Meeting_name":" Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant.",
        "Background":"['Background', '  FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in acute myeloid leukemia (AML) is associated with early relapse after chemotherapy and poor survival. Relapse after HSCT or failure of salvage chemotherapy in FLT3-ITD AML is rarely associated with subsequent HSCT or durable survival. Quizartinib, an oral FLT3 inhibitor, shows promising activity; a Ph 2 study (n=333) of quizartinib monotherapy (Levis et al, ASH 2012) reported that quizartinib often bridged patients (pts) to HSCT.  Methods', '  136 FLT3-ITD(+) and 40 FLT3-ITD(-) pts, relapsed/refractory after HSCT or 1-second line regimen, were included. The response category of composite complete remission (CRc) comprised complete remission [CR] + complete remission with incomplete platelet recovery [CRp] + complete remission with incomplete hematologic recovery [CRi].  Results', '  Quizartinib was discontinued for HSCT in 47/136 FLT3-ITD(+) pts (35%), with 44/47 having at least a PR (2 CRp, 24 CRi, 18 PR). Median overall survival (OS) was 41.5 wks for pts with CRc prior to HSCT and 29 wks for pts with PR. The 1y survival rate was 39% for both response groups. Pts with a CRc (n=36) or PR (n=20) but no HSCT, respectively, had a median OS of 24.5 and 20.9 wks and 1y survival rates of 25% and 5%. Of 27 pts with OS >52 wks, 17 (63%) had HSCT. Quizartinib was discontinued for HSCT in 14/40 FLT3-ITD(-) pts (35%), with 13/14 having at least a PR (1 CR, 1 CRp, 7 CRi, 4 PR). Median OS was not yet reached for pts with CRc, and was 40.7 wks for pts with PR. The 1y survival rate was 78% for pts with CRc and 50% for pts with PR. 8 of these 14 pts had detectable ITD mutation but the level was below the prespecified 10% cutoff.  Conclusions', '  Of clinical significance in these heavily pretreated pts who had failed salvage chemotherapy or HSCT, approximately 1/3 were successfully bridged to potentially curative HSCT, with encouraging 1y survival rates. To extend the potential benefits of FLT3 inhibitor therapy in combination with allogeneic HSCT, studies of maintenance quizartinib to prevent relapse post HSCT are ongoing. Clinical trial information', ' NCT00989261.']",
        "Doc_id":"ASCO_114005-132",
        "Doc_title":" Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant.",
        "_version_":1606189041318887424},
      {
        "Meeting_name":" Up-regulation of BAALC/MN1/MLLT11/EVI1 gene cluster in relation to MYC / BCL2 protein co-expression and poor overall survival in acute myeloid leukemia (AML).",
        "Background":"['Background', ' Molecular heterogeneity is the basis of dismal prognosis in AML. Current clinical risk evaluation by karyotyping and a few genetic mutations appear insufficient to provide defined directions for novel targeted therapies. Complex molecular technologies require transition into widely available laboratory platforms, like immunohistochemistry, for better integration into routine clinical / laboratory practices. MYC and BCL2 protein co-expression is associated with aggressive clinical behaviour in diffuse large B-cell lymphoma; however, this proteomic signature is not studied in AML patients, as risk stratification tool. Methods', ' In a defined subset (MYC+/BCL+ or MYC-/BCL-) of AML patients (n = 20), we utilized diagnostic bone marrow biopsy material to examine expression signature of several genes (n = 12) of established prognostic value in AML (TP53; RB1; NRAS; EVL1; MN1; ERG; MLLT11; PRAME; BAALC; FLT3; WT1; SOCS2; GUSB; TBP). Digital RNA quantification was determined, utilizing nCounter , Nanostring plate form. Transcript levels were correlated with MYC/BCL2 protein expression pattern; karyotype (favourable, intermediate and unfavourable risk group) and overall survival (OS), irrespective (+/-) of therapy or cause of death. Results', ' Unsupervised K-means++ clustering defined two distinct groups with high and low transcript levels of BAALC/MN1/MLLT11/EVI1/SOCS2 genes (> 2.0 fold difference; P < 0.001). Higher mRNA signature correlated with higher prevalence of MYC/BCL2 co-expression (P < 0.05) and poor OS (log rank test, P < 0.036) but remains unrelated to conventional cytogenetic risk groups (fisher exact test, P < 0.084). Conclusions', ' This pilot study present limited but useful data, to stipulate direction to refine the prognostication scheme of AML patients outside conventional cytogenetic risk groups. It also presents some biologic rationale to the use of novel agents targeting MYC and or BCL2 genes in combinational chemotherapy for AML patients.']",
        "Doc_id":"ASCO_171325-176",
        "Doc_title":" Up-regulation of BAALC/MN1/MLLT11/EVI1 gene cluster in relation to MYC / BCL2 protein co-expression and poor overall survival in acute myeloid leukemia (AML).",
        "_version_":1606188974336901121},
      {
        "Meeting_name":" Dual inhibition of FLT3 and Src pathways by ON150030, a type 1 inhibitor, as a novel strategy for relapsed and refractory AML therapy.",
        "Background":"['Approximately one third of patients suffering from Acute Myeloid Leukemia harbor a FLT3 Internal tandem duplication mutation (FLT3-ITD). When mutated, this receptor tyrosine kinase increases the activity of pathways for proliferation and blocks apoptosis. Quizartinib is a 2nd generation FLT3 inhibitor that inhibits FLT3-ITD in AML, but has a median duration response of 12.1 weeks. Studies revealed a secondary mutation in FLT3 at the aspartate of codon 835 (D835X) is responsible for relapse. The D835 substitution renders FLT3 constitutively active. Type 2 inhibitors like Quizartinib bind to FLT3 in its inactive state and fail to inhibit FLT3-ITD harboring a D835 mutation. Here, we tested the utility of ON150030, developed by our group, as a novel therapeutic agent to treat AML. Structural studies suggest ON150030 binds to the active form of FLT3 (Type 1 inhibitor) so mutations such as D835X do not affect the inhibitory activity of the compound. In vitro kinase assays demonstrate that ON150030 potently inhibits Wildtype and FLT3-D835Y forms, while Quizartinib fails to inhibit FLT3-D835Y. Additionally, ON150030 demonstrated time and temperature dependent inhibition of FLT3, suggesting that the compound is an irreversible inhibitor of FLT3. Biological studies reveal that ON150030 specifically inhibits the growth of MV4-11 cells harboring the FLT3-ITD mutation (GI50', ' 10nM). Western blot analysis demonstrates that MAPK and PI3K/AKT pathways in these cells are inhibited with increasing dose of ON150030. The JAK independent phosphorylation of STAT5 seen in the context of FLT3-ITD is also reduced in response to ON150030. Future goals are to introduce FLT3 and its various mutant isoforms into the mouse myeloid cells (32Dcl3) and examine how it affects proliferation and differentiation, and then compare the effects of ON150030 and Quizartinib. In addition to strongly inhibiting FLT3, ON150030 inhibits SRC, which was shown to induce resistance to targeted therapies in several leukemias including AML. We will introduce SRC into the 32D-FLT3-ITD cell lines sensitive to ON150030 and test whether these cells retain their sensitivity to the drug. Next, we will perform cytotoxicity and biochemical assays on patient-derived primary AML cells using ON150030. Mouse xenograft models will be used to determine if ON150030 synergizes with standard chemotherapy agents and inhibits cancer progression in vivo. At the conclusion of this project, we hope to demonstrate that ON150030 can be used in combination therapies in all AML patients harboring a FLT3 mutation, and result in sustained remission of disease.']",
        "Doc_id":"AACR_2017-2094",
        "Doc_title":" Dual inhibition of FLT3 and Src pathways by ON150030, a type 1 inhibitor, as a novel strategy for relapsed and refractory AML therapy.",
        "_version_":1606188973306150912},
      {
        "Meeting_name":" Frequency of rare cytogenetic abnormalities at relapse in acute myeloid leukemia (AML) with FLT3 internal tandem duplication (ITD) and normal karyotype at diagnosis",
        "Background":"['Background', '  FLT3-ITD mutations are present in AML in 30% of patients, most commonly with a normal karyotype, and are associated with short disease-free survival.  In vitro and in vivo studies of FLT3-ITD cell lines and patient samples have demonstrated DNA double-strand break repair by an alternative highly error-prone form of non-homologous end-joining (ALT NHEJ), resulting in illegitimate ligation of non-contiguous DNA breaks, causing DNA deletions and translocations that may contribute to disease progression.  To look for clinical evidence of genomic instability, we reviewed cytogenetic changes at relapse.    Methods', '  Charts of patients with cytogenetically normal AML with FLT3-ITD treated at the University of Maryland Greenebaum Cancer Center were reviewed along with metaphase analysis results at diagnosis and relapse.    Results', '  Cytogenetic data were available from first and, when applicable, subsequent relapses for 12 patients with cytogenetically normal AML with FLT3-ITD who relapsed, including 5 following allogeneic hematopoietic stem cell transplantation (allo HSCT). Ten patients acquired cytogenetic changes, many of them rare translocations and inversions (Table).  Conclusions', '  AML with FLT3-ITD and normal karyotype at diagnosis has a high frequency of rare cytogenetic abnormalities at relapse, providing clinical evidence for genomic instability. These data may support the potential therapeutic role of inhibitors of ALT NHEJ repair proteins, such as PARP1 and DNA ligase IIIa, in AML with FLT3-ITD.   Karyotypes at relapse (*after allo HSCT).']",
        "Doc_id":"ASCO_111251-132",
        "Doc_title":" Frequency of rare cytogenetic abnormalities at relapse in acute myeloid leukemia (AML) with FLT3 internal tandem duplication (ITD) and normal karyotype at diagnosis",
        "_version_":1606188992956465152},
      {
        "Meeting_name":" Insulin-like growth factor 1 receptor (IGF1R) inhibitor BMS754807 is active against FLT3-ITD mutated acute myelogenous leukemia and activity is p53 dependent",
        "Background":"['The Internal tandem mutation (ITD) in the FLT3 gene is associated with shorter remission duration, overall survival and relapse free survival in patients with normal karyotype acute myelogenous leukemia (AML). FLT3-ITD inhibitors are in clinical development but single agent clinical activity is of limited duration with activation of parallel signaling pathways potentially contributing to most relapses thus highlighting the need for new agents. Because common signaling pathways are activated downstream of FLT3 and IGF1R, we investigated the preclinical activity of IGF1R antagonist BMS754807 against AML cells with FLT3-ITD mutations. Results', ' BMS 754807 induced apoptosis (Annexin V binding by flow cytometry) in MOLM13 cells (AML cell line with FLT3-ITD mutation and wild type p53) at 48 hrs at submicromolar concentrations, while OCI AML3 cells (p53 and FLT3 wild type) were resistant. Similarly, murine BAF3 cells expressing human FLT3-ITD underwent prompt apoptosis with BMS 754807 while the same cells with human wt-FLT3 were resistant to BMS 754807(IC50s 2.5 mol vs >10 mol). Western blot analysis confirmed reduction in FLT3, Akt, ERK, S6 ribosomal protein and GSK3 beta phosphorylation and increase in p53 levels in MOLM13 cells. Interestingly, apoptosis induction was not associated with caspase activation. Moreover, apoptosis induction by BMS 754807 appeared to be p53 dependent as MOLM13 cells with stable expression of short hairpin RNA (sh-RNA) targeting p53 (p53-shRNA) were resistant, while MOLM13 cells expressing scramble sh-RNA underwent apoptosis comparable to parental MOLM13 cells. Surface expression of IGF1R was comparable among parental and p53-shRNA MOLM13 cells. Apoptosis induction by BMS 754807 in p53-WT and FLT3-ITD cells was associated with phosphorylation of p53 at serine 15. Conclusion', ' BMS 754807 has selective activity against AML cells with FLT3-ITD mutation and this activity is p53 dependent and associated with phosphorylation of p53 at serine 15. Results suggest that IGF1R inhibition has therapeutic potential as novel targeted therapy for AML with FLT3-ITD mutation.']",
        "Doc_id":"AACR_2012-3871",
        "Doc_title":" Insulin-like growth factor 1 receptor (IGF1R) inhibitor BMS754807 is active against FLT3-ITD mutated acute myelogenous leukemia and activity is p53 dependent",
        "_version_":1606188987111702528},
      {
        "Meeting_name":" CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD.",
        "Background":"['Introduction', ' CPX-351 (Vyxeos) is a liposomal combination of cytarabine and daunorubicin at a synergistic 5', '1 molar ratio. Recently, CPX-351 has been shown to be significantly more effective than the 7+3 standard of care chemotherapy in treating high-risk AML patients, including patients with the FLT3-ITD mutation. We previously treated primary patient samples with CPX-351 ex vivo and found that FLT3-ITD+ samples were significantly more sensitive to CPX-351 and showed enhanced drug uptake. We hypothesized that dysregulated FLT3 signaling results in an activation of liposome uptake pathways, leading to increased sensitivity to CPX-351 and ultimately cell death. Furthermore, we examined the effect of combining CPX-351 with existing FLT3 inhibitors (e.g. quizartinib and midostaurin).']",
        "Doc_id":"AACR_2017-1087",
        "Doc_title":" CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD.",
        "_version_":1606189032274919424},
      {
        "Meeting_name":" TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome",
        "Background":"['AML is a heterogeneous disease with a variety of structural and numerical chromosomal and genetic alterations that provided important prognostic information capable to guide therapy and predict outcome. The reported TP53 mutation rate in AML is low (2.1%). By contrast, the incidence of FLT3 disruption is frequent (20-30%) and is an independent predictor of unfavourable outcome of acquired clinical resistance to FLT3 inhibitors. TP53 mutations in AML with a complex karyotype (CK) is higher (69-78%), but few data are available for association between the most common AML associated lesions such as FLT3, NPM1, DNMT3A, IDH2 and TP53 mutation or CK.Aims', ' To investigate the frequency, the types of mutations, the associated cytogenetic, the molecular abnormalities, the correlation with known molecular alterations (FLT3, NPM, etc.) and the prognostic role TP53 mutations in adult AML pts.Patients and Methods', ' 886 AML patients were analysed for cytogenetic and for a panel of genetic alterations (FLT3, NPM, WT1, DNMT3A, IDH1-2 etc). Of these, 200 adult AML pts were also examined for TP53 mutations using several methods, including Sanger sequencing, NGS and HiSeq 2000 platform (38/200) and were correlated with cytogenetic analysis.Results', ' 55 pts (27.5%) showed 3 or more chromosome abnormalities (CK-AML), 83 (41.5%) presented one or two cytogenetic abnormalities (other-AML) and 43 pts (21.5%) have normal karyotype (nK). In 19 cases the karyotype was not available.Sanger sequencing analysis detected TP53 mutations on 29 patients with 36 different types of mutations (32 deleterious point mutations; 4 deletions); seven pts (4%) have 2 mutations. Mostly (23/29) of the TP53 mutated pts (79.3%) had CK while only 6/29 (21%) mutated pts have no CK. Overall, between pts with CK, TP53 frequency is 41.8% (P>0,0001).120 pts were analysed for concomitant presence of TP53 mutations and FLT3/NPM1 disruption/mutation', ' revealing a significant relation between pts with FLT3-ITD or NPM1 and TP53 wild-type (p = 0.043 and 0.022 respectively).As for clinical outcome alterations of TP53 were significantly associated with poor outcome (OS and EFS p<0.0001). The very worsened outcome of TP53 mutations overcome the negative prognostic role of FLT3 mutations (P0.0001).WES analysis done in 38 pts (33 TP53 wt and 5 pts TP53 mutated) revealed no genes exclusively mutated in the 5 TP53 mutated pts.Conclusions', ' Our data demonstrated that TP53 mutations occur in 14.5% of AML with a higher frequency in the subgroup of CK-AML (p<0.0001) and are mutually exclusive with FLT3 and/or NPM1; they predicted to be deleterious and significantly correlated with worse prognosis and may confer resistance to conventional and innovative therapy. For these reasons, TP53 mutation screening should be recommended at least in CK-AML pts. ELN, AIL, AIRC, PRIN, 2010-12 L. Bolondi, FP7 NGS-PTL project.']",
        "Doc_id":"AACR_2015-4906",
        "Doc_title":" TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome",
        "_version_":1606188976119480320},
      {
        "Meeting_name":" Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.",
        "Background":"['Background', ' Baseline characteristics such as age >60, WBC>100,000/L and FLT3/NPM1/DNMT3A+ve are known to be associated with a poor prognosis in AML. Ivey et al. (NEJM 2016) reported that FLT3-ITD+ve patients (pts) who were MRD+ve after 2 cycles of induction chemotherapy were more likely to relapse as compared to those who became MRD-ve (92% vs 35%). Eradication of FLT3+veclones may lead to reduced relapse rates. Crenolanib is a type I FLT3 TKI, which inhibits both FLT3-ITD and TKD mutations. We here report that a single induction cycle of cytarabine/anthracycline/crenolanib leads to MRD negativity by multiparameter flow cytometry (MPF), and low rate of early relapse in pts with newly diagnosed FLT3+veAML. Methods', ' This abstract includes 29 consecutively treated, newly diagnosed, FLT3+ve AML pts, who achieved CR1 after one course of cytarabine/anthracycline/crenolanib. Pts received 7+3 induction with cytarabine 100 mg/m2/d for 7d and either daunorubicin (<60 y', ' 90 mg/m2; 60 y', ' 60 mg/m2) or idarubicin 12 mg/m2 for 3d. Crenolanib (100 mg TID) was started on day 9 until 72 h prior to next chemotherapy. Results', ' 29 pts (15M, 14F), median age 55y (10pts 60y) are included. MRD at time of count recovery was assessed by MPF in 25/29 pts. 20/25 (80%) became MRDve. With a median follow up of 7mth, 4/25 pts have relapsed (2/5 MRD+ve, 2/20 MRD-ve).Age 60 was a risk factor for MRD+ve and relapse. All 4 pts with WBC>100K as well as 5 pts with FLT3/NPM1/DNMT3A+ve AML became MRD-ve after one induction cycle and none have relapsed. Conclusions', ' These data suggest, in the context of an ongoing trial (NCT02283177), crenolanib in combination with standard induction is associated with a high rate of achieving an MRD negative state by MPF and a low rate of relapse in previously untreated adults with mutant FLT3. Longer follow-up and comparison of MRD data with similar pts treated with standard chemo alone will be necessary to reach more definitive conclusions. Clinical trial information', ' NCT02283177Sub-groupMRD-veRelapse freeTotal20/25 (80%)21/25 (84%)MRD-ve at CR12018/20 (90%)MRD+ve at CR153/5 (60%)<60y14/15 (93%)14/15 (93%)60y6/10 (60%)7/10 (70%)WBC >100,000/L4/4 (100%)4/4 (100%)FLT3/NPM1/DNMT3A+ve5/5 (100%)5/5 (100%)']",
        "Doc_id":"ASCO_193420-199",
        "Doc_title":" Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.",
        "_version_":1606188984082366464},
      {
        "Meeting_name":" High-throughput clonal analysis of AML tumors with droplet microfluidics.",
        "Background":"['Single cell analysis tools are crucial to better understand the role that rare or heterogeneous cancer cells play in the evolution of tumor progression. Although, it is now feasible to perform single-cell RNA-Seq on thousands of, several challenges remain for high-throughput single-cell DNA sequencing. To address these challenges and enable the characterization of genetic diversity in cancer cell populations, we developed a novel approach that barcodes amplified genomic DNA of individual cells confined to microfluidic droplets. The barcodes are used to reassemble the genetic profiles of individual cells from next generation sequencing data. A key feature of our approach is the â€œtwo-stepâ€ microfluidic workflow that releases genomic DNA from cellular proteins prior to amplification. The microfluidic workflow first encapsulates individual cells in droplets, lyses the cells and prepares the lysate for genomic DNA amplification using proteases. Following this lysate preparation step, the proteases are inactivated and droplets containing the genomes of individual cells are then paired with molecular barcodes and PCR reagents. We demonstrate that the two-step microfluidic approach is vastly superior to workflows without the two-step process for efficient DNA amplification on tens of thousands of individual cells per run with high coverage uniformity and low allelic dropout of targeted genomic regions. To apply our single-cell sequencing technology to the study of acute myeloid leukemia (AML), we developed a targeted panel to sequence genes frequently mutated in AML including TP53, DNMT3A, FLT3, NPM1, NRAS, KRAS, JAK2, IDH1 and IDH2. Using this panel, we were able to identify clonal populations from AML research samples; moreover, the single-cell nature of our approach enabled the correlation of multiple mutations within subclones and determination of whether the mutations existed as as a homozygote or heterozygote. Collectively, our results show a greater degree of heterogeneity in AML tumor samples than is commonly appreciated with bulk sequencing methods.']",
        "Doc_id":"AACR_2017-5398",
        "Doc_title":" High-throughput clonal analysis of AML tumors with droplet microfluidics.",
        "_version_":1606188981034156032},
      {
        "Meeting_name":" Outcomes of older acute myeloid leukemia (AML) patients receiving hypomethylating therapy versus standard induction chemotherapy (IC) prior to allogeneic hematopoietic cell transplantation (HCT).",
        "Background":"['Background', ' Patients with AML are typically treated initially with IC, often followed by consolidation with HCT. Hypomethylating agents (HMA) are an alternative initial therapy for patients who are less fit at diagnosis. Whether the choice of therapy prior to HCT affects outcomes after HCT is unknown. We performed a retrospective study to compare outcomes after HCT for older AML patients treated with IC vs. HMA prior to HCT. Methods', ' We identified patients over age 60 with AML who underwent HCT from 2008-2014 while in first remission (CR1). Patients treated with HMA were in the HMA group and patients given IC were in the IC group. We compared the age at diagnosis and baseline AML characteristics between the groups with the t test or Chi-squared test. The primary endpoint was overall survival (OS) and the secondary endpoint was progression-free survival (PFS) from time of HCT, both calculated with the log-rank test. Results', ' We identified 7 HMA and 63 IC patients. No significant differences existed in median age at diagnosis (age 66 for both, t test) or baseline AML characteristics (Table I, Chi-squared test). All HMA patients achieved CR1 prior to HCT with a median of 3 cycles of therapy (range of 2-9). 4 of the 7 patients (57%) in the HMA group are still alive and without relapse at 71, 38, 29, and 17 months after HCT. The remaining 3 HMA patients died during follow up', ' one with relapse at +310 days, one from GVHD 25 months after HCT, and one from sepsis during conditioning at day +32. Among IC patients, estimated 2-year OS was 49% and 2-year PFS was 43% (log-rank test). Conclusions', ' Select patients who achieve CR from initial HMA therapy can successfully undergo HCT. Although this series is small, our findings suggest that outcomes after HCT for patients treated initially with HMA are similar to those treated with IC. Thus, older AML patients who are otherwise fit may benefit from consideration for HCT. Baseline characteristics.Characteristics (%)ICHMAp valueCytogenetic riskp=0.68Favorable3 (5%)0Intermediate48 (76%)5 (71%)Adverse11 (18%)2 (29%)FLT3 statusp=0.49ITD11 (18%)0TKD5 (8%)0NPM1 statusp=0.54Mutant15 (24%)3 (42%)']",
        "Doc_id":"ASCO_171646-176",
        "Doc_title":" Outcomes of older acute myeloid leukemia (AML) patients receiving hypomethylating therapy versus standard induction chemotherapy (IC) prior to allogeneic hematopoietic cell transplantation (HCT).",
        "_version_":1606189011120947201},
      {
        "Meeting_name":" Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts).",
        "Background":"['Background', ' CN AML pts are currently stratified into Low-risk [FLT3-ITD negative (neg)/NPM1 mutated (mut)] and High-risk [FLT3-ITD positive (pos) or NPM1 wild type (wt)] groups (FLT3-ITD/NPM1-only classification). We recently showed that low ERG expression and CEBPAmut identify pts with better outcome within, respectively, the Low- and High-risk groups, and that WT1mut confers poor outcome regardless of FLT3-ITD/NPM1 status. Here, we assess if adding CEBPA and WT1 mutation and ERG expression testing improves the currently used CN AML molecular risk classification. Methods', ' FLT3, NPM1, CEBPA and WT1 mutations and ERG and BAALC expression were tested at diagnosis in 143 CN AML adults enrolled on CALGB treatment protocols 9621 and 19808. Pts were divided into two molecular risk groups', ' i) CALGB Group I that included Low-risk pts with low ERG & High-risk pts with CEBPAmut and ii) CALGB Group II that included WT1mut pts & Low-risk pts with high ERG & High- risk pts with CEBPAwt. Results', ' CALGB Group I (n=56) v Group II (n=87) had more complete remissions (CRs) (P=.005; 96% v 79%), and longer disease-free (DFS; P<.0001; 5 year (y) 69% v 21%) and overall (OS; P<.0001; 5 y 70% v 31%) survival [median follow-up for pts alive 6 y]. In multivariable (MV) analyses, Group I predicted higher rate of CR (P=.02), and longer DFS (P<.0001) and OS (P=.0002), after correcting for other variables (Table). In contrast, for the same cohort of pts grouped by the FLT3-ITD/NPM1-only classification, CRs were 94% v 82% and 5 y DFS 59% v 32% and OS 67% v 36% in the Low- v High-risk groups. Based on the Akaike Information Criterion, MV models for DFS and OS using the CALGB risk Groups were better than those using the FLT3-ITD/NPM1-only risk groups. Conclusions', ' Prognostic classification of younger de novo CN AML pts is improved by adding CEBPA and WT1 mutation and ERG expression testing. While mutational analyses are ready for use in clinical trials, quantification of ERG expression is yet to be standardized. Multivariable analyses for CR, DFS & OSVariables in Final ModelsCRDFSOSOR*PHRPHRPCALGB Group I v Group II6.5.020.28<.00010.34.002BAALC (low v high)6.6.008--0.53.01WBC [10e09/L] (each 50 unit increase)0.5.01--1.65.0001Age (each 10 year increase)0.4.01----*OR', ' odds ratio; HR', ' hazard ratio. ORs >1 (<1) mean higher (lower) CR rate for the first category listed for the dichotomous variables and for the lower (higher) values of the continuous variables. HRs <1 (>1) indicate lower (higher) risk for an event for the first category listed for the dichotomous variables and for the lower (higher) values of the continuous variables. Variables considered in the models were those significant at =0.20 in univariable analyses as follows', ' for CR, Group I v Group II, BAALC, age, WBC, sex; for DFS, Group I v Group II, WBC, race; for OS, Group I v Group II, BAALC, WBC, hemoglobin, platelets, extramedullary involvement.']",
        "Doc_id":"ASCO_34742-65",
        "Doc_title":" Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts).",
        "_version_":1606189017404014592},
      {
        "Meeting_name":" Improvement of leukemia-free survival (LFS) and reduction of relapse incidence by allogeneic stem cell transplantation (SCT) in elderly patients (pts) with AML irrespective of the FLT3-ITD and npm status except npm+/flt3(ITD)-.",
        "Background":"['Background', ' Acquired mutations of the flt3 and npm1 genes have been shown to determine outcome in younger pts with AML. Here, the influence of flt3 and npm1 mutations on outcome of elderly pts (> 60 a) was analyzed in relation to either chemotherapy (CT) or SCT. Methods', ' Of the 498 pts entered into the curative arm of the #69 study for pts > 60 a, 357 are evaluable and 158 of these had flt3 and npm1 available as of Oct 2009. Complete remission was obtained in 191 of the 357 pts after induction chemotherapy. Flt3 and npm1 was available in 53 of 81 and 44 of 59 pts in CR1 receiving either a second consolidation or allogeneic SCT. Consolidation consisted of CT or, in pts with related or unrelated donors, of SCT after 200 cGy TBI. Results', ' Overall survival (OS) of the 158 pts with known npm1 and flt3(ITD) status was 33  3% at 2a. Mutation status did not significantly influence OS, but did influence the EFS of pts in CR1 after induction (27  11% vs. 51  7% for flt3(ITD)+ vs. flt3(ITD)- p < 0.01; 69  9% vs. 34  7% for npm1+flt3- vs. non-npm1+flt3- p = 0.01). Subsequently the effect of CT and SCT on EFS was investigated according to the flt3 and npm1 status. Pts with wild type flt3 and with npm1+/flt3- had better EFS than the rest. However, SCT compared to CT increased EFS irrespective of the flt3-ITD status (EFS 59  9% vs. 43  9% for flt3(ITD)- and 40  15% vs. 15  13% at 2 a for flt3(ITD)+ after SCT and CT respectively; p = 0.036) by reducing the relapse incidence (31  9% vs. 56  9% for flt3(ITD)- and 52  16% vs. 85%  13% at 2 a for flt3(ITD)+ after SCT and CT respectively; p = 0.012). Except for npm1+/flt3(ITD)- pts, SCT was also superior to CT (EFS 62  16% vs. 74  11% for npm1+/flt3- and 51.2  9.4 vs. 11.9  7.7% for all others after SCT and CT respectively; p < 0.01). Conclusions', ' In conclusion, flt3 and npm1 status does not influence OS of AML pts > 60 a. However, EFS of pts in CR1 is highly dependent upon mutation status and, except in npm1+/flt3(ITD)- pts, increased by SCT rather than CT by reducing relapse incidence.']",
        "Doc_id":"ASCO_53398-74",
        "Doc_title":" Improvement of leukemia-free survival (LFS) and reduction of relapse incidence by allogeneic stem cell transplantation (SCT) in elderly patients (pts) with AML irrespective of the FLT3-ITD and npm status except npm+/flt3(ITD)-.",
        "_version_":1606189035387092992},
      {
        "Meeting_name":" Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO).",
        "Background":"['Background', ' Young patients affected by non APL-Acute Myeloid Leukemia (AML) achieve complete remission (CR) using conventional induction chemotherapy in about 55-70%. The addition of Gemtuzumab Ozogamicin (GO) demonstrated to improve clinical outcome, in terms of CR rates. We retrospectively evaluated and compared the efficacy of different induction schedules, in terms of CR rates and Overall Survival (OS), administered to two groups of AML patients. Group 1 (n = 139) was treated with a GO (MyFLAI or MyAIE schedules); group 2 (n = 270) received a non-GO based regimen including or not Fludarabine (FLAI, FLAN, FLAG, 3+7 or DAE). Methods', ' From 1997 to 2014, 409 patients with newly diagnosed AML were treated in 3 Italian Institutions. According to karyotype (performed in 392/409 patients), FLT3 (available for 244/409 patients), and NPM1 mutational status (available for 157/409 patients), based on the NCCN-2013 risk stratification criteria, 35.2% of the patients were considered at High Risk (HR) (31.6% and 36.4% in the two groups, respectively) and 7.6% at low risk (LR) (7.8% and 7.0%, respectively). Results', ' The complete remission (CR) rate after induction was 81.4% and 70.4% for Group 1 and 2, respectively (p = 0.008). Deaths during induction (DDI), occurring in the first 50 days from 1st line therapy, were 4/139 (2.9%) in Group 1 and 22/270 (8.1%) in Group 2. Patients treated with GO showed a better OS than patients of Group 2; the 5-years OS in the two groups was 54.01% and 34.9%, respectively, and different according to age (54.0% and 34.9% respectively (p < 0.001) in patients < 60 years, 30.2% and 13.5% respectively (p = 0.001) in patients > = 60 years). Notably, the analysis on subgroup of HR patients showed a significantly better OS in Group 1 than in Group 2 (p = 0.007, 5-year OS 47.7%; 21.0% respectively) and EFS. Conclusions', ' We may therefore conclude that adding GO to any induction regimen is an independent and strong predictor of better OS and higher CR rate. This new approach to AML front line treatment could be recommended in SR and HR AML patients, in which showed an advantage in terms of OS if compared with other standard regimens.']",
        "Doc_id":"ASCO_169936-176",
        "Doc_title":" Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO).",
        "_version_":1606189011473268736},
      {
        "Meeting_name":" Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy.",
        "Background":"['Background', '  Outcomes of pts with AML who are refractory to High-dose Cytarabine (HiDAC) based induction are dismal. ASCT as initial salvage may be effective and potentially superior to repeat induction with combination chemotherapies in such pts.  Methods', '  1597 AML pts were treated with HiDAC-based induction at MD Anderson Cancer Center between 1995 and 2009. 285 primary refractory pts were identified. 28 (10%) of these underwent ASCT as initial salvage and were reviewed.  Results', '  Median age was 56 years (36 to 77) and 50% were males. Median ECOG PS was 1 (0-2). Antecedent hematological disorders were present in 14 pts (50%). Median white cell count, hemoglobin, platelet count and bone marrow (BM) blast percentage at diagnosis were 3.5 x 109/l (0.6 to 73.6), 7.8 g/l (6.5 to 11.4), 44 x 109/l (9 to 615), and 43% (6-82), respectively. 9 pts (32%) had complex cytogenetics. FLT3 mutations were identified in 2 (15%) of 13 evaluated pts. All pts were refractory to HiDAC-based induction. HiDAC was combined with an anthracycline in 16 pts (57%) and non-anthracycline in 12 pts (43%). Median time from induction to ASCT was 76 days (28 to 184). Median BM blast and peripheral blast at ASCT were 28% (3 to 82) and 4% (0 to 41). 21 pts (75%) had matched related donors (18 sibling and 3 haploidentical) and 7 (25%) had matched unrelated donors. Conditioning regimens were melphalan-based, busulfan-based, fludarabine-based or others in 7 (25%), 10 (36%), 8 (29%) and 3 pts (10%); respectively. Complete remission (CR) was achieved in 23 of 28 pts undergoing ASCT (CR = 82%) with median time to CR of 31 days (26 to 134). 12 pts relapsed with median time to relapse of 5 months (2 to 19). 8 pts remain alive with median follow up of 80 months (28 to 118). Median overall survival (OS) for the entire group is 20 months (5 to 118). In historical series of pts with AML refractory to HiDAC-based induction, salvage chemotherapies induced CR rates of 22% with median OS of 4 months.  Conclusions', '  Initial salvage with allogenic SCT is feasible and yields superior outcomes to salvage chemotherapy in primary HiDAC refractory AML pts. Randomized studies are warranted to further explore this treatment option.']",
        "Doc_id":"ASCO_100916-114",
        "Doc_title":" Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy.",
        "_version_":1606189007118532608},
      {
        "Meeting_name":" Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML",
        "Background":"['In order to discover unexpected anti-cancer efficacies of approved and emerging drugs, we established a diagnostic ex vivo drug sensitivity and resistance testing (DSRT) platform covering the entire cancer pharmacopeia as well as emerging anti-cancer compounds. Here, the platform was applied to analyze bone marrow (BM) mononuclear cells from 17 adult acute myeloid leukemia (AML) patients, 3 healthy donors as well as 7 AML cell lines. The DSRT panel covered FDA-approved small molecule oncology drugs (n=120), as well as emerging, investigational and pre-clinical oncology compounds (n=120), such as kinase (e.g. RTKs, checkpoint and mitotic kinases, Raf, MEK, JAKs, mTOR, PI3K), and non-kinase inhibitors (e.g. HSP, Bcl, activin, HDAC, PARP, Hh). To generate dose-response curves, each of the drugs was applied over a 10,000-fold concentration range. In addition, the samples underwent deep molecular profiling including exome- and transcriptome sequencing, as well as phosphoproteomic analysis. DSRT provided consistent and reliable data from ex vivo samples with a high correlation between data from individual healthy BM samples (r=0.93). Bioinformatic processing of the data from AML resulted in several key observations. First, overall drug response profiles of AML blast cells were distinctly different from healthy BM controls suggesting several potential leukemia-selective effects, such as multi-kinase (dasatinib), MEK, and mTOR inhibitors. Second, the overall drug responses from AML cell lines and the patient ex vivo samples showed differences, suggesting that ex vivo testing may reveal cancer-selective effects not previously seen in established cancer cell line panels. Third, the response data from patient samples clustered many drugs consistently into the expected functional classes (such as topoisomerase II inhibitors, MEK inhibitors and rapalogs), whereas other drug classes were more dispersed (such as FLT3 inhibitors with quizartinib clustering away from all other tyrosine kinase inhibitors), suggesting secondary targets playing a key role in drug efficacy. Fourth, analysis of serial samples from patients developing clinical resistance to targeted agents showed striking agreement between the ex-vivo DSRT profiles and clinical responses. In conclusion, comprehensive DSRT platform generated powerful novel insights on AML drug response and may enable individual optimization of therapies, particularly for recurrent leukemias. DSRT will also serve as a powerful hypothesis-generator for clinical trials, particularly for emerging drugs. The ability to correlate ex vivo response profiles for hundreds of drugs in clinical samples with deep molecular profiling data will yield exciting new translational and pharmacogenomic opportunities for cancer therapy.']",
        "Doc_id":"AACR_2012-3188",
        "Doc_title":" Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML",
        "_version_":1606189038581055488},
      {
        "Meeting_name":" Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy",
        "Background":"['Introduction. Intensive induction chemotherapy in non-M3 young Acute Myeloid Leukemia (AML) patients is represented by the association of an antracycline and Cytarabine. Some treatment regimens including fludarabine or the addition of Gemtuzumab Ozogamicin (GO) as a third or fourth drug, proved to give a benefit in terms of CR rates.Aims of the study. In a group of 49 patients treated with intensive chemotherapy, we evaluated chromosomal abnormalities with SNP 6.0 and Cytoscan HD (Affymetrix) in order to improve conventional cytogenetic analysis and discover novel chromosomic aberrations related to clinical data and therapy response.Patients and Methods. From 2001 to 2014, 489 patients were treated in our Institution. Among those, in 49 newly diagnosed AML patients (median age 54 (range 19-71)), SNP microarray based-genotyping were performed and then analyzed by Nexus Copy Number v7.5 (BioDiscovery) and R Development Core Team.According to karyotype, FLT3 and NPM1 mutational status, 55.9% of the patients were considered at High Risk (HR) and 4.1% at low risk (LR). Ten patients had secondary AML. Patients were treated with induction schemes including MyFLAI, MyAIE, FLAI, FLAN, FLAG, 3+7 or DAE.Results. The CR rate after induction was 87.8% (43/49 patients). Deaths during induction (DDI), occurring in the first 50 days from 1st line therapy, were 1/49. The median OS was 135 months, the 5-years OS in our patients was 55,1%. Patients treated with GO showed a non-statistical trend toward a better OS than patients treated with other regimens (median OS not reached vs 133 months, respectively).We explored the alterations found by SNP array in our patients searching for novel markers of therapy resistance. We found a median of 192,5 total copy number aberrations (range 72- 1071)', \" a median of 145,5 total copy number aberrations in responding patients group (RPG), and a median of 361 total copy number aberrations (p = ns) in non-responding patients group (NRPG).We compared the frequency of detected aberrations in RPG and in NRPG with Fisher's exact test. We found that PIK3CA, Gain chr3\", '178,927,088-178,929,550 (p = 0,0016), SMAD4, Gain chr18', \"48,573,154-48,573,255 (p = 0,0166) and several other gene's loci (CASC18, TCF12, UTY, GRB10, ZFY) are significant aberrations in NRPG compared with RPG.Conclusions. We identified a number of genes with significant aberrations in NRPG, particularly PIK3CA, a protein-coding gene involved in cell proliferation and metabolic pathway with interaction with HRAS/KRAS and EGF, and SMAD4, a transcription factor activated by TGF-beta. Those 2 genes were found overexpressed in other solid tumors.We suppose that those genes may be involved in a hyper-proliferative pathway that underlies a mechanism of chemo-resistance.Acknowledgments Work supported by ELN, AIL, AIRC, Progetto Regione-Universit 2010-12 (L.Bolondi), FP7 NGS-PTL project.\"]",
        "Doc_id":"AACR_2016-368",
        "Doc_title":" Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy",
        "_version_":1606189000447492097},
      {
        "Meeting_name":" CoMEt",
        "Background":"['Identifying driver mutations in cancer genomes is a significant challenge due to the mutational heterogeneity of tumors', ' different combinations of somatic mutations drive different tumors, even those of the same cancer type. This mutational heterogeneity arises because driver mutations target genes in signaling and regulatory pathways, each of which can be perturbed in numerous ways.We introduce CoMEt, an algorithm to identify combinations of candidate driver mutations de novo, without any prior biological knowledge (e.g. pathways or protein interactions). CoMEt searches for combinations of mutations that exhibit mutual exclusivity, a pattern expected for mutations in pathways. CoMEt uses an exact statistical test for mutual exclusivity that is less biased toward high frequency alterations than previous approaches and more sensitive in detecting combinations of lower frequency alterations. We compute the exact test using a novel tail enumeration procedure and also derive a binomial approximation. CoMEt simultaneously identifies collections of one or more combinations of mutually exclusive alterations, consistent with the observation of multiple hallmarks of cancer, and also performs simultaneous analysis of subtype-specific mutations. Finally, CoMEt uses an MCMC algorithm to sample from collections in proportion to their significance, summarizing the distribution in a marginal probability graph. We show that CoMEt outperforms other mutual exclusivity approaches on simulated and real data.We apply CoMEt to hundreds of samples from four different TCGA cancer types', ' gastric cancer (STAD), glioblastoma (GBM) and acute myeloid leukemia (AML), and breast cancer (BRCA). We identify multiple mutually exclusive sets within each cancer type. These include the RTK/RAS pathway in gastric cancer, the Rb and p53 signaling pathways in glioblastoma, and a collection containing multiple kinases, including FLT3, as well as the RAS genes in AML. In addition, we analyze subtype-specific mutations using CoMEt by encoding the subtype of each sample and computing exclusivity between and within subtypes. We apply this approach using four gene expression subtypes of breast cancer and identify several pathways that are enriched for mutations in specific subtypes including the PI(3)K/AKT signaling pathway in the Luminal A subtype. Many of these overlap known pathways, but others reveal novel putative cancer genes. These findings provide testable hypotheses for experimental validation.']",
        "Doc_id":"AACR_2015-1936",
        "Doc_title":" CoMEt",
        "_version_":1606189006244020224},
      {
        "Meeting_name":" ITD Assembler",
        "Background":"['Tandem duplication of coding sequence is an important mechanism of somatic mutation capable of activating oncogenes such as fms-related tyrosine kinase 3 (FLT3) as well as the potential for underlying constitutional or germline disease. Detection of internal tandem duplication (ITD) in short-read sequencing data remains challenging due to deficiencies in short-read alignment where reads carrying signatures of ITD are often unmapped. Assembly based approaches collapse repetitive sequences, resulting in reduced or lost genomic complexity. The majority of structural variation detection tools are limited to finding insertions that are contained entirely within individual read alignments, and are unable to detect read-spanning duplications. Tools designed to detect large structural variation from paired-end reads that map discordantly based on expected fragment size and orientation do not provide the precision needed to detect ITDs. Only tools that consider the characteristic alignment features that signal the presence of ITDs will be able to detect them; these alignment features include', ' an excess of reads with unaligned, soft-clipped bases, read pairs where one end is unmapped located near the site of insertion, and read pairs where both ends are unmapped.We introduce ITD Assembler, a novel approach that searches all unmapped reads from exome capture or whole genome sequencing data to identify duplications. From the entire set of unmapped reads plus subset of mapped reads harboring soft-clipped bases, de Bruijn graph assembly is applied to select reads that form cycles, indicative of duplicated sequence structures. Reads from de Bruijn graph cycles are then assembled using an Overlap Layout Consensus (OLC) methodology thereby alleviating the collapse of repeat sequences affecting de Bruijn graph assembly approaches. Resulting OLC assembled contigs are locally aligned to the reference sequence to annotate the position of ITDs.ITD Assembler was run on The Cancer Genome Atlas (TCGA) acute myeloid leukemia (AML) dataset, and FLT3-ITD detection rates were compared against orthogonal algorithms. ITD Assembler identified the highest percentage of TCGA FLT3-ITDs, reported significantly higher allele fractions, and discovered additional ITDs in the KIT, CEBPA and WT1 cancer genes.']",
        "Doc_id":"AACR_2015-4856",
        "Doc_title":" ITD Assembler",
        "_version_":1606188973586120704},
      {
        "Meeting_name":" Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITDpositive acute myeloid leukemia (AML)",
        "Background":"['Background', ' Internal tandem duplications (ITDs) are commonly observed FLT3 mutations in AML and are a very poor prognostic factor for duration of response and overall survival (OS). While standard chemotherapy (SC) induces a high rate of complete remission (CR) in FLT3-ITD AML, the relapse rate is high with a median time to relapse of 6 months vs 9-11 months for other AML subtypes (Levis M. ASH Education Book 2013', '220-226). Currently, no approved therapies target the FLT3-ITD mutation. Q is an oral, highly potent, and selective FLT3-ITD inhibitor. Q monotherapy results in composite CR (CRc) rates up to 46% in relapsed/refractory FLT3-ITD+ AML (Levis M, ASCO 2014 [abstr 7093]). Q has been safely administered with SC in pts with NDx AML (Burnett AK, ASH 2013 [abstr 622]). Here, we describe a P3, randomized, double-blind, P-controlled trial of Q in combination with IND and CON and as MN in pts with NDx FLT3-ITD+ AML. Methods', ' Pts 18-75 years old with NDx FLT3-ITD+ AML are eligible. During IND, cytarabine (CY) 100 mg/m2/d will be given for 7 days along with investigators choice of anthracycline (either daunorubicin 60 mg/m2/d or idarubicin 12 mg/m2/d) on D1-3. Q/P will be given QD for 14 days starting on C1 D8. If pts require a second cycle of IND, investigators may choose a standard 7+3 or 5+2 regimen with Q/P starting on D8 or 6, respectively. Pts achieving CR, CR with incomplete platelet recovery (CRp), or CR with incomplete neutrophil recovery (CRi) after IND will receive CON. Options include high-dose (HD) CY plus Q/P, allogeneic hematopoietic stem cell transplant (alloHSCT), or HD CY plus Q/P followed by alloHSCT. Pts with CR, CRp, or CRi after CON will receive Q/P MN therapy for a maximum of 12 cycles. The primary endpoint is centrally adjudicated event-free survival, and key secondary endpoints are OS, CR rate, CRc rate, and % of pts achieving CR with no evidence of minimal residual disease (MRD) following IND. MRD will be assessed by a PCR-based assay that detects residual FLT3-ITD mutation. The study will enroll 536 pts at 250 centers worldwide (NCT02668653). Results', ' NA Conclusions', ' NA Clinical trial information', ' NCT02668653']",
        "Doc_id":"ASCO_166342-176",
        "Doc_title":" Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITDpositive acute myeloid leukemia (AML)",
        "_version_":1606188993987215360},
      {
        "Meeting_name":" MIR142 loss-of-function mutations promote leukemogenesis through derepression of ASH1L resulting in increased HOX gene expression.",
        "Background":"['MIR142 mutations have been identified in acute myeloid leukemia (AML) and non-Hodgkins lymphoma. In AML, all MIR142 mutations localize to the miR-142-3p seed sequence. We show that mutated MIR142 is unable to suppress several well-known targets of miR-142-3p. Interestingly, the mutations of miR-142-3p result in their preferential loading into the RNA-induced silencing complex, leading to the degradation of miR-142-5p. Accordingly, miR-142-5p expression is decreased in MIR142 mutated AML. Hence, MIR142 mutations in AML disrupt both miR-142-3p/5p functions. Thus, we modeled the effect of MIR142 mutations on hematopoiesis using Mir142-/- mice. We show that loss of miR142 results in significant increases in myeloid hematopoietic stem/progenitor cells (HSPCs), including granulocyte-macrophage progenitors, myeloid-biased multipotent progenitors (CD150- CD48+ Flk2- Kit+ Sca+ lineage-) and CD229- myeloid-biased HSCs (CD150+ CD48- Kit+ Sca+ lineage-). In contrast, there are significant decreases of megakaryocyte-erythroid progenitors and erythroid precursors. Although the number of HSCs is normal in Mir142-/- mice, HSC transplantation suggest that they are myeloid-biased. In AML, MIR142 mutations are commonly found in conjunction with mutations of IDH1/2. To assess the importance of this association, we transduced wildtype or Mir142-/- HSPCs with retrovirus expressing IDH2 R172K and then transplanted into lethally irradiated recipients. Expression of IDH2 R172K alone was sufficient to induce a lethal myeloproliferative neoplasm (MPN). In contrast, Mir142-/- alone did not result in MPN. However, loss of Mir142 cooperates with IDH2 R172K to produce a more severe MPN, with increased CD34+ blasts and more severe anemia. Moreover, secondary transplantation shows that Mir142-/- x IDH2 R172K cells but not IDH2 R172K cells efficiently engraft and induce MPN, suggesting that loss of miR142 increases leukemia-initiating activity. We identify the histone methyltransferase ASH1L as a target gene of miR142 that contributes to altered hematopoiesis in Mir142-/- mice. The 3â€™-untranslated region of ASH1L has four miR-142-3p binding sites, and luciferase reporter assay shows that miR142 suppresses its translation by 80%. Consistent with this observation, Ashl1 protein expression is 3-fold higher in Mir142-/- bone marrow. ASH1L is a key positive regulator of HOX gene expression. Accordingly, we observed markedly (5-10 fold) increased HoxA9/A10 expression in myeloid progenitors in Mir142-/- mice. Likewise, HoxA9/A10 expression is increased in CD34+ blasts from Mir142-/- x IDH2 R172K transplanted mice. Of note, increased HoxA9 expression has been shown to cooperate with mutant IDH1 to induce AML in mice. Together, these findings support a model in which loss-of-function mutations of MIR142 contribute to hematopoietic malignancies by derepressing ASH1L and inducing HOXA9/10 gene expression.']",
        "Doc_id":"AACR_2017-3042",
        "Doc_title":" MIR142 loss-of-function mutations promote leukemogenesis through derepression of ASH1L resulting in increased HOX gene expression.",
        "_version_":1606189029984829440},
      {
        "Meeting_name":" Clinical testing and implementation of the TruSight Myeloid Next Generation Sequencing (NGS) panel for identification of clinically relevant variants in hematological malignancies",
        "Background":"['Recent cancer genome profiling studies have increased our understanding of the somatic mutation landscape of myeloid malignancies. A number of genes and variants are known to have prognostic/predictive utility in several myeloid malignancies, allowing for more accurate stratification, and enhanced patient management. This has led to consideration of NGS for detection of somatic mutations in myeloid malignancies in the clinical diagnostic setting, to supplant single-gene molecular testing assays in current use. Building on our prior work establishing a novel mass spectrometry-based high throughput mutation detection assay for hematologic malignancies, we investigated the application of NGS to myeloid malignancy diagnostics. To do this, we validated the Illumina TruSight Myeloid Sequencing Panel (54 genes, 568 amplicons) on 71 acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasm (MPN) patient samples, alongside relevant controls. NGS Libraries were prepared using standard protocols, and sequencing performed on the Illumina MiSeq platform. Concordance among NGS calls, single gene tests, and Sanger verification was tested as part of the clinical validation process.Analysis of 41 cases tested in our previously developed mass spectrometry assay indicated 100% concordance (70/70) for reportable variants mutually covered in both assays. Single nucleotide variations detectable in lab-standard single gene assays were all found by NGS (100% concordance). 58/71 (82%) cases had at least one additional potentially clinically relevant variant that would not have been identified in the existing assay (mean 1.95 additional variants/case; range 1-9). Additionally, we determined that AMLs carrying IDH1, IDH2 or TET2 mutations had a higher mutation burden (mean 4.6 mutations/case, range 2-7), compared to AMLs wild-type for these three genes (mean 3.1 mutations/case, range 2-4; p = 0.008). Clinically relevant insertions (up to 33 bp) and deletions (up to 52 bp) associated with AML and MPN, including FLT3 ITD and CALR deletions, were detected in known positive cases. In these cases, our analysis was supplemented with a custom bioinformatics algorithm allowing for alignment against an artificial reference sequence to detect larger indels. Due to low coverage of the clinically actionable CEBPA, we supplemented the NGS assay with Sanger sequencing for this locus. Therefore, we report the validation of an NGS panel for high throughput detection of mutations in myeloid malignancies, and the development of a wet-bench and informatics workflow enabling maximal information benefit in the diagnostic setting. This pipeline allows the detection of variants that impact diagnosis and patient management, with significantly improved information benefit over current tests.']",
        "Doc_id":"AACR_2015-4260",
        "Doc_title":" Clinical testing and implementation of the TruSight Myeloid Next Generation Sequencing (NGS) panel for identification of clinically relevant variants in hematological malignancies",
        "_version_":1606188995080880128},
      {
        "Meeting_name":" Unraveling the mechanism of action",
        "Background":"['The tumor suppressor 2A (PP2A) is a multi-enzyme complex that targets a variety of oncogenic signaling cascades such as Raf, MEK and AKT. Numerous reports have now emerged indicating that the inhibition of PP2A leads to the development of tumors including breast, gastric and lung and a range of hematological malignancies such as chronic and acute myeloid leukemia (CML and AML, respectively). We and others have shown that inhibition of PP2A is crucial for the oncogenic effects of leukemia associated receptor tyrosine kinases such as BCR/Abl, c-KIT and FLT3. Importantly when PP2A is reactivated using pharmacological agents (FTY720 and AAL(S)), growth and survival of these cells is inhibited. This approach targets molecules downstream of these oncogenic kinases and thus PP2A reactivation is designed to avoid resistance associated with kinase inhibitor therapy. As the mechanism of action of these PP2A activators is unknown, it is essential that we now determine the molecular targets of these compounds to generate more effective drugs. Using a chemical proteomics approach incorporating click chemistry linking the drugs to beads, unbiased pull down assays were performed in myeloid leukaemia cells and protein isolates were identified by mass spectrometry. Using this approach we have identified a novel cellular target, which is known to be overexpressed in a range of cancers, including leukemias. We have also shown that this protein associates with PP2A complexes in these cells, and thus may act as an endogenous inhibitor of PP2A activity. We have also performed phospho-proteomics and co-immunoprecipitation studies to identify protein changes in myeloid leukemia cells in response to PP2A activators. In addition to identifying known PP2A targets, such as Akt and ERK, we have also identified a number of novel protein changes, including altered expression of the SET oncoprotein. SET is a known inhibitor of PP2A, suggesting that FTY720 may act via inhibition of SET. Other PP2A regulatory proteins such as CIP2A, PME-1 and PP2A-B56alpha are also affected by FTY720/AAL(S) treatment. Our research findings are thus providing the vital clues necessary for determining the mechanism of action of clinically relevant PP2A activators, thereby moving us towards the provision of novel anti-cancer treatment regimes.']",
        "Doc_id":"AACR_2013-2038",
        "Doc_title":" Unraveling the mechanism of action",
        "_version_":1606189022134140928},
      {
        "Meeting_name":" An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.",
        "Background":"['Background', '']",
        "Doc_id":"ASCO_184062-199",
        "Doc_title":" An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.",
        "_version_":1606189026697543680},
      {
        "Meeting_name":" Co-treatment with NPM1 antagonist and FLT3 inhibitor or pan-histone deacetylase inhibitor exerts superior efficacy against cultured and primary human AML cells co-expressing mutant NPM1 and FLT3-ITD.",
        "Background":"['In approximately 50% of the normal-karyotype (NK) AML, a mutant (mt) NPM1 is localized in the cytoplasm (NPM1c+), which is pathogenetic for AML. Co-expression of FLT3-ITD with mtNPM1 results in poor outcome in AML. We have previously reported that in the cultured (OCI-AML3) cells carrying mtNPM1, shRNA-mediated knockdown of both the wild-type and mtNPM1 induced p53, p21, p27 and CEBP, while attenuating the levels of HOXA9 and Meis1. This was associated with the morphologic features of myeloid differentiation, apoptosis, as well as a marked inhibition of the colony growth of OCI-AML3 cells (p<0.01). Additionally, knockdown of NPM1 sensitized OCI-AML3 cells to all-trans retinoic acid (ATRA) (0.25 to 2.0 M)-induced differentiation and apoptosis (p<0.01). Findings of our present studies demonstrate that, as compared to the shRNA-mediated knockdown of total NPM1 (wild-type and mtNPM1), selective knockdown of mtNPM1 alone induced less differentiation and apoptosis of OCI-AML3 cells, as well as caused less inhibition of the leukemogenic potential of OCI-AML3 cells in NOD/SCID mice. The small molecule inhibitor NSC348884 is known to disrupt the oligomerization of wild-type and mtNPM1. NSC348884 dose-dependently (1.0 to 3.0 M) induced apoptosis and sensitized OCI-AML3 and primary AML cells expressing NPM1c+ to ATRA-induced apoptosis (p<0.01). Patient-derived primary AML cells co-expressing mtNPM1 and FLT3-ITD, as well as OCI-AML3 cells transfected with FLT3-ITD lentivirus (OCI-AML3/FI cells) that co-expressed NPM1c+ and FLT3-ITD were relatively resistant to NSC348884 and/or ATRA. Notably, combination with NSC348884 (2.0-5.0 M) and the FLT3 antagonists ponatinib (0.5 to 1.0 M), AC220 (0.2 to 1.0 M) or midostaurin (100 to 500 nM) induced more apoptosis than either agent alone against OCI-AML3/FI and primary AML cells co-expressing mtNPM1 and FLT3-ITD (p<0.01). Importantly, treatment with the clinically achievable levels of pan-histone deacetylase inhibitor panobinostat (PS, 10 to 50 nM) depleted NPM1 levels and induced differentiation of OCI-AML3, OCI-AML3/FI, and primary AML cells co-expressing mtNPM1 and FLT3-ITD (40 to 70%). Additionally, as compared to treatment with each agent alone, co-treatment with NSC348884 and PS induced significantly more apoptosis in these cells (p<0.01). This was associated with reduction in the levels of p-FLT3, p-AKT, p-STAT5 and NPM1, as well as induction of p53 and p21 levels. Therefore, co-treatment with an NPM1 antagonist and PS or FLT3 inhibitor is highly active against AML cells co-expressing mtNPM1 and FLT3-ITD. These findings support the rationale for in vivo testing of these combination therapies against AML with co-expression of mtNPM1 and FLT3-ITD.']",
        "Doc_id":"AACR_2013-2034",
        "Doc_title":" Co-treatment with NPM1 antagonist and FLT3 inhibitor or pan-histone deacetylase inhibitor exerts superior efficacy against cultured and primary human AML cells co-expressing mutant NPM1 and FLT3-ITD.",
        "_version_":1606189012369801216},
      {
        "Meeting_name":" A phase 1b trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma (NCT01231399).",
        "Background":"['Background', '  Gastric cancer remains a significant problem worldwide with approximately 870,000 new cases and 650,000 deaths per year.  Although the Granite trial did not show any benefit of everolimus over best supportive care in patients with advanced gastric cancer, preclinical combinations of platinum chemotherapy and mTOR inhibition have shown a synergistic effect.  We conducted a phase 1 trial combining mFOLFOX6 with everolimus.  Methods', '  Patients with metastatic gastric, gastroesophageal and esophageal adenocarcinoma were eligible.  A standard 3+3 design was employed and patients received standard dose mFOLFOX6 and escalating doses of everolimus ranging from 2.5 to10 mg/day.  Patients were evaluated for dose limiting toxicities during the first 4 weeks of treatment.  Tumor tissue was collected for next generation sequencing.  Results', '  Six patients were accrued to the first dose level of everolimus at 2.5 mg daily, four with metastatic gastric cancer and 2 with metastatic esophageal cancer.  Two dose limiting toxicities (DLTs) were observed at the first dose level with one patient being hospitalized for fever secondary to a possible infection.  The second patient developed grade 2 neutropenia that resulted in a treatment delay greater than 7 days.  Toxicities were manageable with mucositis, nausea, neutropenia, fatigue and rash being the most common.  Five patients required everolimus dose reduction during their course of treatment.  The median time to treatment failure was 8.9 months.  Next generation sequencing revealed mutations in APC, EGFR, FGFR3, FLT3, KDR, KIT, PDGFRA, PIK3CA, RET, STK11 and TP53.  Conclusions', '  The immunosuppressive effect of chemotherapy in combination with everolimus resulted in two DLTs at the first dose level.  One patient that required dose reductions due to mucositis had a FLT3 mutation which more commonly occurs in acute myelogenous leukemia.  A FLT3 genotype variant associated with the development of pneumonitis in renal cell carcinoma patients treated with mTOR inhibitors was previously reported (Y. Urun, et al, ASCO 2013).  Further research is needed to identify biomarkers of treatment response and toxicity. Clinical trial information', ' NCT01231399.']",
        "Doc_id":"ASCO_131904-144",
        "Doc_title":" A phase 1b trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma (NCT01231399).",
        "_version_":1606189018212466688},
      {
        "Meeting_name":" Real world patient numbers for AML targeted therapies.",
        "Background":"['Background', ' The standard of care for AML patients (pts) has not changed in 40 yrs. Molecular biomarkers FLT3 and IDH1/2 are being tested for prognosis and risk stratification and recent trial results show these will be effective for targeted therapies. We analyzed real world data from a leading clinical lab (BioReference Laboratories Inc) to evaluate the frequency of pts eligible for FLT3 and IDH therapies. Methods', ' FLT3 (ITD/TKD), IDH1 and IDH2 mutation status results from 384 AML patients from Mar 2015 - Dec 2016, tested by a validated NGS assay, OnkoSight, were analyzed and frequencies compared with the literature. Results', ' Of 384 AML pts from 31 US States, 52 were FLT3+ (13.5%, expected (exp) 24-38%). We observed 41 IDH+ pts (10.7%, exp 8-18%), with 27 pts IDH2+ (7%, exp 8-9%) and 13 pts IDH1+ (3.4%, exp 9%). Mutations in both FLT3 and IDH were found in 10 pts (2.6% of AML pts, exp 9%). This equates to 19.2% of FLT3+ pts (exp 31%), 15.4% of IDH2+ pts (exp 26%) and 1.9% of IDH1+ pts (exp 5%). We identified 1 pt harboring an unexpected triple positive (FLT3, IDH1 & 2) as IDH1 and 2 are considered mutually exclusive. Medicare was the single biggest payer (42%). Tests were requested by community based physicians in 92% of cases. Conclusions', ' The data suggest fewer pts may be eligible for FLT3 and IDH therapies in a real world setting than expected from the literature, possibly due to published data usually coming from cohorts of well characterized, filtered AML pts from research projects and/or clinical trials, which may not represent routine clinical testing. We find a lower level of FTL3 and IDH mutation overlap showing approx only 3% of all AML pts as eligible for at least two options of targeted therapies (exp 9%). Gene variantNo. of pts (observed %, expected %)AML pts(N = 384)FLT3+(N = 52)IDH+(N = 41)FLT3-ITD38 (9.9%, 19-28%)38 (73%, 73-79%)7 (17.1%, 35-44%)FLT3-TKD10 (2.6%, 5-10%)10 (19.2%, 21-42%)3 (7.3%, 5%)FLT3-ITD & TKD4 (1.0%, 1-3%)4 (7.7%, 4-8%)0 (0%, 0%)All FLT3+52 (13.5%, 24-38%)10 (24.4%, 31%)IDH113 (3.4%, 9%)1 (1.9%, 5%)13 (31.7%, 50%)IDH227 (7.0%, 8-9%)8 (15.4%, 26%)27 (65.8%, 44-50%)IDH1 & IDH21 (0.3%, 0%)1 (1.9%, 0%)1 (2.4%, 0%)All IDH+41 (10.7%, 8-18%)10 (19.2%, 31%)FLT3+ & IDH+10 (2.6%, 9%)10 (19.2%, 31%)10 (24.4%, 31%)']",
        "Doc_id":"ASCO_192127-199",
        "Doc_title":" Real world patient numbers for AML targeted therapies.",
        "_version_":1606189028997070848},
      {
        "Meeting_name":" A CRISPR/Cas9 knockout screen identify novel drug resistance genes in AML",
        "Background":"['Acute myeloid leukemia (AML) is a malignant hematopoietic disease and the most common type of acute leukemia in adults. Despite remarkable progress made in the therapy of AML, the mainstays of treatment have not significantly changed over the last 20 years. Technological advances have greatly accelerated genomic discovery and precision medicine holds promise to better tailor medications to AML with specific mutations. Importantly, one major obstacle to greater success with target therapy of leukemia is drug resistance. But the mechanisms underlying drug resistance in AML are poorly understood.The activating mutations of FLT3 are now recognized as the most common molecular abnormality in AML and FLT3ITD mutations are found in nearly 30% of AML patients. The poor prognosis of patients harboring FLT3 mutations renders FLT3 an obvious target of therapy. Quizartinib (AC220) is a potent and selective second-generation inhibitor of FLT3. It is in clinical trials for the treatment of relapsed or refractory FLT3ITD positive and negative AML patients and as a maintenance therapy. So far, those clinical trials have showed very promising result. However, drug resistance to AC220 has also been reported through the early clinical studies. To understand the underlying mechanisms of drug resistance to AC220, we undertook an unbiased approach with a novel CRISPR pooled library to screen new genes whose loss of function confer resistance to AC220. In our screen, we identified SPRY3 and GSK3 as positive hits and the related Wnt and FGF-Ras-ERK signaling activation as the major mechanisms to cause resistance to the FLT3 inhibitor AC220. In the next step, we will explore the detailed underlying mechanisms by which SPRY3 and GSK3 mutations lead to drug resistance to AC220. We will also confirm our findings in primary AML patient samples. Taken together, our study will provide new insight into signaling pathways that contribute to the acquired resistance in AML. The knowledge learned from this study may lead to the development of more efficient therapeutic avenues for AML.']",
        "Doc_id":"AACR_2016-5042",
        "Doc_title":" A CRISPR/Cas9 knockout screen identify novel drug resistance genes in AML",
        "_version_":1606188991304957953},
      {
        "Meeting_name":" Oncogenic transformation of FLT3-ITD is partially dependent on tyrosine 842 in the activation loop.",
        "Background":"['Acute myeloid leukemia (AML) is a heterogeneous disease of the blood. About 30 % of AML patients carry an oncogenic mutant of the type III receptor tyrosine kinase FLT3. Among the various mutations in FLT3, the internal tandem duplication (ITD) mutations in the juxtamembrane domain are the most common type of mutation, while point mutations in the kinase domain also occur. Although oncogenic FLT3 mutants are constitutively active, the wild-type receptor needs its ligand (FLT3 ligand, FL) for activation. Ligand binding to the receptor induces dimerization, auto-phosphorylation, and activation of the receptor. Tyrosine phosphorylation sites on FLT3 constitute docking sites for interacting proteins that transduce pro-survival and proliferative signals. The so-called activation loop tyrosine residue (in FLT3, Y842) is well conserved in all receptor tyrosine kinases and long been known essential for the activity of some but not all receptor tyrosine kinases. Recently we have shown that activation loop tyrosine residue in KIT is not essential for its activation but plays an important role in receptor stabilization and downstream signaling. However, so far the role of FLT3 activation loop tyrosine residue remains unknown. We generated 32D cell lines carrying a Y-to-F mutant (Y842F) of FLT3 in either the wild-type or ITD background to study the role of this tyrosine residue. We show that the Y842 residue is not necessary for FLT3 activation or stability but is required for oncogenic transformation. We observed that Y842F mutation results in reduced cell viability, proliferation and in vitro colony formation in semi-solid medium. In addition, cells expressing the Y842F mutant in FLT3-ITD background display a significant reduction in tumor volume and weight in a xenograft model in nude mice. Gene set enrichment analysis (GESA) shows that mutation of Y842 causes suppression of anti-apoptotic genes. Furthermore, we demonstrated that phosphorylated Y842 is one of the binding sites of the protein tyrosine phosphataseSHP2, which is required for activation of signaling through the RAS/ERK pathway. Taken together, our data suggest that activation loop tyrosine residue in FLT3 plays an important role in the cellular transformation which is regulated by RAS/ERK signaling.']",
        "Doc_id":"AACR_2017-2371",
        "Doc_title":" Oncogenic transformation of FLT3-ITD is partially dependent on tyrosine 842 in the activation loop.",
        "_version_":1606189005626408960},
      {
        "Meeting_name":" NMS-P088, a dual FLT3-KIT inhibitor active also on gatekeeper mutations and devoid of QTc prolongation",
        "Background":"['FLT3 (FMS-like tyrosine kinase 3) and KIT are both members of the class III receptor tyrosine kinase family characterized by an autoinhibitory juxtamembrane (JM) domain that docks with the kinase domain to stabilize a catalytically inactive conformation. Therefore, mutations or deletions in this or in adjacent regions cause constitutive activation of these kinases as observed in 30% of AML patients for FLT3 and in 70% of adult GIST and a subset of melanoma patients for KIT.NMS-P088 is a member of a novel indazole sub-series, which selectively targets both FLT3 and KIT kinases, with different mutations, both primary and secondary, some of which involved in resistance to inhibitors clinically used to target these kinases, such as quizartinib for FLT3 and imatinib for KIT.The compound is able to arrest in vitro growth of human cell lines (AMLs and GISTs) which bear constitutively activated FLT3 or KIT, with IC50s in the low nanomolar range and with high selectivity towards cell lines, including AMLs, which are not dependent on these kinases. When tested against a panel of BA-F3 cells engineered to be driven by different FLT3 or KIT mutants, NMS-P088 compared favorably with reference compounds, both in vitro and in vivo. For example, comparative in vivo tumor inhibition values against BA-F3_FLT3-ITD(F691L) model were 85% for 15 mg/kg NMS-P088 vs. 14% for 40 mg/kg quizartinib.In vivo studies conducted on nude mice bearing the human MOLM-13 AML model revealed that repeated oral administration of NMS-P088 was able to significantly inhibit tumor growth and to increase survival time and that strong inhibition of FLT3 signaling is sustained for at least 48 h after a single treatment.Preclinical profiling of the compound showed a good oral bioavailability in all species, indicated a good therapeutic window in 7-day repeated toxicological studies in rat and in dog and excellent BBB penetration. The low myelotoxicity observed in exploratory toxicological studies suggests that NMS-P088 is potentially well-suited to combination with myelotoxic chemotherapeutic agents and this point is currently subject of preclinical evaluation. Furthermore, no adverse effects on cardiac parameters were observed in a canine telemetry study in which animals were exposed to Cmax levels several fold higher than those required for efficacy in the mouse. NMS-P088 is currently undergoing advanced preclinical development activities.']",
        "Doc_id":"AACR_2015-798",
        "Doc_title":" NMS-P088, a dual FLT3-KIT inhibitor active also on gatekeeper mutations and devoid of QTc prolongation",
        "_version_":1606189019619655680},
      {
        "Meeting_name":" Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias.",
        "Background":"['Background', ' Sorafenib is a multikinase inhibitor with activity against B-raf, VEGF, and FLT3. Based on preclinical activity in FLT3 mutant AML, sorafenib was studied in refractory acute leukemia. Methods', ' The primary objective was to determine the safety and tolerability of sorafenib in refractory acute leukemias. Secondary objectives included pharmacokinetics (PK) and pharmacodynamic (PD) effects of sorafenib on FLT3 phosphorylation. Dose escalation began at 400 mg BIDx14days per month, and proceeded through 600 mg BID x 21 days per month. Plasma concentration of sorafenib and its primary metabolite sorafenib N-oxide were measured by LC/MS//MS method. The plasma inhibitory assay was used to measure target inhibition of phosphorylated FLT3 and phosphorylated Erk. Results', ' Fifteen patients (13 = AML, 2 = ALL) were enrolled (ages 37-85) and treated on three dosing schedules (400 mg BID x 14 d, 400 mg BID x 21 days, 600 mg BID x 21days) of single agent sorafenib. The maximally tolerated dose was 400 mg BID x 21 days per month. Grade 3 or greater toxicities were experienced in 55% of cycles, most common grade 3 or greater toxicities being fatigue (16%) and hypokalemia (13%). No patients met criteria for complete or partial response, but 11 of 15 (73%) patients experienced stable disease as best response, with 6 showing a reduction in bone marrow blasts after only one cycle, half of who experienced a >50% reduction in bone marrow blasts. Interestingly, 2 pts with FLT3-ITD mutations both showed marrow blast response (1 pt >50%). Sorafenib resulted in sustained complete inhibition of FLT3 and Erk as demonstrated in all patients assessed (n = 11). Importantly, this inhibition was maintained throughout treatment cycle and 3/5 pts had FLT3 inhibitory activity 7 days post their last dose. Correlative studies suggest sorafenib N-oxide is an active metabolite. Conclusions', ' Sorafenib is a potent inhibitor of FLT3 with favorable PK and PD properties. Clinical activity as a single agent was limited to transient reductions in bone marrow blast counts and dose escalation was limited due to toxicities. Based on PK data in conjunction with standard curves for inhibition of FLT3 by sorafenib in plasma, the minimum FLT3 inhibitory dose of sorafenib is likely less than 400 mg BID.']",
        "Doc_id":"ASCO_35319-65",
        "Doc_title":" Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias.",
        "_version_":1606189019589246976},
      {
        "Meeting_name":" Identification of potent, dual PIM/FLT3 kinase inhibitors for AML treatment.",
        "Background":"['Acute myeloid leukemia (AML) is a highly heterogeneous disease with numerous signaling pathways that contribute to its pathogenesis. Advances in our understanding of molecular mechanisms of AML pathogenesis and prognosis so far did not translate into significant clinical improvements. AML is still the highest unmet medical need within hematological malignancies area, particularly in case of the elderly patients. FLT3 inhibitors were investigated in the recent years as possible therapeutic agents, however to date the clinical trials of FLT3 inhibitors have yielded disappointing results. On the other hand, PIM kinases have been identified in the last years as critical downstream components of FLT3 signaling, especially in the case of oncogenic FLT3 mutants. PIM kinases are being overexpressed in a range of hematopoietic malignancies and solid cancers and the overexpression of PIMs is associated with a poor prognosis and decreased survival of patients suffering from cancer. In many cases also, PIM overexpression was associated with development of drug resistance. As dual and simultaneous inhibition of various pathway components is an emerging therapeutic idea, exemplified by several compounds in development for cancer treatment, we have developed a series of dual PIM/FLT3 small molecule inhibitors to investigate this concept. Similarly to examples of small molecule inhibitors from the JAK/STAT or PI3K/AKT pathways, where compounds are being developed as a way to improve efficacy, resistance development and overcoming the negative feedback loops, often seen after single target inhibition, we have observed increased potency of compounds developed in this series of dual PIM/FLT3 inhibitors. Synthesized inhibitors showed higher activity towards mutated FLT3 (FLT3-ITD and other FLT3 mutants) than wild type kinase and the selectivity profile on a panel of 450 kinases was comparable to best clinical examples of kinase inhibitors. In contrast to selective PIM inhibitors, the treatment with dual PIM/FLT3 inhibitors showed potent apoptosis induction as a results of Erk and S6 phosphorylation inhibition. The in vitro activity in FTL3-ITD positive cells was also confirmed in vivo in a PK/PD xenograft experiment, where sustained biomarker inhibition was observed already after single compounds administration. Oral administration of dual PIM/FLT3 inhibitors led to potent effect in vivo and in certain cases also to remissions in subcutaneous xenograft models. Observed activity profile and synergistic effects observed with other targeted therapies and standard of care compounds, makes dual PIM/FLT3 inhibitors an exciting approach for treatment of FLT3-mutant positive AML patients with high chances of clinical success.']",
        "Doc_id":"AACR_2013-3245",
        "Doc_title":" Identification of potent, dual PIM/FLT3 kinase inhibitors for AML treatment.",
        "_version_":1606189002688299008},
      {
        "Meeting_name":" Phase I study of midostaurin and azacitidine in relapsed and elderly AML.",
        "Background":"['Background', '  The Fms-like tyrosine kinase 3 (FLT3) receptor is expressed in 80% of AML and activating mutations are associated with  an adverse prognosis. Midostaurin (mdn), an orally available agent, has been shown to inhibit FLT3 receptor signaling and induces cell cycle arrest and apoptosis of leukemic cells expressing both mutant and wild type FLT3 receptors. Preliminary data has shown modest single agent activity as well as safety and tolerablility of mdn in combination with standard induction chemotherapy.   Methods', '  We conducted a phase I study of azacitidine (75 mg/m2 iv X 7days) with escalating doses of oral mdn  (25 mg bid, 50 mg bid, and 75 mg bid) days 8-21 of a 28 day cycle in untreated elderly and relapsed AML. The protocol was IRB approved at participating institutions and all patients gave written informed consent. Dose limiting toxicities (DLTs) were defined as > grade 3 non-heme toxicity during cycle 1 excluding grade 3 hepatotoxicity < 7 days, grade 3/4 stomatitis  or diarrhea that resolved by day 28, infections, and electrolyte abnormalities of any grade. Pharmacokinetics (pK) were obtained on day 8,15, and 21 before mdn dosing.    Results', '  17 pts (11 females and 6 males) ages 57-83 ( median 73) were enrolled of whom 5 patients had prior intensive treatment for AML. All pts were FLT3 negative; 5 had normal cytogenetics and 12 had high risk cytogenetics. ECOG PS', ' 0 (4pts),  1 (11pts), 2 (2pts). No DLT were observed during escalation or in the expansion cohort of 75 mg bid. Responses were evaluable in 14/17 pts and included 2 CR, 1 PR, and 2 HI (clearing of  peripheral blasts,  platelet  tx independence).  Median survival from enrollment was 3.5 months (range 1-12 months).  4 pts remain on treatment (2- 9+ cycles). 3 pts died within 60 days (2 PD, 1 treatment-related). Non-infectious, non hematologic SAEs are listed on the table below.  Plasma concentrations of mdn accumulated in the first week of treatment and declined thereafter despite continued dosing. Conclusions', '  The combination of azacitidine and midostaurin in safe and tolerable in elderly AML and should be further studied in FLT3 positive leukemia.  Clinical trial information', ' NCT01093573.']",
        "Doc_id":"ASCO_113062-132",
        "Doc_title":" Phase I study of midostaurin and azacitidine in relapsed and elderly AML.",
        "_version_":1606188977286545408},
      {
        "Meeting_name":" Targeting MCL1 in NPM1-mutant AML",
        "Background":"['MCL1 and BCL2 are pro-survival molecules which inhibit the apoptosis of AML cells treated with cytotoxic chemotherapy. The nuclear chaperone NPM1 is the most frequently mutated gene in AML. Using siRNA, we established that knockdown of NPM1 reduced expression of both MCL1 (P=0.034) and BCL2 (P=0.025) and increased p53 expression (P=0.03) in NPM1-mutant OCI-AML3 cells. These effects were not seen in cells expressing wildtype NPM1. The differentiating agent ATRA also reduced expression of both MCL1 (P=0.005) and BCL2 (P=0.0005). ATRA (3 days, 500 nM) reduced cell number by 50% in OCI-AML3 cells through growth inhibition, inducing features of differentiation and very little apoptosis. Whereas inhibition of BCL2 using up to 3 M ABT199 did not augment ATRA-mediated cell reduction in OCI-AML3 cells, RNApolymerase II inhibitors, which preferentially target proteins with a short half-life such as MCL1, and which induce apoptosis, acted additively with ATRA to kill OCI-AML3 cells. Primary AML cells with mutant NPM1 (n=38) expressed higher levels of MCL1 but not of BCL2 than NPM1 wildtype samples (n=61). Primary AML cells frequently co-harbour mutant NPM1 and mutations of the receptor tyrosine kinase FLT3. As FLT3 mutation drives aberrant MCL1, we examined the effects of ATRA on MCL1 in NPM1 mutant samples with and without a FLT3 mutation. ATRA (3 days, 500 nM) induced the downregulation (>20%) of MCL1 in 4/4 primary NPM1 mutant/FLT3 wildtype AML samples compared to 0/3 primary NPM1 mutant/FLT3 mutant AML samples. MCL1 was also downregulated by ATRA in 2/5 double wildtype samples. BCL2 was downregulated by ATRA in 1/4 primary NPMmutant/FLT3 wildtype AML samples, 2/3 primary NPM1 mutant/FLT3 mutant AML samples and 2/5 double wildtype samples. In conclusion, we show that MCL1 levels can be downregulated by mutant NPM1 inhibition and by ATRA in NPM1mutant/FLT3wildtype AML cells. RNA polymerase II inhibitors are clinically available and this work shows that ATRA can enhance their cytotoxic activity.']",
        "Doc_id":"AACR_2014-331",
        "Doc_title":" Targeting MCL1 in NPM1-mutant AML",
        "_version_":1606189003662426112},
      {
        "Meeting_name":" Proteasomal alterations in a newly created model of FLT3-ITD positive AML with acquired pan-TKI resistance",
        "Background":"['Acute myeloid leukemia (AML) is an aggressive hematologic cancer. Thirty percent of AMLs express mutations in the FMS-like tyrosine kinase receptor-3 (FLT3) that render it constitutively active. The internal tandem duplication (ITD) mutation of FLT3 is associated with poor clinical prognosis as it results in aberrant signaling leading to proliferation and survival. As such, tyrosine kinase inhibitors (TKI) directed against FLT3 are being developed. However, as with most TKI therapies, de novo and acquired resistance occurs. We have developed an isogenic cell line model of acquired resistance to FLT3 TKIs by treating BaF3/FLT3-ITD cells (FLT3-ITD) with lestaurtinib over time (FLT3-ITDR cells). Challenge of FLT3-ITDR cells with lestaurtinib showed >3-fold resistance to this TKI as measured by proliferation and propidium iodide sub-diploid analysis. In addition, we tested FLT3-ITDR cells for sensitivity to quizartinib, a more potent and selective inhibitor of FLT3, and found that FLT3-ITDR cells were 7-fold more resistant, suggesting pan-FLT3-TKI resistance. To confirm this resistance was specific for TKI, FLT3-ITDR and FLT3-ITD cells were treated with the histone deactylase inhibitor vorinostat and the anthracycline doxorubicin. Similar sensitivities were noted between the two cell lines to both of these drugs suggesting that resistance of FLT3-ITDR cells to FLT3-directed TKI is specific. Combination therapy is often utilized as a mechanism to overcome clinical resistance. Recently, proteasome inhibitors have been explored as an option for combinatorial therapeutics in leukemia. To determine if the proteasome may be a good target for combination therapy in FLT3-ITDR cells, the proteasomal chymotrypsin-like activity was measured in FLT3-WT, FLT3-ITD, and FLT3-ITDR cells. Chymotrypsin-like proteasome activity was significantly reduced in both FLT3-ITD (41%) and FLT3-ITDR (59%) vs. FLT3-WT cells. This activity stems from activation of the 5 subunit of the proteasome; therefore we performed western blotting with antibodies directed against 5. As seen with chymotrypsin-like activity, FLT3-ITD cells had a significant decrease in 5 protein expression (58%) compared to FLT3-WT. However, despite decreased proteasome activity, FLT3-ITDR had no decrease in 5 protein compared to FLT3-WT cells. One potential explanation for this result is that FLT3-ITDR cells have increased levels of inactive free 5 subunits compared to FLT3-WT. Future studies will examine the implication of these alterations. Despite these changes in proteasome sub-unit regulation and activity, all three cell lines were sensitive to single agent treatment with the reversible FDA-approved proteasome inhibitor bortezomib and its irreversible counterpart marizomib. As such, we will continue to explore the efficacy of proteasome inhibitors in combination therapy for TKI resistant FLT3-ITD-positive AML.']",
        "Doc_id":"AACR_2014-1711",
        "Doc_title":" Proteasomal alterations in a newly created model of FLT3-ITD positive AML with acquired pan-TKI resistance",
        "_version_":1606188977513037824},
      {
        "Meeting_name":" Apogossypolone derivative -BI97D6 effectively targets MCL1 overexpressing Acute Myeloid Leukemia cells.",
        "Background":"['Aberrant expression of anti-apoptotic proteins such as BCL2, MCL1, and BCL-XL is observed in many tumors including Acute Myeloid Leukemia (AML). An obvious strategy for AML therapy would be to target the anti-apoptotic BCL2 family members. While compounds such as ABT-737 have shown promise for treatment of some malignancies, the compound binds poorly to MCL1 and thus cells that overexpress MCL1 usually display high resistance to the drug. Furthermore, ABT-737 activates ERK signaling resulting in MCL1 overexpression in surviving cells (Konopleva, et al, Leukemia 2011). The apogossypolone derivative -BI97D6 binds MCL1 and BCL2, BCL-XL, BFL1 with high affinities (Wei, et al, J Med Chem 2010). We recently reported that -BI97D6 (a) efficiently kills AML cell lines even in the presence of protective mesenchymal stroma cells, (b) interferes with the association between MCL1/BIM and BCL2/BAX, (c) stimulates BAX conformational change, (d) requires BAX or BAK for cell killing, and (e) does not induce ER stress. These data suggests that -BI97D6, unlike other gossypol or apogossypol compounds, acts mainly as a BH3 mimetic.In the current study, we first examined the role of MCL1 in -BI97D6-mediated killing. OCI-AML3 cells are extremely resistant to ABT-737 due to its high expression of MCL1. MCL1 expression was suppressed by lenti-viral shRNA in OCI-AML3 cells and knockdown of MCL1 protein by 80% was achieved as determined by quantitative western blot. Compared to cells with non-specific control shRNA, cells with MCL1 shRNA were greatly sensitized to ABT-737, and significantly sensitized to AraC, while -BI97D6, which binds MCL1 with high affinity, is almost equipotent in knockdown and control cells. Since results with AML cell lines have been promising, we examined the efficacy of -BI97D6 on primary AML samples. Flow cytometry analysis revealed that -BI97D6 potently induced apoptosis in AML blast cells at low nM concentration (EC50<50nM). -BI97D6 also effectively killed putative CD34+CD38- leukemia stem cells (LSC). Importantly, primary AML with FLT3-ITD and FLT3-D835 mutations showed similar sensitivity as those without FLT3 mutations (EC50<50nM). As FLT3 mutations are associated with poor prognosis in AML, these findings suggests that -BI97D6 can target AML LSC and could benefit even high risk patients. In summary, compound -BI97D6 may be a promising drug candidate for MCL1-targeted AML therapy.']",
        "Doc_id":"AACR_2013-605",
        "Doc_title":" Apogossypolone derivative -BI97D6 effectively targets MCL1 overexpressing Acute Myeloid Leukemia cells.",
        "_version_":1606189033168306177},
      {
        "Meeting_name":" Prognostic impact of aberrant t/NK cell marker expression in AML.",
        "Background":"['Background', ' Aberrant expression of NK and T cell antigens (NK/T) in AML blasts is well known.However,their influence on EFS(after standard first line AML induction) & OS has not been well studied.We conducted such an analysis in AML with normal cytogenetics.We also studied the prognostic significance of NK/T expression in FLT3 & NPM1 negative cases. Methods', ' A retrospective analysis of 266 cases of AML over 10 years was conducted. Flow cytometry done at the time of initial diagnosis was available for 201 of the 266 cases.NK/T cell markers such as CD2,CD3,CD5,CD7 & CD56,available in 83 cases,were analyzed.NK/T positivity threshold was set at > 20% of the gated blast population. EFS and OS were compared between NK/T+ and NK/T- groups using log-rank tests/Kaplan-Meier curves.FLT3 and NPM1 proportions in NK/T+ and NK/T- cases were compared using Fishers exact test. Results', ' NK/T+ and NK/T- frequencies were 46% (38/83) and 54% (45/83) respectively. Amongst NK/T+ cases CD56 (67%) was the most commonly expressed marker and \"AML with myelodysplasia related changes\" (47%) was the most common subtype. Amongst AML cases in which cytogenetic analysis was performed (n = 198), 72 cases had normal cytogenetics (AML CyNO).Within this group 41(71.9%) were NK/T+ and 16(28.1%) were NK/T-.While trends demonstrated an inferior EFS and OS in NK/T+ cases,given our small sample size,statistical significance was not reached. EFS of NK/T+ was 0 weeks (95% CI', '0-20) versus 15.6 weeks (95% CI', '0-36) in NK/T- (p = 0.515).Median EFS for NK/T+ and NK/T- was 3.6 weeks (95% CI', '0-24).OS for NK/T+ was 32 weeks (95% CI', ' 12-96) versus 112 weeks (95% CI', ' 28-163.2) in NK/T- (p = 0.077).Median OS for NK/T+ and NK/T- was 47.9 weeks (95% CI', '28-112). In FLT3- and NPM- AML CyNO cases both EFS(0 versus 3.6 weeks) and OS(24 versus 120 weeks) showed a statitically insignificant trend toward inferior survivals in NK/T+ arm.FLT3 or NPM1 distribution was not statistically different between NK/T+ and NK/T- cases in AML CyNO. Conclusions', ' When known confounding low/high risk cytogenetic abnormalities affecting survival in AML were eliminated, trends suggested worse survivals for AML CyNO NK/T+; however they failed to reach statistical significance. We are therefore currently analyzing a larger cohort.']",
        "Doc_id":"ASCO_161342-176",
        "Doc_title":" Prognostic impact of aberrant t/NK cell marker expression in AML.",
        "_version_":1606188977348411392},
      {
        "Meeting_name":" Preclinical development of a Pim kinase inhibitor for cancer treatment",
        "Background":"['Pim kinases were identified as the crucial downstream effectors various important oncogenes like Jak, FLT3 or Ras kinases. Multiple targets phosphorylated by Pim kinases, such as 4EBP1, p21Waf, p27KIP1, c-Myc or CXCR4 play important roles in intracellular signaling and contribute to pathways involved in cell survival, proliferation, stress response and cellular motility. Moreover, the significance and relevance of Pim kinases as valid therapeutic targets is further confirmed by their expression levels in variety of cancer types, especially in various types of lymphomas, leukemias or myelomas. For example Pim kinase overexpression contributes to the development of diffuse large B cell lymphoma, mantle cell lymphoma, B-cell chronic lymphocytic leukemia and FLT3-mediated acute myelogenous leukemia. As members of the family, Pim-1, Pim-2 and Pim-3 were shown to be prevent apoptosis, promote protein translation and cell survival thereby enhancing proliferation of malignant cells, Pim kinases emerged as a novel and interesting target with significant potential for therapeutic intervention in cancer. In the current study we are reporting the results of a second generation small molecule Pim kinase inhibitors that were developed by Selvita and results for the best characterized potent Pim kinase inhibitor developed so far. The small molecule inhibitors exert high potency in vitro both on all three Pim kinases as well as on a large panel of cancer cell lines. Mechanism of action for selected compounds was confirmed both in vitro in variety of cell lines and in vivo in xenograft models by downregulation of c-Myc and 4EBP1 phosphorylation inhibition. Selected compounds were tested in a range of combinations with standard anti-cancer therapeutics in both leukemias and solid tumor cell lines and showed potent synergistic effects. Strong synergies were observed particularly in combination with targeted therapies like the PI3K/Akt pathway inhibitors or Jak kinase inhibitors. Data will be presented on in vivo efficacy of lead compounds examined in xenograft models. Additionally, the results of safety assessment of the lead compound will be presented revealing preferable safety profile with no effect on ion channel mediated cardiotoxicity and favorable pharmacokinetic profile. Taken together, presented data will further support the rationale of using Pim kinase inhibition as a novel approach to standalone cancer therapy, and in combination with other targeted and cytotoxic therapies, especially to overcome developing drug resistance.']",
        "Doc_id":"AACR_2012-2826",
        "Doc_title":" Preclinical development of a Pim kinase inhibitor for cancer treatment",
        "_version_":1606188987404255232},
      {
        "Meeting_name":" Acute myeloid leukemia (AML) in adolescents and young adults (AYA)",
        "Background":"['Background', ' AML is a heterogeneous group of hematopoietic neoplasms demonstrating clonal proliferation of myeloid precursors and is typically a disease of older adults. Little is known about outcomes of AYA with AML. Methods', ' We retrospectively analyzed all patients (pts) with AML treated at MDACC from 1965 to 2008. Pts ages 16 to 21 years (yrs) were defined as AYA. Results', ' Among 3,934 adult AML pts treated during this period, 163 pts (4%) were AYA with median age of 19 yrs. This cohort included 27 (17%) pts with Core Binding Factor (CBF)-AML [inv(16), t(8', '21)] and 19 pts (12%) with acute promyelocytic leukemia (APL). Among the other pts, 50% had diploid cytogenetics, 11% had 5 or 7 abnormalities, 39% had other cytogenetic changes. Antecedent hematologic disorders were present in 33 pts (20%). Among 20 evaluated pts, FLT3 internal tandem duplication (ITD) was present in 4 pts and FLT3 kinase domain mutation was found in 2 pts. Complete remission (CR) rates were 89% for CBF AML, 79% for APL, and 75% for all other pts. Median survival for the total cohort was 1.7 yrs with 36% alive at 3 yrs, and median CR duration of 1.3 yrs (30% CR at 3 yrs). Outcome is better for pts with CBF leukemia (3 yr survival 56%, sustained CR 49%) and APL (3 yr survival 51%, sustained CR 36%) compared to other AML (3 yr survival 28%, sustained CR 24%). CR rates have improved from 71% in 1965-1984, to 85% in 1985-1994, and 83% after 1994. Similarly, overall survival (OS) has increased during the same time periods (3-yr survival 18%, 44%, and 53%, respectively) together with CR duration (3 yr CR duration 21%, 32% and 39%, respectively) as early mortality has decreased (11%, 8%, and 4%, respectively). To compare outcomes of AYA with older adults, we focused on those with diploid cytogenetics.CR for pts ages 16-21 was 81%, with 3 yr survival of 46%; for ages 22-45, CR was 75% and 3 yr survival 36%; for ages 46-60 CR was 68% with 3 yr survival 28%; and for pts age greater than 60, CR was 54% with 3 yr survival of 22%. Conclusions', ' The outcome of AYA pts with AML is significantly better than for older adults with AML. Despite the advances in treatments over time, there is still significant room for improvement, particularly among those AYA with AML other than CBF and APL. Exploration of new treatment options is needed in this patient population.']",
        "Doc_id":"ASCO_31991-65",
        "Doc_title":" Acute myeloid leukemia (AML) in adolescents and young adults (AYA)",
        "_version_":1606188994045935616},
      {
        "Meeting_name":" Inhibition of heme oxygenase 1 decreases proliferation and resensitizes TKI-resistant Flt3-ITD-positive AML cells",
        "Background":"['Acute myelogenous leukemia (AML) afflicts 12,330 new patients per year in the United States. Regrettably, only 25% of patients will survive five years past diagnosis. The most common mutation in AML is internal tandem duplication (ITD) of the juxtamembrane domain of the fms-like tyrosine kinase receptor-3 (Flt3), which renders it constitutively active. This mutation correlates with poor clinical prognosis and has been targeted therapeutically. Unfortunately, Flt3-directed tyrosine kinase inhibitors (TKI) have shown only modest benefit as single agents. Additionally, relapse and resistance are major factors in the treatment of Flt3-ITD+AML. In addition to its prominent role in regulating proliferative signaling, Flt3-ITD also increases production of reactive oxygen species (ROS) which act as secondary messengers, mediating oncogenesis and drug resistance. Heme oxygenase 1 (HO-1) is a ROS-responsive antioxidant that mediates proliferation and drug resistance in some cancer types. Initial analysis of patient samples from the AML TCGA cohort suggests that HO-1 is up-regulated in a subset of AML patients where its expression correlates with poor prognosis. Interestingly, HO-1 over-expression co-occurs with Flt3 receptor alterations. Thus, we hypothesized that Flt3-ITD-dependent signaling and ROS production increase HO-1, resulting in proliferation and drug resistance in AML. Constitutive expression of HO-1 protein and mRNA was elevated in murine (BaF3/Flt3-ITD) and human (MOLM13 and MV4.11) ITD+ cell lines as compared to Flt3-WT cells. This expression was dependent on Flt3-kinase, as treatment with Flt3-directed TKIs (quizartinib or lestaurtinib) attenuated HO-1 expression. Further, oxygen consumption and respiration analyses, as well as chemical inhibitors revealed a role for non-mitochondrial ROS producing enzymes in HO-1 expression in ITD+ cells. To determine a functional role for HO-1, we inhibited HO-1 with zinc protoporphyrin (ZnPP) or utilized siRNA knockdown of HO-1, both of which resulted in decreased proliferation of ITD+ cells. To determine the contribution of HO-1 in resistance to Flt3-directed TKI, we created a model of acquired resistance to Flt3-directed TKI (ITDR). HO-1 expression was elevated in ITDR compared to parental cells. However, HO-1 was no longer under control of Flt3-kinase signaling, as treatment with Flt3-directed TKI had no effect on HO-1. Similar to parental cells, knockdown of HO-1 or treatment with ZnPP resulted in decreased proliferation of ITDR cells. Further, combined treatment with Flt3-directed TKIs and ZnPP or HO-1 knockdown resulted in increased induction of cell death of ITDR cells. These data provide impetus for direct targeting of HO-1 in TKI resistant ITD+ AML. Together, our data suggest HO-1 as a growth and resistance factor in Flt3-ITD+ AML; therefore, targeting HO-1, or the mechanisms that control its expression, may prove therapeutically valuable.']",
        "Doc_id":"AACR_2015-3591",
        "Doc_title":" Inhibition of heme oxygenase 1 decreases proliferation and resensitizes TKI-resistant Flt3-ITD-positive AML cells",
        "_version_":1606189013589295105},
      {
        "Meeting_name":" Correlation between cytidine deaminase single nucleotide polymorphisms and in vitro drug sensitivity, DNA methylation and outcome in normal karyotype acute myelogenous leukemia.",
        "Background":"['Background', ' De novo AML with normal karyotype (NK-AML) comprise a large group of patients without common cytogenetic alterations but with a large variation in treatment response. New tools such as the analysis of nucleophosmine 1 (NPM1), FMS-like tyrosine kinase 3 (FLT3) and CCAAT/enhancer binding protein (CEBPA) mutations has emerged as clinical markers of prognosis, but there is still a need for additional tools to explain the variation in outcome. Cytarabine (Ara-C), a cornerstone in AML chemotherapy, is activated intracellularly by deoxycytidine kinase (dCK), and deactivated by cytidine deaminase (CDA) and poor treatment outcome or development of chemotherapy resistance can be due to altered activity of these enzymes. Single nucleotide polymorphisms (SNPs) of CDA genes have previously been reported to result in lower CDA allelic expression and to affect the outcome of treatment. In addition, pharmacological inhibition of CDA has been shown to reduce the degree of DNA methylation. DNA methylation may be an important regulatory mechanism for the expression of genes related to drug effect, and we therefore aimed to investigate the relationship between CDA polymorphisms and outcome in NK-AML, DNA methylation, and in vitro drug cytotoxicity. Method', ' 207 Swedish NK-AML patients were genotyped for the CDA SNPs 79A>C (rs2072671) and -451C>T (rs532545) and the results were correlated to treatment response and overall survival (OS) in the material as a whole as well as stratified based on FLT3 and NPM1 status. Cells from a subset of the patients were also investigated for genotype association with in vitro drug cytotoxicity (n=56) and global DNA methylation (n=82). Results', ' CDA 79C/C or -451T/T genotype was associated to a shorter OS compared to other genotypes (0.44 vs. 1.86 years, p=0.004; and 0.45 vs. 1.79 years, p=0.051) for FLT3-ITD+ patients, and this was even more pronounced in the FLT3-ITD+/NPM1+ cases. There was significantly less DNA methylation in cells heterozygous for both polymorphisms (A/C+C/T) compared to homozygous A/A+C/C cells (p=0.018). There was also a lower degree of methylation in homozygous C/C+T/T cells, but due to the small number of samples in this group significance was not reached. An altered in vitro sensitivity towards topoisomerase inhibitory drugs, but not towards nucleoside analogues was seen for both CDA SNPs with homozygous C/C or T/T cells being more sensitive. Conclusions', ' We found a significant correlation between CDA genotype and OS in NK-AML, the degree of DNA methylation in AML cells, and in vitro drug sensitivity. The change in methylation related to CDA genotype may be associated with differences in drug activation and subsequent sensitivity, making these polymorphisms potential markers of use for future individual chemotherapy decisions such as dose adjustments.']",
        "Doc_id":"AACR_2013-1170",
        "Doc_title":" Correlation between cytidine deaminase single nucleotide polymorphisms and in vitro drug sensitivity, DNA methylation and outcome in normal karyotype acute myelogenous leukemia.",
        "_version_":1606189022573494273},
      {
        "Meeting_name":" The Antioxidant heme oxygenase 1 promotes proliferation and survival of Flt3-ITD-positive AML.",
        "Background":"['Acute myelogenous leukemia (AML) afflicts 12,330 new patients per year in the United States. Regrettably, only 25% of patients will survive five years past diagnosis. The most common mutation in AML is internal tandem duplication (ITD) of the juxtamembrane domain of the fms-like tyrosine kinase receptor-3 (Flt3), which renders it constitutively active. Flt3-ITD regulates proliferation and survival, and also increases the production of reactive oxygen species (ROS), which act as secondary messengers for oncogenic signaling. ROS can cause the induction of a number of molecules, however, one protein, heme oxygenase 1 (HO-1), a well-known antioxidant, has been connected to both proliferation and drug resistance of various cancers. We hypothesized that Flt3-ITD-dependent signaling and ROS production increase constitutive expression of HO-1, leading to the activation of antioxidant and anti-apoptotic pathways, resulting in proliferation and drug resistance in AML. Western blotting revealed a two-fold increase of HO-1 protein in Flt3-ITD+ cells as compared to Flt3-WT; a four-fold up-regulation of HO-1 mRNA was noted by quantitative real-time PCR suggesting transcriptional control. To determine if this up-regulation was due to the altered redox status of Flt3-ITD+ cells, the flavonoid inhibitor diphenylene iodonium (DPI) was used. Consistent with published results implicating the flavonoid protein complex NADPH oxidase (NOX) as a primary source of ROS in these cells, DPI reduced ROS levels as early as two hours post treatment. This ROS reduction coincided with a decrease in HO-1 protein, suggesting that NOX may be involved in HO-1 up-regulation. Our previous results in chronic myeloid leukemia suggest that a Rac1-dependent isoform of NOX controls HO-1 expression, however, in Flt3-ITD+AML, dominant negative inhibition of Rac1 was insufficient to alter HO-1 expression suggesting that either a Rac1-independent NOX isoform is involved or that another flavonoid protein modulates HO-1 expression in this leukemia subtype. Interestingly, when HO-1 expression was knocked down using RNAi, there was a 50% reduction of proliferation and 40% reduction of viability as measured by trypan blue exclusion in Flt3-ITD+AML cells. These data suggest that the function of HO-1 up-regulation is to promote survival and proliferation of Flt3-ITD+AML. Additionally, we have created a model of acquired resistance to lestaurtinib, a Flt3 kinase inhibitor, by treating with increasing doses of the drug over time. Preliminary results suggest that HO-1 is further elevated in these resistant cells as compared to parental Flt3-ITD cells; thus, we will use this model to test the functional role of HO-1 in acquired resistance. Together, our data suggest that HO-1 is a growth and survival factor in Flt3-ITD+AML; therefore, targeting HO-1 or the mechanisms that control its expression may prove therapeutically valuable.']",
        "Doc_id":"AACR_2013-4124",
        "Doc_title":" The Antioxidant heme oxygenase 1 promotes proliferation and survival of Flt3-ITD-positive AML.",
        "_version_":1606189025493778432},
      {
        "Meeting_name":" Low frequency of RAS and absence of FLT3-ITD gene mutations in patients with Myelodysplastic Syndromes in India",
        "Background":"['Background', ' Chromosomal abnormalities and molecular detection has potential importance for diagnosis and prognosis of MDS, although the mechanisms underlying the development of MDS and their progressive evolution to AML are still largely unknown. Since, no studies have been reported from India on the prevalence of N-RAS, K- RAS point mutation in codon 12 and FLT3-ITD mutations in patients with MDS, we undertook this study. Methods', ' DNA and RNA were extracted from bone marrow /peripheral blood. Using RT-PCR the patients were screened for length mutations in FLT3 gene. PCR-RFLP and nested PCR-RFLP were used for the detection of point mutation in codon 12 of N-RAS and K-RAS. Results', ' A total of 53 patients (median age 39 yrs, range 9-78yrs; M', ' F 2', '1; median TLC-3.9X109/l, range 0.8-116 x109/l Median platelet count- 87 x109/l, range 1-349 x109/l, Median hemoglobin -6.8 g/dl , range 2.7- 16.1 g/dl, were studied. One out of 53 patients (2%) was found positive for N-RAS and four patients were positive for K-RAS (8%) mutation. FLT3-ITD mutation was studied in 47 patients; all the patients were found negative. The mean observation of all the patients was 30 months and the median overall survival was 28 months. Nine patients died during follow up. The presence of N-RAS codon 12 mutation was associated with the poor survival. FLT3-ITD mutation was not observed in any of our cases, which is in contrast to 3% reported from the West. Conclusions', ' Thus, it appears that the RAS and FLT3 mutations are uncommon in MDS patients in India.']",
        "Doc_id":"ASCO_34510-65",
        "Doc_title":" Low frequency of RAS and absence of FLT3-ITD gene mutations in patients with Myelodysplastic Syndromes in India",
        "_version_":1606188995039985664},
      {
        "Meeting_name":" Outcomes, characteristics and molecular profile of myeloid sarcoma",
        "Background":"['Background', ' Myeloid Sarcoma(MS) is characterized by extramedullary infiltration with immature myeloid cells. Due to rarity of MS, its clinical characteristics and outcomes are yet to be clarified. Methods', ' This is a comprehensive retrospective analysis of 23 patients(pts) with pathologically confirmed MS, diagnosed between 2002  2015 at UAMS. We evaluated the clinical features, pathology and treatment outcomes of MS. The effect of age and complete remission(CR) on overall-survival(OS) were analyzed using Kaplan-Meier curves & log-rank test. Results', ' The median age at diagnosis was 58 (range 36-84) years, 70% were male, 52% were < 65 years. Skin/subcutaneous tissues were involved in 87% pts; and spleen, gums and cortical bone, in 1 pt each. Thirty percent(n = 7) had isolated MS, while 60%(n = 14) had a prior history of or concomitant AML, with a median time from AML to MS of 10.6 months. Upon immunohistochemistry, 95%(n = 19) were positive for classical myeloid markers', ' lysozyme, chloracetate-esterase, MPO, CD68, CD34 & CD117. Cytogenetic abnormalities were seen in 52%(n = 12) pts on bone-marrow aspirate, with 5 pts displaying a complex(3 pts) or monosomal(2 pts) karyotype. One-third of those with a normal karyotype, had evidence of genetic alterations on further molecular testing, including mutations in FLT3, ASXL, STAG and JAK2 genes. Anthracycline based induction therapy(7+3/IdaFLAG) was employed in 60%(n = 14) pts. Fourteen(60%) pts achieved a CR. Four pts underwent allo-HSCT. The OS was significantly better for pts < 65 years (24.6 vs. 3.4 months, p = 0.009) and those attaining a CR to induction therapy (25.7 vs. 0.8 months, p < 0.001). All four pts who underwent allo-HSCT were alive at last follow-up, with a median follow-up of 54(range 32-120) months. Conclusions', ' MS is a deceptive disease, which is not always associated with concurrent bone-marrow involvement. In our series, 27% patients with a normal karyotype had presence of deleterious mutations (FLT3, ASXL, STAG and JAK2) on myeloid mutation panel. Failure to achieve CR after induction and advanced age( > 65 years) are associated with poor outcomes. Upfront allogeneic stem-cell transplant is the most effective modality to achieve long-term remission.']",
        "Doc_id":"ASCO_168421-176",
        "Doc_title":" Outcomes, characteristics and molecular profile of myeloid sarcoma",
        "_version_":1606188990680006656},
      {
        "Meeting_name":" AZD1208 PIM kinase inhibitor - Preliminary evidence of target pathway inhibition in Phase I clinical trials of AML.",
        "Background":"['PIM kinases have been shown to play a key role as downstream effectors of growth factor signalling pathways including Flt3 and the Jak-STAT signalling pathways in AML, NHL and other solid tumors. AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases and is currently undergoing Phase I testing and dose escalation studies in AML. Here we describe a multiplexed biomarker strategy measuring pBAD, p4EBP1 and p-p70S6K as downstream pharmacodynamic biomarkers for PIM kinase inhibition in clinical trials. Patient bone marrow aspirates and peripheral blood samples were collected pre- and post-AZD1208 treatment in AML patients during the Phase I dose escalation and expansions. Primary patient samples were analyzed for quantitative changes in pBAD, p4EBP1 by NanoPro and MesoScale assay platforms as well as a qualitative evaluation of p-p70S6K and other exploratory endpoints. Preclinical PK-PD modeling data with AZD1208 had suggested that greater than a 50% decrease in the levels of one of these phosphorlyated substrates would be indicative of efficacy and PIM pathway inhibition. Following a single dose of AZD1208 at 120mg, the first dose level, approximately 60-70% inhibition of pBAD, S112 was seen in the bone marrow and peripheral blasts. Taken together, the data presented here provide evidence for single agent AZD1208 activity in AML patients based on quantitative reduction in these biomarkers. Correlations of these biomarker endpoints with Phase I pharmacokinetic data underscore the therapeutic potential of Pim kinase inhibition by AZD1208 for the treatment of AML, and strongly support further investigation of this agent in other indications where PIM signaling may play a role in tumorigenesis and survival.']",
        "Doc_id":"AACR_2013-3516",
        "Doc_title":" AZD1208 PIM kinase inhibitor - Preliminary evidence of target pathway inhibition in Phase I clinical trials of AML.",
        "_version_":1606189032069398528},
      {
        "Meeting_name":" Response and survival rates with frontline hypomethylating agent (HMAs) in favorable risk AML.",
        "Background":"['Background', ' HMAs are an accepted frontline therapy for AML patients (pts) who are unfit for intensive induction therapy (IIT), particularly pts with unfavorable cytogenetics and/or p53 mutations. However, little is known about the response of favorable risk AML to HMAs. We previously reported that NPM1 mutated and/or CD34- AML status were predictors of response to HMAs. Here, we evaluated responses to frontline HMAs in AML. Methods', ' A total of 117 patients with de novo AML diagnosed between 7/2013 and 9/2016 were evaluated based on pt and disease related variables, overall response rate (ORR = CR + CR with incomplete count recovery + hematologic remission (ANC > 1000/L, Hgb > 10g/dL, Plts > 100,000/L, & no circulating blasts)), and overall survival (OS). Categorical variables were compared using Fishers exact test. Kaplan Meier methods estimated survival outcomes, and log rank tests compared survival between groups. Multivariable analyses were performed using Cox proportional hazards models. Results', ' 51 pts, considered unfit for IIT, received frontline HMAs. ORR and OS were highest in the ELN favorable risk AML pts (n = 13; ORR = 92%, p = .009; median OS = 17.5 months, p = .022). Among 41 NPM1 mutated pts, 15 received HMAs; and 26 received intensive induction. ORRs were 73% and 84%, respectively (p = .434). No difference was found in OS distributions between the HMA and IIT groups in univariate and multivariate (adjusted for age and FLT3 status) models (p = .329 and .241, respectively). Interestingly, ORR was 100% among 9 HMA-treated pts with NPM1 mutated, CD34-, FLT3/ITD-, cytogenetically normal AML. Conclusions', ' HMA therapy is highly effective frontline treatment in favorable risk AML pts considered unfit for IIT. Survival results with HMAs in NPM1 mutated AML are comparable to those of fitter pts treated with IIT. In selected favorable risk pts considered unfit for standard induction, HMAs can be a successful bridge to potentially curative therapy, including more intensive therapy or transplant. Cytogenetically normal AML with an isolated NPM1 mutation and CD34- status appears to be exceptionally responsive to frontline treatment with HMAs. Prospective validation of these findings is necessary.']",
        "Doc_id":"ASCO_188585-199",
        "Doc_title":" Response and survival rates with frontline hypomethylating agent (HMAs) in favorable risk AML.",
        "_version_":1606188984850972672},
      {
        "Meeting_name":" Frequency and type of JAK3 variants in adult patients with leukemia.",
        "Background":"['Background', ' Janus kinases (JAK) family members (JAK1, JAK2, JAK3, TYK2) are involved in tumorigenesis. JAK3 activating variants, including V722I, demonstrably induce cellular transformation in vitro. The prevalence of JAK3 variants/mutations in leukemia, particularly in AML, and their role in leukemogenesis, remains unclear Methods', ' We retrospectively reviewed leukemia patients (pts) treated at MD Anderson Cancer Center between 2012 and 2016, whose marrow samples were tested for JAK3 variants/mutations by next generation sequencing. We evaluated the type and prevalence of variants, the demographics, laboratory, treatment, and clinical information for JAK3 pts. Results', ' A total of 28 leukemia pts with JAK3 variants were identified, and included', ' MDS/MPN (n = 4), CLL (n = 2) and B-cell ALL (n = 1). All 7 non-AML pts had V722I variant (in the pseudokinase domain). Twenty-one AML pts were identified; this included 15 pts with V722I (1.5%) out of total 977 AML pts tested, demonstrating this variant was significantly more prevalent in AML pts than in the general population (1.5 vs 0.9%, P= 0.04). Three pts (0.3%) had P151R (FERM domain), and 1 pt each (0.1%) had V718L (pseudokinase), R925L (kinase), and L940V (kinase), none of which have been previously described. A pt with T815M (between pseudokinase-kinase domains) was identified from outside genetic testing. For AML pts, median allelic frequency for variants was 52% (range, 41-88) and median marrow blasts was 42% (range 21-97); 10% of AML patients had complex karyotype. Concomitant mutations were most commonly found in IDH1/2 (n = 10), TP53 (n = 8), FLT3 (n = 5), NPM1 (n = 5), ASXL1 (n = 5), RUNX1 (n = 4), DNMT3A (3), and TET2 (n = 3). Conclusions', ' We report the largest survey of JAK3 variants among adult leukemia pts, with detailed and novel variants described for AML. Given allelic frequencies, JAK3 variants may represent germline polymorphisms in most cases; however the activating V722I variant has increased prevalence among AML pts. The existence of an FDA-approved JAK3 inhibitor tofacitinib, and the prevalence and location of JAK3 variants provide a basis for additional investigations.']",
        "Doc_id":"ASCO_194959-199",
        "Doc_title":" Frequency and type of JAK3 variants in adult patients with leukemia.",
        "_version_":1606189035131240448},
      {
        "Meeting_name":" Clinical observations of AML expressing mutant RUNX1 and pre-clinical studies of RUNX1-targeted novel therapy of AML.",
        "Background":"['Background', ' Runt-related transcription factor 1 (RUNX1) is critically involved in normal and malignant hematopoiesis. Somatic mutations in RUNX1 occur in ~10% of AML, especially in older patients with history of radiation or antecedent hematologic disorder. Presence of mRUNX1 is reported to confer relative resistance to therapy and poorer prognosis in AML, and there are no mRUNX1-targeted or specific therapies available. Methods', ' We retrospectively analyzed outcomes of 94 mRUNX1 and 444 wild-type RUNX1 AML patients treated at our institution from 9/2013 to 12/2016. We also determined the pre-clinical efficacy of a targeted therapy against cultured and primary AML cells expressing mRUNX1. Results', ' 67% of mRUNX1 patients were > 65 years of age. Co-occurring mutations with mRUNX1 were ASXL1 (33%), N/KRAS (20%), FLT3 (20%), IDH2 (18%), IDH1 (13%) and TET2 (10%). In patients > 65 years treated with hypomethylating agent-based therapy, the presence or absence of mRUNX1 did not impact response rate (42% vs 46% CR/CRp, p = 0.67), median event-free survival (3.4 vs 4.7 mo, p = 0.82) or overall survival (11.5 vs 9.3 mo, p = 0.97). In mRUNX1 expressing AML OCI-AML5 and MonoMac1 cells, knockdown of RUNX1 by shRNA repressed its targets, e.g., MYC and PU.1, inhibited growth and induced apoptosis. Ex vivo knockdown of RUNX1 abrogated in vivo leukemia initiation by OCI-AML5 cells. After engraftment, inducible shRNA-mediated in vivo knockdown of RUNX1 restored survival of immune-depleted NSG mice engrafted with OCI-AML5 cells. RUNX1 transcription is driven by a super enhancer occupied by the bromodomain extraterminal protein (BETP), BRD4. Accordingly, BRD4 knockdown by shRNA or treatment with the BRD4-inhibitor OTX015 depleted RUNX1 and its targets, and induced apoptosis of AML cells. Treatment of OCI-AML5 cell-engrafted NSG mice with OTX015 (50 mg/Kg/day X 5, for 3 wks) reduced AML burden and improved survival (p < 0.01). Co-treatment with the BETi and BCL2 inhibitor venetoclax or CDK4/6 antagonist palbociclib or decitabine synergistically induced apoptosis of OCI-AML5 and primary AML blasts. Conclusions', ' These findings highlight a novel, promising, BETP antagonist-based therapy of AML expressing mtRUNX1.']",
        "Doc_id":"ASCO_188351-199",
        "Doc_title":" Clinical observations of AML expressing mutant RUNX1 and pre-clinical studies of RUNX1-targeted novel therapy of AML.",
        "_version_":1606189039483879424},
      {
        "Meeting_name":" Analysis of clonal evolution of leukemia in vivo following novel targeted treatments",
        "Background":"['Acute myeloid leukemia (AML) is a genetically heterogeneous disease characterized by significant clonal evolution. It is critical to understand clonal diversity and evolution during cancer progression and drug resistance in order to tailor curative therapies that block the growth of the multiple AML subclones in each patient.In our individualized systems medicine (ISM) initiative, we performed ex-vivo drug sensitivity and resistance testing (DSRT) with a comprehensive set of 306 cancer drugs on primary cells from 22 AML patients (Pemovska et al, Cancer Discovery, 2013). Objective clinical responses were seen in 3/6 chemorefractory patients treated based on DSRT results. Here, we applied next-generation genome and transcriptome sequencing in order to a) follow clonal progression of adult AML in patients during treatment with novel targeted drugs, b) identify putative cancer predisposing mutations in patients who later develop aggressive relapsed AML.Serial samples were obtained from each patient during diagnosis, treatment, remission and relapse. The data indicated significant clonal evolution and emergence of new subclones after relapse and drug resistance. In one such case, treatment of an AML patient with a combination of dasatinib-sunitinib-temsirolimus led to the selection of an already existing low-frequency subclone carrying ETV6-NTRK3 fusion. DSRT of the relapsed sample indicated addiction to IGF1R signalling, compatible with the NTRK3-fusion acting as a driver gene for drug resistance after this treatment. Similar trend where a low-frequency subclone was selected for in the resistance sample was seen in 3 other cases analyzed. Thereby, in depth analysis of clonal evolution from paired AML samples should facilitate the design of new combinatorial regimens to block relapse from arising.Altogether, we analyzed the genomic profile of 20 recurrent, chemorefractory AML cases. The profile was different between the individual patients and showed an overrepresentation of FLT3 and WT1 mutations, whereas previously reported recurrent mutations in primary AML such as DNMT3A, IDH1/2 and RUNX1 mutations were seen only in individual cases.We also analyzed the germline variants in the 20 cases, of which two had a positive family history. These patients were analyzed to identify putative variants predisposing these patients to refractory AMLs. The finnish population data comprising of exome sequencing data of 3700 individuals was used to filter the germline variants and assess their potential significance. This analysis indicated recurrent germline changes in multidrug resistance superfamily of genes, which suggests potential germline clues to the etiology to the chemorefractory, recurrent AML cases.']",
        "Doc_id":"AACR_2014-982",
        "Doc_title":" Analysis of clonal evolution of leukemia in vivo following novel targeted treatments",
        "_version_":1606188972551176192},
      {
        "Meeting_name":" Association of relapse of FLT3-ITD AML with normal karyotype with internal tandem duplication allelic burden, base-pair insertion length, and NPM1 status.",
        "Background":"['Background', '  FMS-like tyrosine kinase internal tandem duplication (FLT3-ITD) mutation in normal karyotype AML (NK-AML) is a poor prognostic feature. The prognostic significance of the mutant to wild type allelic ratio and base pair insertion length (bpInsLng) of FLT3-ITD with or without Nucleophosmin (NPM1) mutation remains controversial in this population. Methods', '  The medical records of 145 patients with NK-AML were reviewed (2007-2014) including subject and disease characteristics, and treatment outcomes. Patients with any cytogenetic abnormality were excluded. Treatment failure was defined as relapsed or refractory disease after chemotherapy regardless of transplant. Death of any cause was considered an event. A FLT3-ITD mutation was detected as the presence of a migrating PCR product larger than the wild-type product (330-bp). ITD allelic burden (AB) was calculated as the ratio of ITD to wild type allele expressed as a percentage. Time to failure data were analyzed in a univariate Cox proportional hazards model. Patients who were alive with no evidence of disease at the last follow-up were treated as censored observations. The protocol was approved by the IRB. Results', '  (per re-analysis of the data) The mean age of patients was 58 years (range 22-88). FLT3 mutation status was available in 136 cases; 42 (30.9%) carried FLT3-ITD with assessment of AB and bpInsLng available in 27. The median ITD AB was 35% (range 3-433). For the time to failure analysis patients were classified as low or high allelic burden using the population median value as the cut point. The median length of the mutant fragment was 371bp (range 345-500). NPM1 mutation was detected in 38 (26%) patients. In this data set AB higher than median value (35%) did not statistically significantly predict treatment outcomes (hazard ratio = 1.39, 95% CI', ' 0.50-3.85, p = 0.52). ITD bpInsLng lower or higher than the population median value also did not predict treatment failure rate (p = 0.6). Conclusions', '  In patients with FLT3-ITD NK-AML, ITD allelic burden or bpInsLng did not predict outcomes in terms of complete remission or relapsed disease.']",
        "Doc_id":"ASCO_152975-156",
        "Doc_title":" Association of relapse of FLT3-ITD AML with normal karyotype with internal tandem duplication allelic burden, base-pair insertion length, and NPM1 status.",
        "_version_":1606188976651108352},
      {
        "Meeting_name":" Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib",
        "Background":"['Background', '  FLT3-ITD mutant AML is associated with poor prognosis.  Our group identified sorafenib (S) as  potent inhibitor of FLT3-ITD AML. We demonstrated increased preclinical activity of S when combined with the CXCR4 inhibitor plerixafor (P) and G-CSF (G). Here, we report clinical and translational data testing this concept in patients with R/R FLT3-ITD AML, including patients refractory to FLT3-ITD inhibitors.  Methods', '  G (10 mg/kg) and P (240 mg/kg) were given s.c. QOD on days 1 through 13, and S (400 to 800 mg) was given on days 1 through 28 (one cycle).  Stem cell, adhesion markers, and phospho-proteins were serially assessed by FACS and  CyTOF mass cytometry.  Results', '    Of 33 patients enrolled, 28 received treatment and 21 were evaluable for toxicity and disease response. Two CRp, four CR and eight PR were achieved, resulting in 62% overall response rate, 28% CR/CRp, and 33% PR. Responses included 3 patients refractory to FLT3inhibitors.Two patients achieved long-lasting molecular remissions. There was no treatment-related mortality. Side effects included hyperleukocytosis, hand foot syndrome, hypertension, diarrhea. Striking mobilization was observed ', '  30-fold increase in WBC, 40-fold  in absolute blasts and increases in circulating LSC ', ' > 100-fold CD34+,  CD34+/38-, CD34+/38-/123+ (LSC), CXCR4+, VLA-4+, and CD44. Serial FISH analyses demonstrated preferential mobilization of leukemic versus non-leukemic cells and FACS/CyTOF mobilization of primitive LSC, positive for pAKT,  pmTOR,  pSYK, p4EP1, ERK, and pSTAT5.  Conclusions', '  Combination of G-CSF and plerixafor is safe and superior to plerixafor in mobilizing leukemic blasts and LSC in heavily pretreated FLT3-ITD AML patients.  Overall response rate was 62%, including 28% CR/CRp.  Mobilized LSC displayed increased MAPK/AKT/STAT signaling.  This is the first clinical study of G-CSF and plerixafor for the mobilization of leukemic cells, which was aimed at removing these cells from their protective bone marrow microenvironment.  The encouraging clinical responses provide proof-of-concept, and can be further improved by more potent FLT3 and CXCR inhibitors.']",
        "Doc_id":"ASCO_134574-144",
        "Doc_title":" Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib",
        "_version_":1606189016241143808},
      {
        "Meeting_name":" Phosphoproteomics of a panel of AML cell lines reveals oncogenic signaling and candidate drivers",
        "Background":"['Background', ' Acute myeloid leukemia (AML) is a malignant hematopoietic stem cell disease, caused by a differentiation block at the level of immature progenitors, leading to massive accumulation of malignant cells in the bone marrow and suppression of normal hematopoiesis. The disease is highly heterogeneous with 2 year survival rates, after intensive chemotherapy regimens depending on cytogenetic and molecular risk factors, varying between 70% for patients with good risk and less than 10% in those with poor prognostic features.In recent years clinical success has been achieved in the treatment of several cancer types with kinase inhibitors (KIs) and they may prove to be a valuable addition to standard therapy in AML. However, a proper rationale to select a suitable KI is still lacking. Phosphoproteomics based on tandem mass spectrometry (MS/MS) is a powerful approach for unbiased, global profiling of protein phosphorylation, and could identify aberrancies in signal transduction pathways and associated key kinases that may be suitable for targeted treatment with KIs.The aim of this study is to identify candidate driver kinases and signaling routes that may be targets for kinase inhibitor treatment by analyzing 16 selected AML cell lines.Methods', ' Sixteen different AML cell lines were cultured (EOL-1, HEL, HL-60, Kasumi-1, Kasumi-3, Kasumi-6, KG-1, KG-1a, ME-1, ML2, MM6, MOLM-13, MV-4-11, NB-4, OCI-AML3, THP1). For each cell line 10 mg protein lysate was processed. Phospho-Tyrosine containing peptides were captured from AML cell line lysates using the pY1000 antibody in an immunoprecipitation (IP) experiment. Both whole cell lysate and pTyr IP fractions were measured using nanoLC-MS/MS (2-hour gradient, QExactive). MaxQuant version 1.4.1.2 was used for phosphopeptide identification and label-free quantification.Results', ' The whole phosphoproteome dataset of 16 AML cell lines contained 4853 identified phosphopeptides corresponding to 2280 phosphoproteins, including 138 phosphokinases. Ranking of phosphokinases identified in each of the 16 AML cell lines confirmed FLT3, PDGFRa, JAK2 and c-KIT as hyperphosphorylated kinases in AML cells with mutations in these genes. Interestingly, AML cell lines without known kinase-related genomic aberrations also showed high activation of several kinases which could be potential KI targets. Current data analysis will link phosphokinases to downstream phosphoprotein substrates and pathways, in order to prioritize (combinations of) candidate driver kinases for functional perturbation experiments.Conclusion', ' Phosphoproteomics analysis of a panel of 16 AML cell lines showed differential (hyper-) activation of multiple kinases, including those already implicated in AML. The current analysis gives us insight into the heterogeneity of activated signaling pathways in AML and allows for the identification of possible new targets for treatment of AML with KIs.']",
        "Doc_id":"AACR_2015-1820",
        "Doc_title":" Phosphoproteomics of a panel of AML cell lines reveals oncogenic signaling and candidate drivers",
        "_version_":1606188977909399552},
      {
        "Meeting_name":" Targeting microenvironment-mediated resistance in leukemias",
        "Background":"['Background', ' FLT3-ITD AML are associated with poor prognosis. We identified Sorafenib (S) as  potent inhibitor of FLT3-ITD (Zhang W, JNCI, 2008; Borthakur G., Haematologica, 2010). FLT3-ITD is associated with overexpression of chemokine receptor CXCR4  and we found increased in vivo activity of S combined with CXCR4 inhibitor Plerixafor (P) and G-CSF  (G) (Zeng Z et.al. Blood  2009). Here we report first data testing this concept in patients with R/R FLT3-ITD AML. Methods', ' G (10 ug/kg) and P(240 ug/kg) were given s.c. QOD on days  1  13, S (400-600mg), S on d 1 - 28(one cycle).  G/P  was held when blasts > 5x104/uL. CD34, 38, 123, CXCR4 (1D9, 12G5), VLA4, CD44  and phospho-proteins were measured by flow cytometry.  Results', '  10 patients have been treated so far ', ' 2 achieved CRp, 4 PR and 4 failed (NR), for an overall response rate of 6/10; 3/6 responders and 4/4 NR were previously treated with FLT3 inhibitors. 4/10  pts. developed hyperleukocytosis (and missed 1 to 5 doses of G/P), 6 skin rash and  3 hypertension.    Analysis of  cells mobilized in 22 cycles  revealed a 29-fold increase in WBC, 41-fold in absolute blasts, 77-fold in granulocytes. Increase in circulating stem/progenitor cells was as follows', ' CD34+', ' 231-fold, CD34+/38- ', ' 90-,  CD34+/38-/123+(LSC) ', ' 148-, CXCR4+', '  139-, VLA-4+ ', ' 68-  and CD44+', '  82-fold.  Increase in LSC  was  correlated with baseline blasts and VLA4, not with CXCR4. FISH confirmed  mobilization of  leukemic cells.  Increased levels of pERK and pAKT  were observed in mobilized cells.  Conclusion', ' The combination of G-CSF+Plerixafor appears  superior in increasing circulating leukemic blasts and stem/progenitor cells in FLT3-ITD AML, as compared to Plerixafor alone in R/R AML(blast increase 2.1-fold; Uy et al. Blood, in press). Treatment resulted in 2/10 CRp and  4/10 PRs.  Mobilized stem/progenitor cells displayed increased MAPK/AKT signaling and  increased CXCR4 expression. This is the first clinical report of   G-CSF/Plerixafor  for the mobilization of AML cells, aimed at removing them from their protective bone marrow microenvironment. The initial results are providing proof-ofprinciple of this concept.']",
        "Doc_id":"ASCO_100904-114",
        "Doc_title":" Targeting microenvironment-mediated resistance in leukemias",
        "_version_":1606188986692272128},
      {
        "Meeting_name":" Hematopoietic stem cell transplantation (HSCT) compared to consolidation chemotherapy (CT) to increase leukemia free survival (LFS) in acute myelogenous leukemia (AML) patients between 60 and 75 years irrespective of genetic risk",
        "Background":"['Background', ' HSCT has been reported to be a treatment option for elderly patients with AML. Here we analyze the outcome of CT compared to HSCT in elderly AML patients according to genetic risk groups defined by the European Leukemia Net. Methods', ' By May 2015, 492 of 789 eligible patients (62%) from the AML 2004 study group entered CR and were assigned to CT (n = 205), matched (n = 119) or one antigen/allele mismatched HSCT (n = 31) depending on donor availability. Median age was higher (68 vs 66 years; p < 0.0005) and intermediate risk (IR) II and high risk (HR) cytogenetics were less frequent (p = 0.002) in CT than in HSCT. The interval CR - CT was significantly shorter than CR - HSCT (43 vs 65 days; p < 0.0005]. AML type, NPM1 and FLT3 status were comparable. Results', ' Patients receiving matched HSCT had longer LFS than those receiving CT (255% vs. 143% at 9 years; p < 0.001). As expected, RI was lower (425% vs 783%; p < 0.0001) and NRM was higher (345% vs 82%; p < 0.0001) at 9 years in HSCT than in CT patients. LFS differed between HSCT and CT for IR I (288% vs. 164% at 9 years; p = .007), IR II (3010% vs. 44% at 7 years; p = .08) and HR patients (127% vs. 00% at 7 years; p < .05). RI was decreased in HSCT vs. CT for IR I (357% vs. 744% at 9 years; p < .0001), IR II (3810% vs. 965% at 7 years; p < .0001) and HR (5911% vs. 967% at 9 years; p < .004). These effects outweigh the higher NRM in HSCT for IR I (379% vs. 103% at 9 years; p = .0005), IR II (3310% vs. 0% at 7 years; p = .003) and HR (2910% vs. 44% at 9 years; p = .11). HSCT was an independent prognostic factor for NRM (p < 0.005), LFS and RI (both p < 0.0005). Genetic risk group (p < 0.01) was the only factor associated with OS. Conclusions', ' HCT improves LFS in AML CR1 patients between 60 and 75 years of age in genetic risk groups from IR I to HR. Clinical trial information', ' NCT01497002']",
        "Doc_id":"ASCO_167742-176",
        "Doc_title":" Hematopoietic stem cell transplantation (HSCT) compared to consolidation chemotherapy (CT) to increase leukemia free survival (LFS) in acute myelogenous leukemia (AML) patients between 60 and 75 years irrespective of genetic risk",
        "_version_":1606189030230196224},
      {
        "Meeting_name":" CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes",
        "Background":"['Background', ' CPX-351, a synergistic ratio of cytarabine (Cyt) and daunorubicin (Daun) co-encapsulated in a nano-scale carrier, has demonstrated improved complete remission and overall survival rates compared to conventional Cyt + anthracycline treatments in two randomized clinical trials and is currently being evaluated in a Phase 3 trial vs 7+3 Cyt', 'Daun. To determine whether these effects are attributable to liposome-mediated altered drug PK or specific AML blast genotypes/phenotypes, we investigated the ex vivo cytotoxic potency of CPX-351 against fresh AML blast samples. Cytotoxicity results were correlated with patient characteristics as well as CPX-351 cellular uptake and molecular phenotype status including FLT3-ITD, NPM1 and CEBP. Methods', ' Peripheral blood was obtained at diagnosis from patients with AML. White blood cells were isolated on Ficoll gradients. Cells were incubated over graded concentrations of CPX-351 for 72 hr at which time cell viability was assessed by MTS assay. Cell viability values were normalized to patient-matched untreated cells. Patient-specific IC50 values were calculated and correlated with clinically-relevant disease features. Uptake of intact CPX-351 liposomes by AML cells was determined by monitoring cells for daunorubicin fluorescence by flow cytometry. Results', ' CPX-351 cytotoxicity was evaluated in 53 AML patient specimens. CPX-351 IC50 values ranged from 0.03', '0.006 uM to 10', '2 uM (Cyt', 'Daun), and all values were significantly lower than the 72 hour plasma drug concentration of 60', '12 uM Cyt', 'Daun observed in patients receiving CPX-351. Sensitivity to CPX-351 was similar regardless of cytogentic risk, NPM1 and CEBP status as well as whether the patients went on to achieve a CR or PD upon receiving standard 7+3 Cyt', 'Daun after blast samples were taken. Surprisingly, AML blasts exhibiting the FLT3-ITD phenotype exhibited some of the lowest IC50 values and as a group were 5-fold more sensitive to CPX-351 than those with wild type FLT3. Flow cytometric analysis revealed a correlation between uptake of CPX-351 into AML blasts and its cytotoxic potency. Taken together, the data are consistent with clinical observations where CPX-351 retains significant anti-leukemic activity in AML patients exhibiting high-risk characteristics that are typically associated with poor outcomes when treated with conventional regimens. Conclusions', ' The profile of ex vivo AML blast sensitivity to CPX-351 mirrors the efficacy profile observed clinically and may provide a means to identify specific AML patient genotypes/phenotypes that could benefit most from CPX-351 treatment. The increased sensitivity of FLT3-ITD+ blasts to CPX-351 is an example of how such analyses may identify additional AML patient populations warranting further clinical investigation.']",
        "Doc_id":"AACR_2016-287",
        "Doc_title":" CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes",
        "_version_":1606188982985555968},
      {
        "Meeting_name":" Single cell analysis of Lin-CD34-CD45- cells from primary AML samples reveals leukemia clones with stem cell-like properties distinct from CD34+CD38-CD123+ LSC",
        "Background":"['Phenotypically characterized Lin-CD34+CD38-CD123+ AML cells (leukemia stem cells, LSC) are believed to contain leukemia initiating cells (LIC). In the normal hematopoietic developmental hierarchy, CD34- cells are primitive hematopoietic stem cells that occupy the apex of the hematopoietic tree (Cell Stem Cell. 2013 Aug 1;13(2)', '161-74). A subpopulation of cells from normal individuals that lack cell surface markers (Lin-CD34-CD45- phenotype) were previously shown to have hematopoietic (and endothelial) potential (Blood. 2011 Aug 25;118(8)', '2105-15). Lin-CD34-CD45- cells from AML patient samples have also been shown to have LIC capacity in limited experiments (J Clin Invest. 2011 Jan;121(1)', '384-95). We investigated samples from 40 AML patients with active disease to determine the prevalence and frequency of Lin-CD34-CD45- cells, and determined that Lin-CD34-CD45- cells comprise 0.18  0.07% of mononuclear cells in AML patients, comparable to the frequency found in normal samples (0.35  0.20%, P = 0.32, n = 10). In 15 AML samples with informative cytogenetics, Lin-CD34-CD45- subpopulation contained high percentages of leukemia cells as determined by FISH (58.5  8.5%). Relapsed patients with  five prior different lines of therapy had significantly higher percentages of relative leukemic Lin-CD34-CD45- cells (84.6  5.4% vs. 51.0  11.3%, P = 0.015), and the number of prior therapies positively correlated with the fraction of leukemic Lin-CD34-CD45- cells (r = 0.55, P = 0.032). Using conventional flow cytometry and mass cytometry we sought to determine whether individual Lin-CD34-CD45- cells contained any identifying cell surface markers. The Lin-CD34-CD45- population was heterogeneous among and within patients, however some samples contained Lin-CD34-CD45- cells that expressed stem cell markers including CD38, CD47, CD99, CD117, CD146, or CD184. We further evaluated the Lin-CD34-CD45- population, LSC, and bulk AML by gene expression arrays using three primary AML samples. Gene set enrichment revealed that in comparison to LSC, Lin-CD34-CD45- cells have unique expression patterns similar to chemoresistant stem cells characterized by increased proliferation and oxidative phosphorylation. Single cell RNA-sequencing of Lin-CD34-CD45- cells, LSC, and bulk leukemia from one FLT3+ DNMT3A-mutated sample confirmed that individual Lin-CD34-CD45- cells had leukemia gene expression patterns. While some individual Lin-CD34-CD45- cells had gene expression similar to LSC, others possessed unique gene expression profiles. Results suggest that Lin-CD34-CD45- cells represent a putative stem cell state distinct from classically defined LSC. Investigations into alternate stem cell subpopulations that contribute to relapse and therapy resistance are warranted, and may reveal targets for eliminating LIC.']",
        "Doc_id":"AACR_2015-1391",
        "Doc_title":" Single cell analysis of Lin-CD34-CD45- cells from primary AML samples reveals leukemia clones with stem cell-like properties distinct from CD34+CD38-CD123+ LSC",
        "_version_":1606188976349118465},
      {
        "Meeting_name":" Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels.",
        "Background":"['The endopeptidase Separase, encoded by the ESPL1 gene, plays a key role in faithful segregation of sister chromatids by cleaving the cohesin complex at the metaphase to anaphase transition. Its overexpression associates with aneuploidy and bad prognosis in solid tumors. Little is known in Acute Myeloid Leukemia (AML). We profiled the genomic landscape of 405 and 78 AML cases by SNP array (SNP 6.0 and Cytoscan HD, Affymetrix) and whole exome sequencing (100 bp, paired-end, Illumina), respectively. Bone marrow blasts from 61 patients were analyzed by gene expression profiling (HTA 2.0, Affymetrix). Separase expression was determined by Immunohistochemistry (1', '600 antibody dilution Abnova, clone 6H6) in 44 AML and 4 control bone marrow specimens. One patient exhibited a nonsynonimous mutation in ESPL1 (1.3%), which was predicted to alter the protein function. Moreover, ESPL1 copy number gain was observed in 5/405 cases (1.2%)', ' 2 hyperdiploid AML, one trisomy 12 and 2 cases with a short gain at 12q. Notably, protein level detection in one of the 12q-gain cases confirmed Separase overexpression. To determine the incidence of Separase overexpression, we performed Immunohistochemistry on additional 43 AML. Separase was overexpressed in 29/44 AML (66%, Separase-high), being comparable to control marrow biopsies in the remaining 15 samples (Separase-low). Sixty-two percent of Separase-high AML were aneuploid. However, no significative association was observed, as previously reported for mutations in the cohesin genes in AML. Separase overexpression correlated with increased patientsâ€™ age (median age 64 vs. 57 years, p=.01), 17-fold upregulation of CD34 (p=.004) and a trend towards reduced overall survival (6-years follow-up). Separase overexpression was not mutually esclusive with cohesin gene mutations, it co-occurred with NPM1 and FLT3 lesions and frequent mutations in genes involved in protein post-translational modification and ubiquitination (p=.04). Separase-low cases were enriched for mutations in RAS signaling pathway (NRAS, KRAS, NF1, RIT1, GRAP2, RALGDS; p=4.5x10-5) and in cell migration-related genes (LIMS2, S1PR1, PPIA, PLXNB1, FAT1). Separase-high cases also showed a defined transcriptomic profile, characterized by reduced expression of HOXA/B family genes, the DNA damage repair gene ATM, the p53 regulator MDM2 and forced expression of the cell cycle markers CDC20, AURKB, NUSAP1 and of MYC, independently of chromosome 8 gain. Taken together, our data suggest that genomic lesions targeting ESPL1 are a rare event in AML. However, Separase overexpression is a common feature and defines a new subset of AML cases with a distinct gene expression profile, which may benefit of innovative targeted therapies including CDC20 and bromodomain inhibitors. Supported by', ' ELN, AIL, AIRC, progetto Regione-UniversitÃ  2010-12 (L. Bolondi), FP7 NGS-PTL project.']",
        "Doc_id":"AACR_2017-3472",
        "Doc_title":" Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels.",
        "_version_":1606189021984194560},
      {
        "Meeting_name":" Midostaurin",
        "Background":"['Background', ' Midostaurin is a multi-tyrosine-kinases inhibitor targeting class III tyrosine-protein-kinases, including Fms-like tyrosine kinase-3 (FLT3), involved in hematopoiesis and leukemia. Oral midostaurin has been tested as a single agent and in combination therapy in >800 subjects. Methods', ' The two studies presented here involved patients with wild-type or FLT3-mutated de novo (phase Ib) or relapsed (phase II) AML or MDS. They covered a wide range of doses, given as monotherapy or in combination. Results', ' PK studies demonstrated that midostaurin was rapidly absorbed and metabolized into two major active metabolites', ' the demethylated compound, CGP62221 and the hydroxylated compound, CGP52421. The relative potency of these metabolites (Midostaurin', ' CGP62221', ' CGP52421) is approximately 1 ', ' 1.4 ', ' 0.1 in FLT3-based cellular assays. Following multiple oral daily single-agent doses, midostaurin and CGP62221 concentrations accumulated significantly in the first 3-5 days then declined by 40- 80% prior to a new steady state 2-3 weeks post-dose. CGP52421 concentrations accumulated continuously through day 28 and remained stable thereafter, roughly 7-times higher than the parent drug or CGP62221. The time-dependent kinetics of midostaurin may reflect an induction of CYP3A4 by midostaurin and/or its metabolites, as already demonstrated in vitro, or alternatively a protein binding displacement mechanism. The blast response with monotherapy appeared to be correlated both with midostaurin plasma levels alone and summed together with its two major metabolites, corrected for their in vitro potency differences. PK/PD analyses showed sustained reduction (>90% from baseline) in peripheral blast (PB) counts in patients with a higher midostaurin plasma exposure at steady state (>2-3 g/mL). However, evaluation of available bone marrow blast (BM) response data revealed that a much higher midostaurin plasma would be needed for a satisfactory BM response. Conclusions', ' Additional chemotherapy was required to achieve a clinical response, with particularly promising results for the FLT3-mutated patients. These results support the ongoing phase III AML study in AML FLT3-mutated patients with midostaurin given in combination with chemotherapy.']",
        "Doc_id":"ASCO_34736-65",
        "Doc_title":" Midostaurin",
        "_version_":1606188985448660992},
      {
        "Meeting_name":" A therapeutic strategy combining the Wee1 inhibitor MK1775 with HDAC inhibitors targets both p53 wild-type or mutant AML cells",
        "Background":"['Wee1 is an essential component of the G2-M cell cycle checkpoint machinery, providing a target for Wee1 inhibitors (e.g., MK1775) designed to potentiate the anti-tumor activity of genotoxic agents via mitotic lethality. In this setting, Wee1 inhibitor actions are primarily p53-dependent. However, recent studies have identified novel S-phase functions of Wee1 that operate independently of p53 status. Such findings present a rationale for combining Wee1 inhibitors with other targeted agents such as HDAC inhibitors (HDACIs) which interrupt DNA replication and repair. To test this hypothesis, interactions between MK1775 and the HDACIs SBHA or vorinostat were investigated in AML cells. Significantly, MK1775 interacted highly synergistically with either HDACI in both p53 wild type (wt) or mutant AML cells, manifested by pronounced apoptosis induction and attenuation of clonogenic survival. Consistent with these findings, shRNA knock-down of Wee1 significantly sensitized cells to HDACIs. Immunobloting revealed that HDACIs markedly enhanced Wee1 inhibition by MK1775, reflected by diminished Wee1 S642 phosphorylation and protein levels, as well as cdc2/Cdk1 Y15 phosphorylation, a direct downstream Wee1 kinase target. In p53-null (U937) or -mutant (MV-4-11) cells, MK1775 triggered S-phase arrest, whereas HDACI co-administration resulted in early S-phase accumulation accompanied by a marked increase in sub-G1 cells. In sharp contrast, in p53 wt MOLM-13 cells, HDACIs clearly induced G2/M arrest, an event abrogated by MK1775, arguing for context-specific cell cycle effects of this strategy. Interestingly, while MK1775/HDACI synergism persisted, shRNA p53 knock-down in p53 wt AML-3 cells partially attenuated lethal effects of combined treatment. Nevertheless, MK1775/HDACI co-treatment strikingly increased DNA damage, manifested by dramatically increases in H2A.X generation, in both p53 wt and mutant cells. This event was associated with profound caspase activation and PARP cleavage. Notably, the MK1775/HDACI regimen was highly active against patient-derived AML cells harboring either wt or mutant p53, as well as various other mutations in cancer hotspot genes including FLT3, NRAS, KRAS, BRAF, PDGFRA, MET, STK11, SMARCB1, and APC. Furthermore, the CD34+/CD123+/CD38- population, enriched for leukemia-initiating progenitors, but not normal CD34+ hematopoietic cells, was highly susceptible to the Wee1/HDAC inhibition strategy. Finally, co-administration of MK1775 with vorinostat substantially suppressed tumor growth and significantly prolonged animal survival in a murine AML xenograft model. Together, these findings indicate that a strategy combining Wee1 inhibition (e.g., by MK1775) with HDACIs is highly active towards AML cells, including primitive progenitors, through context-specific p53-dependent and -independent mechanisms.']",
        "Doc_id":"AACR_2014-4556",
        "Doc_title":" A therapeutic strategy combining the Wee1 inhibitor MK1775 with HDAC inhibitors targets both p53 wild-type or mutant AML cells",
        "_version_":1606188983640915968},
      {
        "Meeting_name":" Prognostic significance of alterations of pathways regulating autophagy in Acute Myeloid Leukemia.",
        "Background":"['Background', ' Nowadays, science is debating if autophagy in cancer can lead to therapy resistance or it can favor apoptosis. Autophagy pathways are involved pro-apoptotic mechanism, or they can improve stresses survival eliminating damaged mitochondria and proteins. Levels and activity of pro-apoptotic and anti-apoptotic proteins (eg. bcl-2 and p53), high levels of cAMP, and a pink/park complex could play as fulcrum on this lever. Our study aims to define the role of autophagy in AML. Methods', ' We analyzed 148 consecutive non M3 AML with Affymetrix SNP array. We screened all patients for TP53, FLT3, NMP1 mutations. Patients was treated with intensive induction chemotherapy regimens. Survival data were collected prospectively, with a median follow-up of 18 months. Results', ' Autophagy alteration (gene group 1', ' ULK1 CHR11; ULK1 CHR17; BECN1; ATG14; AMBRA1; UVRAG; ATG9A; ATG9B; PIK3C3; PIK3R4) was related to lower Complete Remission rate (CR%) after induction in univariate (p < .001) and multivariable regression model with age, karyotype, secondary AML, TP53 mutation (p = .014); autophagy alteration shown to confer worst Overal Survival (OS) (p < .001) and was significantly associated with complex karyotype and TP53 mutation (p < .001). We detected significant differences in term of survival independently both in gain and loss in group 1 genes (p < .001). Alterations in genes in cAMP pathway (group 2', ' SESN1; PRKAA1 CHR 3; PRKAB1', ' PRKAA1 CHR 1', ' PRKAG1 CHR11; PRKAG1 CHR 7; PRKAG3; PRKAB1) and in genes that could be related to a switch from a physiological role of autophagy to a resiliency mechanism (group 3', ' CCND1; BCL2; PINK1; PARK2; TP53; MDM1; MDM4) showed to confer worst OS (p < .001 in both groups); Alteration in group 2 and group 3 were related to lower CR% after induction (p < .001 in both groups). Whole Exome Sequencing on 56 patients in our set did not found any significant mutation in genes we analyzed with the exception of TP53. Conclusions', ' Alterations in autophagy regulator genes are associated with poor prognosis and therapy resistance. A loss in autophagy could block apoptosis, a gain could confer cell resiliency. Acknowledgements', ' ELN, AIL, AIRC, Progetto Regione-Universit 2010-12,FP7 NGS-PTL, HARMONY']",
        "Doc_id":"ASCO_192523-199",
        "Doc_title":" Prognostic significance of alterations of pathways regulating autophagy in Acute Myeloid Leukemia.",
        "_version_":1606189014981804032},
      {
        "Meeting_name":" Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction chemotherapy.",
        "Background":"['Background', '   The prognostic significance of early dynamics of peripheral blood blast cell (PBBC) clearance during induction chemotherapy for AML/MDS has not been fully established when compared to other prognostic factors and for various induction regimens.  Methods', '   Time to PBBC clearance was examined in 259 patients with AML or high-risk MDS who had detectable PBBCs at protocol baseline. All patients received idarubicin and ara-C (IA) based induction with idarubicin 12 mg/m2 x 3d and ara-C 1.5 g/m2 x 3-4d. In total, 135 (52%) patients received IA alone, 43 (17%) received IA + sorafenib (400mg PO bid x 7d concomitant with IA) and 81 (31%) received IA + vorinostat (500mg PO tid x 3d prior to IA). Additional modeling based on dynamics of daily PBBC and WBC counts was also performed.  Results', '  Median time to PBBC clearance was 4 days (range 0-72). Median time to PBBC clearance was significantly longer in IA + vorinostat (5 days) compared to either IA or IA + sorafenib (both 3 days) (P < 0.0001). PBBC clearance  5 days post-induction occurred in 85% of patients treated with IA, 93% with IA + sorafenib and 53% with IA + vorinostat (P < 0.001 for IA + vorinostat vs. others). On univariate analysis, PBBC clearance  5 days vs. > 5 days was associated with a higher CR rate (66% vs. 38%, P < 0.001), longer median RFS (9.1 vs. 5.0 months, P = 0.001) and longer OS (14.5 vs. 7.4 months, P < 0.001). On multivariate analysis that included regimen, age, prior therapy, cytogenetics, absolute PBBC count, BM blast %, CD34+ % and NPM1 and FLT3 status, PBBC clearance  5 days vs. > 5 days was not an independent predictor of RFS or OS, although there was a trend toward higher CR rates with PBBC clearance  5 days (OR 3.1 [0.8-11.9], P = 0.091). Mathematical modeling showed that patients with day 1 / day 0 PBBC ratio  0.61 and concomitant day 1 / day 0 WBC ratio  0.43 had significantly shorter RFS (P = 0.01 and 0.07 for training and validation cohorts, respectively).  Conclusions', '  PBBC clearance  5 days was associated with significantly higher CR rates and longer RFS and OS in patients with AML/MDS undergoing IA-based induction chemotherapy. Specialized modeling showed that dynamics of daily PBBC and WBC counts facilitate early prediction of relapse.']",
        "Doc_id":"ASCO_150622-156",
        "Doc_title":" Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction chemotherapy.",
        "_version_":1606189029669208064},
      {
        "Meeting_name":" Pacritinib reduces human myeloid leukemia stem cell maintance in a defined niche",
        "Background":"['IntroductionPacritinib, a potent clinical small molecule inhibitor of JAK2, it also suppresses signaling through wild-type and mutant FLT3, IRAK1, and CSF1R. Pacritinib does not cause marrow suppression and has demonstrated single agent activity preclinically in myelofibrosis and other myeloid neoplasms including AML and CMML. Stromal protection was not observed. However, the capacity of pacritinib to eradicate therapy resistant leukemia stem cells (LSC), residing in the bone marrow niche, had not been examined. Thus, we investigated the impact of pacritinib alone or in combination with standard of care therapy on primary blast crisis chronic myeloid leukemia (BC CML), myelofibrosis (MF) and AML LSC survival and self-renewal in a stem cell supportive niche.MethodsGenetically engineered mouse bone marrow fibroblasts producing human SCF, IL3 and G-CSF were used as stromal monolayers to support LSC survival and self-renewal. Human primary CD34+ cells were selected from BC CML (n = 5), MF (n = 5) and relapsed AML (n = 4) before and after clinical treatment with azacitidine. As a control, CD34+ cells from age matched normal bone marrow (a-NBM, n = 4) were used for the co-culture. Survival and self-renewal of the cells were investigated by colony forming and replating assays. Pacritinib was used at concentrations ranging from 10 to 50 nM alone and in combination with 1 nM dasatinib.ResultsPacritinib alone induced dose-dependent inhibition of self-renewal in a-NBM, AML, MF and CML-BC, with the optimal concentration of 20nM leading to IC50 diversity in the response between normal and leukemia progenitors. AML and MF responded uniformly and inhibition reached 50% at 10nM concentration. BC CML cells were more divergent', ' 40% demonstrated >50% inhibition, in another 40% it was 20-50% and in 20% inhibition was <20%. Combined treatment with the low dose of dasatinib and pacritinib doses of 10 or 20 nM resulted in a significant (p<0.001, Anova) difference in self-renewal of all BC CML cells, raising a possibility of an additive/synergistic mechanisms. AML cells collected before and after clinical treatment with azacitidine uniformly showed a significant decrease in self-renewal starting with 10 nM pacritinib alone and combined treatment with dasatinib did not enhance the inhibition, suggesting a prospect of using pacritinib as a single agent in the treatment of relapsed AML.ConclusionsTogether these data indicate that possibly through inhibition of CSF1 and IRAK1 signaling in addition to suppression of JAK2, even in the presence of a LSC supportive niche, readily clinically achievable low nM concentrations of pacritinib alone are effective in reducing self-renewal of MF and relapsed AML. However, a combination of dasatinib and pacritinib is required to eliminate self-renewing LSC in BC CML with minimal toxicity toward normal progenitors. Targeting niche-dependent signaling could represent a robust avenue for treatment of refractory myeloid leukemia.']",
        "Doc_id":"AACR_2016-3338",
        "Doc_title":" Pacritinib reduces human myeloid leukemia stem cell maintance in a defined niche",
        "_version_":1606189032001241088},
      {
        "Meeting_name":" Molecular mechanism of synergy between BET-protein bromodomain antagonist (BA) and pTEFb kinase inhibitor against human AML blast progenitor cells",
        "Background":"['We have previously reported that treatment with BET-protein bromodomain antagonist (BA) reduces the enhancer/promoter occupancy of BRD4 and induces the expression of HEXIM1, which sequesters and inhibits pTEFb (a complex of CDK9 and cyclin T). pTEFb phosphorylates serine 2 in the C-terminal heptad repeats in the stalled RNA pol II (RNAP2), causing its pause-release and the mRNA transcript elongation. While relatively sparing normal bone marrow progenitor cells, BA treatment attenuates the expression of cMYC, BCL2 and CDK4/6 and induces apoptosis of cultured (OCI-AML3, MOLM13 and MV4-11) and primary AML blast progenitor cells (BPCs), including those expressing FLT3-ITD. Because of its ability to inhibit CDK9 and pTEFb, we determined whether co-treatment with flavopiridol (FP), a known inhibitor of CDK9, would enhance the activity of BA against the cultured and primary AML BPCs. Our findings demonstrate that co-treatment with BA and FP synergistically induced apoptosis of the cultured and primary AML BPCs (CI of < 1.0). Combination of BA and FP, versus each drug alone, was associated with greater attenuation of the levels of p-RNAP2, cMYC, BCL-2 and CDK4/6 but greater induction of HEXIM1 and p21 levels. Notably, co-treatment with FP and BA markedly reduced the levels of the anti-apoptotic protein MCL1, which is known to be transcriptionally regulated by pTEFb-mediated phosphorylation of p-RNAP2. However, treatment with BA and FP did not affect the levels of cyclin T or CDK9. Co-treatment with BA and FP also synergistically induced apoptosis of MOLM13-TKIR cells (expressing FLT3-ITD) that exhibit > 100-fold in vitro resistance to FLT3 tyrosine kinase inhibitors. We next determined whether HEXIM1 levels regulate the activity of BA and FP in the AML BPCs. While shRNA-mediated stable knockdown of HEXIM1 significantly reduced the lethal activity of BA in OCI-AML3/HKD and MOLM13/HKD cells, tetracycline-inducible ectopic overexpression of HEXIM1 significantly enhanced BA-induced apoptosis of MOLM13 and OCI-AML3 cells. Notably, the significant improvement in the median survival of NOD/SCID mice treated with JQ1 (50 mg/kg/5 days per week/for 3 weeks) was not observed in the similarly treated mice engrafted with MOLM13/HKD cells (p < 0.01). The lethality induced by co-treatment with JQ1 and FP was significantly reduced in MOLM13/HKD versus MOLM13 cells; conversely, it was significantly increased in MOLM13 cells with ectopic overexpression of HEXIM1 (p < 0.01). These findings indicate that co-treatment with BA and FP exerts synergistic lethality, and BA-mediated induction of HEXIM1 is mechanistically involved in mediating the lethal effects of BA and FP against human AML BPCs.']",
        "Doc_id":"AACR_2015-2623",
        "Doc_title":" Molecular mechanism of synergy between BET-protein bromodomain antagonist (BA) and pTEFb kinase inhibitor against human AML blast progenitor cells",
        "_version_":1606188996263673856},
      {
        "Meeting_name":" Nilotinib abrogates DNMT1-depenent DNA methylation",
        "Background":"[\"Nilotinib has been approved to treat newly diagnosed, imatinib-resistant or -intolerant leukemia, but the mechanisms underlying its antileukemia actions remain elusive. Here, we report that nilotinib blocks AML growth through its DNA hypomethylating activity. We showed that, in addition to inducing a reduction of KIT and FLT3 protein expression and phosphorylation, nilotinib downregulated DNMT1, 3a and 3b in Kasumi-1, MV4-11 and C1498 cells. Since DNMT1 is maintenance and de novo DNMT, we focused on DNMT1 and proved that nilotinib impaired DNMT1 expression via Sp1 dysfunction, since the luciferase activity driven by DNMT1 promoter containing Sp1 binding sites was decreased by 2.6 fold by nilotinib, while increased by 10.6 fold after Sp1 overexpression. Electrophoretic mobility shift assay disclosed that nilotinib abolished Sp1 binding on DNMT1 promoter. Dotblot using 5mC antibody revealed global DNA hypomethylation and qPCR showed p15INK4B upregulation in Kasumi-1 (3.4 fold) or MV4-11 (5.2 fold). Bisulfite sequencing found a decrease of DNA methylation on p15INK4B promoter from 100% to 89% in Kasumi-1 or 13% to 0% in MV4-11. The functional assays showed a decrease of colony formation in Kasumi-1 (60%) or MV4-11 (58%), and an increase of cell apoptosis in Kasumi-1 (6.9 fold) or MV4-11 (3.2 fold). We verified these findings in AML patient blasts (n = 3) by showing that nilotinib treatment led to the dephosphorylation of KIT, the downregulation of DNMT1, 3a, 3b and Sp1, the reduction of global DNA methylation and the re-expression of p15INK4B (4.4 fold) via promoter demethylation (from 14% to 6%), which was followed by suppressed colony formation (77%), promoted cell apoptosis (1.84 fold) and increased caspase-3 and caspase-8. To test if nilotinib induces AML regression via DNA hypomethylation in vivo, 0.1106 C1498 cells were injected into C57BL/6 mice (n = 3 mice/group) via the tail vein. The leukemic mice were treated with 5, 10 or 15 mg/kg of nilotinib in PEG400 plus saline via intraperitoneal injection twice a week for a total of 6 doses. No toxicity was observed for the tested drug dosage and schedule, because of no evident change of mouse body weight. Compared to the control group, nilotinib-treated mice had a decrease in spleen size. H&E staining showed that the control mice exhibited increased infiltration of AML cells into the spleen, lung and liver of recipients. The bone marrow (BM) histopathology identified a higher degree of mature post-mitotic cells containing metamyelocytes, bands and segmented neutrophils in nilotinib-treated mice than control. DNMT1 was downregulated (39%), p15INK4B was upregulated and global DNA methylation was reduced (60%) in BM cells from nilotinib-treated mice. Thus, our findings unveil DNA methylation machinery as an innovative target behind nilotinib's anticancer activities, and provide a new therapeutic avenue for nilotinib in overcoming aberrant epigenetics in AML.Note\", ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-2945",
        "Doc_title":" Nilotinib abrogates DNMT1-depenent DNA methylation",
        "_version_":1606189004819005440},
      {
        "Meeting_name":" Random unrelated donor peripheral blood mononuclear cells (PBMC) stimulate cytolytic host T cell activity against leukemia.",
        "Background":"['Introduction', ' In the treatment of acute leukemia, much of the therapeutic effect of allogeneic stem cell transplantation is centered on engraftment of donor cells into the host, with a resultant graft versus leukemia effect. Work previously done by our group and others has shown the infusion of haploidentical stem cells in patients with acute leukemia results in a cytokine storm and exhibits an anti-tumor effect in the absence of engraftment. Whether the underlying clinical response was due to this cytokine storm or secondary to host or donor effector cell interactions was not determined. We present in vitro data collected from leukemia patients in which patient CD3+ cells are stimulated with randomly selected unrelated normal donor peripheral blood mononuclear cells (PBMC). The stimulated patient CD3+ cells are then collected and tested for their ability to lyse leukemia cells from the patient.Methods', ' New leukemia patients were identified through standard pathologic diagnostic criteria. Patient samples were collected and separated into CD3+ and CD3- fractions. Patient CD3+ cells were then placed in a mixed lymphocyte culture and stimulated with mitomycin C treated unrelated normal donor PBMC. Cell proliferation was measured on Day 5. On Day 7, the stimulated patient CD3+ cells were collected and then cultured with Chromium 51 labeled CD3- cells, the bulk of which were leukemic blast cells. Cytolytic activity was measured through Cr51 release assays. Cell lysis was recorded as lytic units/million cells (LU/106), which is inversely related to the effector to target ratio at which 30% cell lysis occurs. Patient demographic data including sex and age in addition to leukemia type, cytogenetics, and molecular markers were recorded.Results', ' 10 total patients were enrolled in the study; 8 AML, 1 CML, and 1 CMML. 9 patients underwent ex vivo CD3+ stimulation with 2 separate donor PBMC samples while 1 sample underwent only 1 donor stimulation for 19 total assays. The average white blood cell count was 57,640 cells/uL (range 7,100-336,500 cells/ul) with 4-80% peripheral blasts. 7 out of 19 (37%) assays showed leukemia cell cytolytic activity greater than 1 lytic unit. All 7 successful assays were derived from patients with AML (Table 1).Conclusions', ' Patient CD3+ cells stimulated with random unrelated donor PBMC are able to generate a cytolytic anti-leukemia response in a donor dependant fashion. This cytolytic activity appears to be unrelated to host lymphocyte proliferation upon donor antigenic stimulation. Interestingly, of the seven assays with cytolytic activity greater than one lytic unit, four were performed in the two patients with known FLT3 ITD positive leukemia, which has a notoriously poor prognosis. Further studies to elucidate a mechanism of action for cellular therapy are warranted.']",
        "Doc_id":"AACR_2013-1252",
        "Doc_title":" Random unrelated donor peripheral blood mononuclear cells (PBMC) stimulate cytolytic host T cell activity against leukemia.",
        "_version_":1606189010885017600}]
  }}
